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ABSTRACT 
 
 
In this thesis, I examine the contribution of cigarette smoking and human 
papillomavirus infection, two independent risk factors for cervical neoplasia, to the 
epigenetic modulation of cellular genes in cervical epithelium. 
  
To determine the temporal relationship between cigarette smoking and the detection 
of CDKN2A methylation in cervical cytological samples, I used a unique cohort of 
2011 women aged 15-19 who were recruited soon after they first had sexual 
intercourse. I have shown that compared with never-smokers, women who first started 
to smoke during follow-up had an increased risk of acquiring methylation of the 
tumour suppressor gene (TSG), CDKN2A (odds ratio=3.67; 95% confidence interval: 
1.09 to 12.33; p=0.04). I was also able to show that this epigenetic change was often 
reversible following smoking cessation. 
  
To determine the spectrum of epigenetic changes associated with HPV infection I 
performed CpG island and gene expression arrays on two in vitro models, a HPV 
replication model and a cervical disease progression model. I went on to show that 
HPV infection is followed by the up-regulation of the DNA methyltransferase 
DNMT1 which binds to the TSG, RARB, resulting in its de novo methylation. Specific 
CpG loci in the RARB promoter appeared to be targeted for de novo methylation, 
rather than methylation of all the CpGs, and may represent the methylation pattern 
seen at the earliest stages of HPV-induced carcinogenesis. 
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Introduction 
This chapter is divided into 3 sections. In the first section, I provide a general 
introduction to epigenetics focusing in particular on DNA methylation and its 
contribution to the regulation of gene expression. 
 
1.1 Introduction to epigenetics 
Epigenetics refers to the study of heritable changes in gene expression that are 
mediated by changes in DNA other than the nucleotide sequence (Holliday, 1987). 
Four inter-related types of epigenetic modifications are recognised including DNA 
methylation, histone modification, chromatin structure, and RNA interference (Bird, 
2002; Feinberg & Tycko, 2004; Esteller, 2008). 
 
1.1.1 DNA methylation 
DNA methylation involves the enzymatic transfer of a methyl group from the 
universal methyl donor S-adenosylmethionine to the carbon-5 position of the cytosine 
ring, producing the modified base 5-methylcytosine (Jones & Baylin, 2002; Herman 
& Baylin, 2003). This covalent modification occurs after DNA synthesis and is 
catalysed by the DNA methyltransferase (DNMT) family of enzymes, which I 
describe in more detail later (Jones & Baylin, 2002; Herman & Baylin, 2003). In the 
human genome, cytosine methylation occurs almost exclusively at cytosine bases that 
are located 5’ to a guanosine base (the CpG dinucleotide); in embryonic stem cells, 
cytosine methylation has also been reported at CpA and to a lesser extent CpT 
dinucleotides, but such non-CpG methylation is barely detectable in adult somatic 
cells (Ramsahoye et al, 2000). 
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The frequency of the CpG dinucleotide is actually substantially lower than expected 
in most of the human genome, present at approximately one-fifth of its expected 
frequency, and about 80% of these are methylated in normal cells (Bird, 1980). 5-
methylcytosine undergoes spontaneous deamination to thymine at a relatively high 
rate, and the failure to recognise and repair this mutation is thought to be the 
mechanism by which the CpG dinucleotide has been progressively depleted from the 
bulk of the genome over evolution (Bird, 1980; Sved & Bird, 1990). In contrast, CpG 
islands contain CpG dinucleotides at the expected frequency, and in normal cells these 
are usually unmethylated, regardless of the transcriptional state of the gene (Bird, 
1986; Gardiner-Garden & Frommer, 1987; Antequera & Bird, 1993; Takai & Jones, 
2002). CpG islands may be defined as short regions of DNA (longer than 500bp) with 
a GC content greater than 55% and an observed/expected CpG ratio of 0.65 
(Gardiner-Garden & Frommer, 1987; Takai & Jones, 2002). There are approximately 
29 000 CpG islands in the genome predicted by computational analysis (Lander et al, 
2001; Venter et al, 2001), and the majority of these are located in the proximal 
promoter regions of 40-50% of human genes (Antequera & Bird, 1993; Bird, 2002).  
 
1.1.2 DNA methyltransferases 
The DNA methyltransferase (DNMT) family of enzymes catalyse the transfer of a 
methyl group from the methyl donor S-adenosylmethionine to the carbon-5 position 
of the cytosine ring (Jones & Baylin, 2002; Herman & Baylin, 2003). There are 2 
distinct methyltransferase activities, de novo and maintenance. De novo 
methyltransferases methylate unmethylated DNA, thus establishing new DNA 
methylation patterns. In contrast, maintenance methyltransferases recognise 
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hemimethylated DNA, and copy the pre-existing methylation pattern onto the nascent 
DNA strand after DNA replication, thus maintaining the methylation pattern in 
proliferating cells (Chen & Li, 2004). There are 3 known biologically active DNMTs 
in mammalian cells, DNMT1, DNMT3A and DNMT3B. DNMT3L is an additional 
member of the DNMT3 family, but has no methyltransferase activity (Bourc'his et al, 
2001).  
 
DNMT1 was the first mammalian DNA methyltransferase to be identified (Bestor et 
al, 1988). In vitro, DNMT1 exhibited a 5- to 30-fold preference for hemimethylated 
DNA, and it was therefore originally classified as a maintenance methyltransferase 
(Yoder et al, 1997). DNMT3A and DNMT3B were identified shortly after from 
searching expressed sequence tag (EST) databases; both enzymes were found to 
methylate CpG dinucleotides without a preference for hemimethylated DNA and were 
thus classified as de novo methyltransferases (Okano et al, 1998). DNMT3A and 
DNMT3B were also found to be essential for de novo methylation in mice, further 
supporting this classification (Okano et al, 1999).  
 
Currently, several lines of evidence suggest that all 3 DNMTs possess both de novo 
and maintenance methyltransferase activities, and that they cooperate in vivo. 
Following disruption of both alleles of DNMT1 in the HCT116 colorectal carcinoma 
cell line, only a 20% decrease in the overall genomic methylation was observed, and 
most of the loci examined remained fully methylated and silenced, suggesting that 
other methyltransferases can maintain the methylation of most of the genome (Rhee et 
al, 2000). Similarly, following disruption of both alleles of DNMT3B in the HCT116 
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cell line, only a 3% decrease in the global methylation level was observed, whereas 
disruption of both DNMT1 and DNMT3B in the same cells nearly eliminated 
methyltransferase activity and decreased the overall genomic methylation by over 
95%, despite the presence of DNMT3A, suggesting that DNMT1 and DNMT3B 
cooperate to maintain DNA methylation in human cancer cells (Rhee et al, 2002). 
Cooperation between the maintenance and de novo methyltransferases was also 
demonstrated in a separate study using Micrococcus luteus genomic DNA. Very little 
methylation was observed in the presence of DNMT3A or DNMT3B alone or in 
combination. However combinations of de novo and maintenance enzymes (DNMT1 
+ DNMT3A, DNMT1 + DNMT3B, DNMT1 + DNMT3A + DNMT3B) showed 
increased rates of methylation, which was much higher than with any of the individual 
enzymes alone (Kim et al, 2002). 
 
1.1.3 DNA methylation: normal role 
DNA methylation is essential for normal embryonic development, and plays an 
important role in regulating gene expression (see below), maintaining genome 
stability, genomic imprinting and X-chromosome inactivation. 
 
1.1.3.1 Embryonic development 
Properly established and maintained DNA methylation patterns are essential for 
embryonic development, and require both de novo and maintenance methyltransferase 
activities (Li, 2002; Jaenisch & Bird, 2003). Consistent with this, inactivation of 
DNMT1 or DNMT3A and DNMT3B in mouse embryos resulted in global 
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demethylation or inhibition of de novo methylation respectively, both leading to 
embryonic lethality (Okano et al, 1999; Li et al, 1992). 
 
In the early embryo an initial wave of genome-wide demethylation of parental DNA 
occurs in the first cleavage divisions after fertilisation. This erases most, but not all, of 
the methylation patterns that are inherited from the gametes; methylation of imprinted 
genes is protected from demethylation at this time (see below). Demethylation is 
followed by a wave of global de novo methylation between blastocyst implantation 
and gastrulation, re-establishing the overall methylation pattern. This methylation 
pattern is then maintained throughout life in the somatic cells (Jaenisch et al, 1997; Li 
et al, 2002; Jaenisch & Bird, 2003). In the paternal genome, demethylation is an 
active process, although the demethylase responsible for this has not yet been 
identified (Mayer et al, 2000; Oswald et al, 2000). In contrast, the maternal genome is 
passively demethylated during successive rounds of replication in the absence of 
nuclear DNMT1 (Rougier et al, 1998; Mayer et al, 2000). 
 
1.1.3.2 Maintaining genome stability 
DNA methylation also helps to maintain transcriptional silence in the noncoding 
regions of the genome. These regions contain repeat elements, inserted viral 
sequences and transposons, the transcription of which could be harmful to cells 
(Yoder et al, 1997; Walsh et al, 1998; Remus et al, 1999; Herman & Baylin 2005).  
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1.1.3.3 Genomic imprinting 
Genomic imprinting refers to the conditioning of maternal and paternal genomes 
during gametogenesis which leads to the preferential expression of a specific parental 
allele in the somatic cells of the offspring (Feinberg & Tycko, 2004). The majority of 
imprinted genes show differences in DNA methylation between the parental alleles, 
and also differences with respect to bulk chromatin structure and histone 
modifications (Figure 1.1) (Reik & Walter, 2001). 
 
The imprints are reprogrammed in the gametes to ensure that they reflect the sex of 
the germ line. This first involves erasure of all the imprints by genome-wide 
demethylation in the germ cells, followed by de novo methylation during oogenesis in 
females and spermatogenesis in males, in order to establish the correct pattern of 
allele-specific methylation. This pattern is then maintained throughout development 
(Reik & Walter, 2001). Evidence suggests that establishment of maternal imprints 
requires cooperation of DNMT3L, which itself has no methyltransferase activity, with 
DNMT3A and DNMT3B (Bourc'his et al, 2001; Hata et al, 2002).  
 
The continuous expression of DNMT1 is essential for maintenance of imprinting. In 
studies of DNMT1-deficient mice embryos, the H19 gene, which is normally 
maternally expressed, was found to be transcribed from both alleles, and the normally 
active paternal allele of the Igf2 gene and the normally active maternal allele of the 
Igfr2 gene were both silenced (Li et al, 1993). These findings indicate that in the 
absence of DNA methylation, other epigenetic mechanisms such as histone 
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modifications are insufficient to maintain the mono-allelic expression of imprinted 
genes (Li et al, 1993). 
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Figure 1.1 Characteristics of imprinted genes. The figure shows a schematic pair of imprinted 
alleles. The enlarged region below the chromosomes highlights the allele-specific epigenetic changes, 
such as nucleosomal condensation through deacetylation, and methylation (allele 1) and opening of the 
chromatin by acetylation and demethylation (allele 2). The transcriptional competence of allele 2 is 
indicated by the binding of a transcription complex (from Reik & Walter, 2001). 
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1.1.3.4 X-chromosome inactivation 
X-chromosome inactivation refers to transcriptional silencing of one of the 2 X 
chromosomes in the female, in order to ensure equivalent levels of gene expression 
from the X chromosome in both males and females (Avner & Heard, 2001; Li, 2002). 
Inactivation of the X chromosome occurs early in embryogenesis, both X 
chromosomes have an equal probability of being silenced, and once established the 
inactive state is stably maintained during subsequent cell divisions (Heard, 2005).  
 
Inactivation of the X chromosome is initiated by transcription of the noncoding Xist 
(X-inactive-specific transcript) RNA, which is expressed exclusively from the 
inactive X-chromosome. The Xist transcripts spread from their site of synthesis to coat 
the entire X chromosome, triggering transcriptional silencing of the entire 
chromosome (Avner & Heard, 2001; Heard, 2005). Several mechanisms then act 
synergistically to maintain the inactive state: continuous expression of Xist transcript; 
histone modifications, such as hypoacetylation of histone H3 and H4, di-methylation 
of H3 lysine 9 (H3K9me2) and tri-methylation of H3 lysine 27 (H3K27me3); and 
DNA methylation (Csankovski et al, 2001; Heard et al, 2001; Plath et al, 2003; 
Heard, 2005). In particular, the recruitment of DNA methylation appears to be crucial 
for the stable silencing of the X chromosome in somatic cells; in DNMT1-knockout 
embryos, reactivation of an X-linked transgene was observed when the levels of DNA 
methylation decreased below a certain threshold (Sado et al, 2000). 
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1.1.4 Epigenetic regulation of gene expression 
The local chromatin structure is central to the epigenetic regulation of gene expression 
and determines whether a gene is transcribed or repressed (Figure 1.2). The chromatin 
structure is regulated by both nucleosome structure and histone acetylation: 
Nucleosomes which are in a more open configuration enable regulatory proteins to 
access chromatin and are thus associated with active gene transcription, while more 
tightly compacted nucleosomes are associated with gene silencing. Similarly, 
acetylated histones help to maintain the chromatin in an open and transcriptionally 
active state, enabling binding of transcription factors and other regulatory proteins 
that promote gene transcription, while histone deacetylases (HDAC) keep the histones 
deacetylated and thus transcriptionally silent (Baylin, 2005). 
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Figure 1.2 Effects of chromatin structure and DNA methylation on gene transcription in normal 
cells. The chromatin around the transcriptionally active (green arrow), unmethylated promoter (white 
circles) is occupied by widely spaced nucleosomes composed of histone complexes in which key 
residues in the tails of histone H3 are in the acetylated state (green ovals). This region is accessible to 
key components of the gene-transcription apparatus – primary transcription factors (TF), proteins with 
histone acetyltransferase activity (HAT) and co-activators (CA). The flanking regions to either side of 
the unmethylated CpG island contain methylated cytosines (black circles). The chromatin structure 
here is characteristic of transcriptionally silenced regions: nucleosomes are more tightly compacted, 
with deacetylated histones (purple ovals), and methylcytosine binding proteins (MBP) are bound to 
methylated DNA. The MBP are also part of complexes that contain histone deacetylases (HDAC), 
which facilitate histone deacetylation. The apparatus for DNA methylation, consisting of DNMTs, 
transcriptional co-repressors and HDAC, have access to the flanking regions but not to the 
unmethylated CpG island in the promoter (from Herman & Baylin, 2003). 
12 
 
Introduction 
1.1.4.1 DNA methylation and regulation of gene expression 
DNA methylation has been reported to repress gene transcription through several 
distinct mechanisms. One mechanism involves directly inhibiting the binding of 
activating transcription factors to their target sequences. Many transcription factors 
are targeted to GC-rich sequences and methylation has been shown to prevent the 
binding of several transcription factors to these sites (Comb et al, 1990; Prendergast 
& Ziff, 1991; Gaston & Fried, 1995; Clark et al, 1997). A second mechanism involves 
the methyl CpG binding proteins (MeCPs), which specifically recognise and bind to 
methylated DNA (Li, 2002; Klose & Bird, 2006). A family of 5 MeCPs have been 
identified (MeCP2, MBD1, MBD2, MBD3, MBD4), each containing a homologous 
methyl CpG binding domain (MBD) (Nan et al, 1993; Nan et al, 1997; Hendrich & 
Bird, 1998). In addition, the Kaiso family of proteins, which lack a MBD domain, 
have also been shown to bind to methylated DNA through their zinc-finger domains 
(Prokhortchouk et al, 2001; Filion et al, 2006). The MeCPs mediate repression of 
gene transcription by recruiting chromatin remodelling co-repressor complexes to 
regions containing methylated DNA (Jones et al, 1998; Nan et al, 1998; Ng et al, 
1999; Wade et al, 1999; Zhang et al, 1999; Feng et al, 2001; Ng et al, 2000; Fujita et 
al, 2003; Sarraf & Stancheva, 2004). The DNMT family of proteins can also directly 
repress transcription, independent of their methyltransferase activity. DNMT1, 
DNMT3A and DNMT3B contain transcriptional repression domains that function by 
recruiting histone deacetylases and other co-repressor proteins, similar to the MeCPs, 
also resulting in chromatin remodelling and transcriptional silencing (Fuks et al, 
2000; Robertson et al, 2000; Rountree et al, 2000; Bachman et al, 2001; Fuks et al, 
2001).  
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DNA methylation can also repress gene expression in association with covalent 
histone modifications (Bird and Wolffe, 1999; Fuks, 2005). The 2 most studied 
histone modifications associated with gene silencing are histone deacetylation and 
methylation of histone H3 lysine 9 (H3K9). Some studies have demonstrated that 
histone modifications are a prerequisite for DNA methylation (Lehnertz et al, 2003; 
Bachman et al, 2003). For example, H3K9 methylation was shown to initiate 
silencing of CDKN2A independently of DNA methylation, with DNA methylation 
acting subsequently to lock the chromatin in a repressed state (Bachman et al, 2003). 
This is also a feature of X-chromosome inactivation (see above). Other investigators 
have revealed that DNA methylation may be the dominant epigenetic mechanism 
regulating gene transcription, with subsequent recruitment of repressive histone 
modifications to gene promoters (Cameron et al, 1999; Fahrner et al, 2002; Suzuki et 
al, 2002). For example, treatment of malignant cells with the DNA demethylating 
agent 5-aza-2’-deoxycytidine, resulted first in demethylation of the hypermethylated 
hLMH1 promoter, second to reactivation of gene expression, and finally to reversal of 
the histone code (enrichment of acetylated H3 and H3K4 methylation with loss of 
H3K9 methylation), while treatment with the histone deacetylase inhibitor, 
trichostatin A, failed to reactivate the hypermethylated gene or to dramatically alter 
histone modifications (Fahrner et al, 2002). It seems likely that both DNA 
methylation and histone modifications play a role at the promoters of different genes. 
 
Another epigenetic mark of transcriptional repression is trimethylation of H3K27 
(H3K27me3). While enrichment of H3K27me3 has recently been reported at the 
promoters of many genes that are hypermethylated and silenced in cancer (McGarvey 
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et al, 2006), the functional relationship between these 2 repressive mechanisms 
remains unclear. One study demonstrated a direct interaction between EZH2 (which 
catalyses trimethylation of H3K27) and the DNMTs both in vitro and in vivo (Vire et 
al, 2005), but several subsequent studies have provided compelling evidence that 
H3K27me3 and DNA methylation function independently (McGarvey et al, 2007; 
Kondo et al, 2008). 
 
1.1.5 DNA methylation: cancer 
A link between DNA methylation and cancer was first demonstrated in 1983 
(Feinberg & Vogelstein, 1983). Since that time, nearly every tumour type examined 
has been characterised by both the global loss of methylation in the CpG-poor regions 
of the genome where the CpG dinucleotides are usually methylated, and by 
hypermethylation in the CpG islands located in the promoters of genes where the CpG 
dinucleotides are usually not methylated (Figure 1.3) (Herman & Baylin, 2003).  
 
1.1.5.1 Hypomethylation and cancer 
Hypomethylation at CpG dinucleotides was the first epigenetic abnormality to be 
identified in cancer cells; using methylation-sensitive restriction enzymes, Feinberg 
and Vogelstein (1983) observed that a substantial proportion of CpGs that were 
methylated in normal tissues, were unmethylated in cancer cells. 
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Figure 1.3 Distribution of DNA methylation in normal and cancer cells. In normal cells, most CpG 
sites outside of CpG islands are methylated (black circles), whereas most of the CpG sites within CpG 
islands located in the promoter regions are unmethylated (white circles). In cancer cells, many of the 
CpG sites in the bulk of the genome become unmethylated, with aberrant methylation of CpG islands 
located in the promoter regions, which is associated with transcriptional silencing (from Herman & 
Baylin, 2003). 
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Several mechanisms have been proposed to explain the contribution of 
hypomethylation to the development of cancer (Esteller, 2008). Firstly, 
hypomethylation may contribute to carcinogenesis by inducing chromosomal 
instability. Aneuploidy and a large increase in the number of novel chromosomal 
translocations have been reported following disruption of the DNMTs in the HCT116 
colorectal carcinoma cell line (Karpf & Matsui, 2005). In sporadic colorectal cancers, 
tumours with global hypomethylation were also reported to have a significantly 
increased number of loci with loss of heterozygosity (LOH) (Matsuzaki et al, 2005). 
Secondly, loss of methylation may allow the reactivation of transposable elements 
which can then be translocated to other genomic regions, disrupting normal cellular 
genes (Bestor et al, 2005; Esteller, 2008). Thirdly, loss of methylation may also allow 
the expression of normally silenced genes such as imprinted genes. The first gene to 
display loss of imprinting in cancers was IGF2 (insulin-like growth factor gene), and 
loss of imprinting of this gene has been associated with the development of 50% of 
Wilm’s tumours in children and with an increased risk of colorectal cancer in adults 
(Wilkins, 1988; Ravenel et al, 2003; Cui et al, 2003). In addition hypomethylation 
may also lead to the activation of oncogenes. Mechanistically, while genome-wide 
hypomethylation has been associated with the activation of normally silent genes in 
some cancers eg MAGE-1, for other genes, hypomethylation appears to gene-specific 
rather than random by-products of global hypomethylation (De Smet et al, 1996; Sato 
et al, 2003). 
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1.1.5.2 Hypermethylation and cancer 
The first tumour suppressor gene reported to be hypermethylated was the 
retinoblastoma gene (Rb) (Greger et al, 1989; Sakai et al, 1991). Since then, 
hypermethylation of CpG islands in the proximal promoter region of tumour 
suppressor genes has been reported in virtually every tumour type and is frequently 
associated with aberrant silencing of gene expression. Indeed, the number of tumour 
suppressor genes inactivated by aberrant promoter hypermethylation equals or 
exceeds the number that are inactivated by mutations or deletions (Herman & Baylin, 
2003). 
 
However the causes of aberrant hypermethylation in cancer remains poorly 
understood. In particular, it is not known why some CpG islands become 
hypermethylated in cancer while others do not. Increased DNMT1 and DNMT3B 
mRNA levels have been observed in a number of solid and haematological 
malignancies, and the DNA methyltransferases are considered to be central to the 
process of aberrant methylation (Esteller, 2005). However, it is clear that methylation 
is not a random process; different tumour suppressor genes are inactivated by 
methylation in different cancers, and there has been no TSG which has been found to 
be hypermethylated in every cancer type (Costello et al, 2000; Esteller et al, 2001; 
Issa et al, 2004; Keshet et al, 2006). Studies investigating methylation following 
exposure to carcinogens such as smoking and viruses are beginning to increase our 
understanding of the possible underlying mechanisms and these aspects will be 
discussed in more detail later; smoking and HPV-induced DNA methylation are the 
main focus of this thesis. 
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Recently, DNA methylation has been reported to be a function of promoter CpG 
content (Weber et al, 2007). In this study, promoters were classified into 3 categories 
based on CpG ratio, GC content and the length of the CpG-rich region. Promoters 
with a high CpG content represented ‘strong’ CpG islands, promoters with an 
intermediate CpG content represented ‘weak’ CpG islands and the promoters with low 
CpG content represented promoters with no local enrichment of CpG dinucleotides. 
The promoters with intermediate CpG content were found to be methylated in somatic 
cells but not in the germline, suggesting that ‘weak’ CpG islands are the preferential 
targets for de novo methylation during development. Conversely, the promoters with 
high CpG content were usually not methylated even when inactive, and were possibly 
protected from de novo methylation by the high levels of H3K4 di-methylation 
present (Weber et al, 2007). 
 
Another recent mechanism that has been reported to predispose genes to DNA 
methylation in cancer is the presence of a stem cell-like chromatin pattern. Embryonic 
stem cells are pluripotent cells which rely on the Polycomb-mediated tri-methylation 
of H3K27 to reversibly repress genes that are essential for differentiation (Ringrose et 
al, 2004; Lee et al, 2006). Several studies have demonstrated that genes that become 
de novo methylated in cancer are frequently marked by H3K27me3 in embryonic 
stem cells (Widschwendter et al, 2007; Schlesinger et al, 2007). Subsequent studies 
have revealed that the promoters of key developmental genes in embryonic stem cells 
are actually marked by a ‘bivalent’ chromatin pattern, the active mark H3K4 tri-
methylation (H3K4me3) and the repressive mark H3K27me3, which keeps these 
genes in a ‘transcription-ready’ state (Berstein et al, 2006; Ohm et al, 2007; Zhao et 
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al, 2007). These bivalent domains are usually lost during embryonic stem cell 
differentiation, and differentiated cells are typically marked by either H3K27me3 or 
H3K4me3, but not by both (Berstein et al, 2006). This bivalent chromatin pattern 
characteristic of stem cells has been shown to predispose genes to DNA 
hypermethylation during the initiation and progression of malignancy (Ohm et al, 
2007). 
 
In Chapter 5 of this thesis, I perform an analysis based on these 2 determinants of 
DNA methylation, promoter CpG content and stem cell-like chromatin pattern. 
 
1.1.5.3 Epigenetic switching 
It is clear the relationship between H3K27me3 and DNA methylation is complex. The 
recently described process of epigenetic switching adds yet another layer to this 
complicated relationship. In embryonic stem cells, genes essential for differentiation 
are repressed by H3K27me3 in the absence of methylation. In prostate cancer cells it 
has been shown that these marks can be removed and replaced with DNA 
methylation, which changes the reversible gene repression to one of permanent 
silencing (Figure 1.4) (Gal-Yam et al, 2008). In Chapter 5 of this thesis, I also 
investigate possible epigenetic switching for one candidate gene. 
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Figure 1.4 Epigenetic switching. Schematic promoters are shown. Arrows represent transcription. 
Black circles represent methylated CpG loci. White circles represent unmethylated CpG loci. In 
embryonic stem cells, genes can be repressed by polycomb repressive complexes (PRC) in the absence 
of DNA methylation. In cancer, loss of the PRC occurs and this is replaced with DNA methylation 
(from Gal-Yam et al, 2008). 
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1.1.6 Clinical implications: Reversal of epigenetic silencing 
Unlike mutations, epigenetic gene silencing is potentially reversible, and there is 
therefore great interest in developing new therapeutic strategies using epigenetic 
agents for the management of patients with cancer. 
 
In experimental settings, inhibitors of DNA methylation rapidly reactivate genes that 
have become epigenetically silenced. The prototype inhibitors of DNA methylation, 
5-azacytidine (azacitidine), and 5-aza-2’-deoxycytidine (decitabine) were initially 
developed as classical cytotoxic agents over 40 years ago (Sorm et al, 1964). 
Subsequently it was found that these drugs could inhibit DNA methylation in human 
cell lines, inducing gene expression and differentiation (Constantinides et al, 1977; 
Jones & Taylor, 1980). Both drugs are nucleoside analogues and are converted to 
deoxynucleoside tri-phosphates which are then incorporated into DNA in place of 
cytosine. They are therefore only active during S-phase. These ‘false’ bases then form 
covalent bonds with the DNA methyltransferases, trap these enzymes and target them 
for degradation, resulting in demethylation of DNA during subsequent rounds of cell 
division (Jones & Taylor, 1980; Egger et al, 2004). In patients with high-risk 
myelodysplastic syndrome (MDS), a pre-leukaemic bone marrow disorder, azacitidine 
and decitabine have been tested in phase 3 clinical trials and have both demonstrated 
high response rates, reduced risk of leukaemic transformation and improved median 
survival (Silverman et al, 2002; Kantarjian et al, 2006). In vivo, demethylation and 
gene reactivation have also been demonstrated (Daskalakis et al, 2002; Mund et al, 
2005; Yang et al, 2006). Consequently, both drugs have now been approved by the 
FDA for treatment of MDS. 
22 
 
Introduction 
 However decitabine was found to be ineffective when initially used in patients with 
various solid tumours (Abele et al, 1987). It is now thought that this lack of activity 
may be related to the use of too high doses, limited number of days of drug exposure 
and assessment of response after only one cycle (Issa, 2007). These drugs are also 
limited by being S-phase dependent, thus they will be inactive in non-cycling cells. 
They cause significant myelosuppresion and they are also unstable in aqueous 
solutions. As they are incorporated into DNA, this is also thought to contribute to 
their cytotoxicity (Herman & Baylin, 2003; Egger et al, 2004). Consequently the 
development of new agents is an active area of research. Rationally designed 
inhibitors of the DNMTs are emerging, but as the DNMTs are known to cooperate, it 
is likely that simultaneous inhibition of several DNMTs will be required. Rational 
design of combination therapies, such as DNA methylation and histone acetylation 
inhibitors, which are known to act synergistically in vitro, are also being considered 
(Issa, 2007). 
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1.2 Cervical cancer 
In this section I provide an introduction to cervical cancer, focusing in particular on 
the role of the 2 main risk factors, human papillomavirus (HPV) and smoking. 
 
1.2.1 Epidemiology of cervical cancer 
Cervical cancer is the second most common cancer among women worldwide. In 
2007, there were an estimated 555,000 new cases and 309,000 deaths from cervical 
cancer worldwide (American Cancer Society website, May 2010). The majority of 
cases occur in developing countries, where they account for 15% of all female 
cancers. In comparison, the incidence rate is low in developed countries, accounting 
for less than 5% of all female cancers; in the UK, there were 2,828 new cases in 2007, 
making it only the eleventh most common cancer in women in the UK (Parkin & 
Bray, 2006; CRUK website, May 2010). The incidence rate is highest among those 
aged 30-39, with a second peak seen in older women in some countries (Bosch & de 
Sanjose, 2003; Franceschi et al, 2006).   
 
Since the introduction of population-based screening programmes in the 1960s and 
the 1970s, the incidence and mortality from cervical cancer has declined dramatically 
in many developed countries. In some populations, the decline in mortality predated 
the introduction of screening, and thus factors such as improved socioeconomic 
levels, earlier stage at diagnosis and more effective treatments may have also 
contributed to this improvement. In developing countries, the incidence and mortality 
rates have remained relatively stable, and cervical cancer remains the most common 
cause of cancer death in females in these countries (Parkin & Bray, 2006). 
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Squamous cell carcinoma (SCC) is the most common histological type, accounting for 
approximately 80% of all cervical carcinomas, while adenocarcinomas account for 
most of the remaining cases (International Collaboration of Epidemiological Studies 
of Cervical Cancer 2006a). In many developed countries the incidence of cervical 
SCC has fallen considerably as a consequence of cervical screening. Conversely, 
numerous studies in the past 2 decades have reported increasing rates of 
adenocarcinoma, particularly in younger women (age <40 years), although since the 
mid- to late-1990s declining rates of adenocarcinoma are now being observed in some 
countries (Schwartz & Weiss, 1986; Antilla et al, 1999; Smith et al, 2000; Hemminki 
et al, 2002; Bulk et al, 2005; Howlett et al, 2007; Andrae et al, 2008; Sasieni et al, 
2009; Mathew & George, 2009). This initial increase in the incidence of 
adenocarcinoma is thought to be related to generational changes in sexual behaviour 
leading to increased transmission of HPV in younger generations; younger age at first 
intercourse, increased number of sexual partners, and increasing risk that each sexual 
partner is HPV positive (Bray et al, 2005). The poorer detection of adenocarcinomas 
by screening programmes is also thought to have contributed to the increasing rates of 
adenocarcinoma: as adenocarcinomas and their precursor lesions arise from glandular 
epithelium within the endocervical canal, they are therefore less amenable to detection 
by cytological screening which involves scraping cells from the epithelium of the 
ectocervix (Bray et al, 2005; Parkin & Bray, 2006; Sasieni et al, 2009). In turn, an 
increased awareness of adenocarcinoma precursor lesions among pathologists and 
clinicians and improved specimen collection are both thought to have contributed to 
the more recent decline in the incidence of adenocarcinoma seen in some countries 
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(Howlett et al, 2007; Andrae et al, 2008; Sasieni et al, 2009; Mathew & George, 
2009). 
 
1.2.2 Histology of the cervix 
The epithelial lining of the cervix varies; the endocervix is lined by a single layer of 
columnar epithelium, while the ectocervix is covered by non-keratinising, stratified 
squamous epithelium. The junction between the endocervix and the ectocervix is 
known as the original squamo-columnar junction (Figure 1.5a). This junctional region 
undergoes continuous dynamic modification which is greatest at puberty and during a 
woman’s first pregnancy, when hormonal changes result in extension of the columnar 
epithelium onto the ectocervix forming an ectropion or cervical erosion (Figure 1.5b). 
Exposure of the columnar epithelium to the acidic environment of the vagina (post-
puberty) then induces squamous metaplasia, where the columnar epithelium becomes 
replaced by new squamous epithelium, and this area is known as the transformation 
zone (Figure 1.5c) (Stevens & Lowe, 1992; Critchlow et al, 1995; Jacobson et al, 
1999). The transformation zone is the most common site for the development of 
cervical neoplasia (Arends et al, 1998). 
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Figure 1.5 Squamo-columnar junction of the cervix. a) The squamo-columnar junction is originally 
situated in the region of the external os. b) At puberty, the endocervical epithelium extends distally into 
the acid environment of the vagina, forming an ectropion. c) A transformation zone forms as squamous 
epithelium grows over the ectropion (from Stevens & Lowe, 1992). 
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1.2.3 Pre-invasive lesions 
Pre-invasive lesions of the cervix are asymptomatic and are usually detected during 
routine cervical cytological screening. 
 
1.2.3.1 Cervical intraepithelial neoplasia 
Cervical intraepithelial neoplasia (CIN) represents a spectrum of histological 
abnormalities. The grading of CIN refers to the level in the epithelium at which 
cytoplasmic maturation occurs (Wells, 1996): 
 
• CIN grade 1 (CIN1) represents mild dysplasia; mild nuclear abnormalities are 
present throughout the epithelium, and cytoplasmic differentiation is present in the 
upper two-thirds of the epithelium. 
• CIN grade 2 (CIN2) represents moderate dysplasia; nuclear abnormalities are 
more marked and are again present throughout the epithelium, and cytoplasmic 
differentiation is limited to the upper third of the epithelium. 
• CIN grade 3 (CIN3) represents severe dysplasia and carcinoma in situ; severe 
nuclear abnormalities are present throughout the epithelium, and there is virtually 
no normal cytoplasmic differentiation visible. 
 
A modification of the original CIN classification was introduced in 1990, where CIN1 
is now designated low-grade CIN, and CIN2 and CIN3 are classified together as high-
grade CIN (Richart, 1990). In the UK, women with low-grade CIN may be kept under 
colposcopic surveillance, but all women with high-grade CIN are treated immediately 
(NHS Cervical Screening Programme website, May 2010). Treatment of CIN lesions 
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involves either removal of the transformation zone (where the abnormalities arise) by 
large loop excision of the transformation zone (LLETZ), cone biopsy or rarely, 
hysterectomy, or by destroying the cells in the abnormal area with laser therapy, cold 
coagulation, or cryotherapy (Schiffmann et al, 2007). In the UK, LLETZ is the most 
common method used.  
 
1.2.3.2 Adenocarcinoma in situ 
The pre-invasive component of adenocarcinoma is known as adenocarcinoma in situ 
(AIS). The management of women with AIS is challenging: The colposcopic changes 
associated with AIS may be minimal, which makes it difficult to determine the full 
extent of the lesion. AIS also tends to extend a considerable distance into the 
endocervical canal, making complete excision difficult. In addition, AIS is often 
multifocal and skip lesions are commonly found, thus negative margins from a 
diagnostic excision specimen do not necessarily mean that the lesion has been 
completely excised. Consequently hysterectomy is the treatment of choice in women 
who have completed childbearing (Wright et al, 2007). 
 
1.2.4 Invasive disease 
Eventually the abnormal epithelial cells may breach the basement membrane and 
invade into the cervical stroma. 
 
1.2.4.1 Squamous cell carcinoma 
This is the most common histological type of invasive cervical cancer. The earliest 
sign of SCC is early stromal invasion, when small foci (<1mm) in the basal 
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epithelium breach the basement membrane. The tumour can then spread both locally 
and via the lymphatic vessels. The 2 most important prognostic factors in SCC are the 
depth of the invasion of the primary tumour and the presence and extent of lymph 
node metastases (Wells, 1996). 
 
1.2.4.2 Adenocarcinoma 
Adenocarcinoma of the cervix is the second most common histological type of 
cervical cancer, after SCC. Adenocarcinoma has a pattern of dissemination which is 
different to that of SCC. For example adenocarcinoma more frequently metastasises 
to the lymph nodes and ovary. The most important prognostic factors for 
adenocarcinoma are clinical stage and the presence of lymph node metastases (Gien et 
al, 2010). 
 
1.2.5 Natural history of cervical cancer 
The natural history of cervical cancer is thought to be characterised by a well-defined 
pre-malignant phase. However, an accurate assessment of the rates of progression or 
regression of cervical epithelial abnormalities in the modern era is difficult to attain 
because all women with high-grade CIN and many women with low-grade CIN are 
now treated. Based on a review of the early natural history studies (1950s onwards), it 
was estimated that the majority of low-grade CIN lesions will regress spontaneously 
(60%), while 30% will persist, 10% will progress to CIN3 and only 1% will progress 
to invasive cancer. High-grade CIN lesions may still spontaneously regress in up to 
33% of cases, however the probability of an atypical epithelium becoming invasive 
increased with the severity of the atypia (Ostör, 1993). Currently cytological and 
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histological examination is not able to accurately predict the minority of women with 
CIN who will progress from the vast majority whose abnormalities will spontaneously 
regress, consequently all high grade lesions are treated (Woodman et al, 2007). More 
useful prognostic markers than those provided by morphological examination are 
clearly needed. 
 
The time to progression from pre-invasive disease to invasive cervical cancer is also 
thought to be a slow process; the mean age of a woman with CIN is approximately 15 
years younger than that of a woman with invasive cervical cancer (zur Hausen, 2002). 
 
1.2.6 Risk factors for cervical neoplasia 
The single most important risk factor for the development of cervical neoplasia is 
infection with high-risk types of human papillomavirus (HPV) and this will be 
discussed in more detail below. In addition, the number of sexual partners, younger 
age at first sexual intercourse, high parity, younger age at first full term pregnancy, 
increasing duration of oral contraceptive use and smoking are all associated with an 
increased risk of developing cervical neoplasia (International Collaboration of 
Epidemiological Studies of Cervical Cancer 2006b, 2006c, 2007, 2009). Recently a 
re-analysis of 12 epidemiological studies involving 8,097 women with SCC and 1,374 
women with adenocarcinoma, demonstrated that all the risk factors listed above are 
common to both cervical SCC and adenocarcinoma, with the exception of smoking. 
Current smoking was associated with a significantly increased risk of SCC (RR=1.50, 
95% CI: 1.35-1.66) but not of adenocarcinoma (RR=0.86, 95% CI: 0.70-1.05), and 
the difference between these 2 histological types was statistically significant 
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(International Collaboration of Epidemiological Studies of Cervical Cancer 2006a). 
This was also demonstrated in the larger pooled analysis of individual data from 
13,541 women with cervical cancer from 23 epidemiological studies (International 
Collaboration of Epidemiological Studies of Cervical Cancer 2006b). With the 
exception of infection with HPV, the magnitude of the risk imparted by all the other 
risk factors is only modest, with relative risks between 1.5-2.5 (International 
Collaboration of Epidemiological Studies of Cervical Cancer 2006b, 2006c, 2007, 
2009). 
 
1.3 Human papillomavirus 
Human papillomaviruses (HPVs) are small double-stranded DNA viruses that infect 
basal epithelial cells, causing benign and malignant lesions in the cutaneous and 
mucosal epithelia. More than 100 HPV types have been identified, and over 40 of 
these are known to infect the anogenital tract. The genital HPV types are further 
subdivided into low-risk and high-risk types (Table 1.1). The low-risk types usually 
cause benign lesions such as warts and condyloma acuminata, and are rarely 
associated with malignancy. In contrast, the high-risk types are frequently associated 
with cervical cancer. Fifteen high-risk HPV types have been identified and 5 of these 
(types 16, 18, 45, 31 and 33) account for 90% of all cases of cervical cancer 
worldwide (Muñoz et al, 2003). 
 
Classification HPV types 
High-risk 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, 82 
  
Probable high-risk 26, 53, 66 
  
Low-risk 6, 11, 40, 42, 43, 44, 54, 61, 70, 72, 81 
 
Table 1.1 Classification of the major HPV types 
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1.3.1 Organisation of the HPV genome 
The HPV virion consists of a non-enveloped, double-stranded circular DNA within an 
icosahedral capsid (Doorbar, 2006). The HPV genome is approximately 8kb in length 
and can be divided into 3 major regions, an early coding region, a late coding region 
and an 850bp long control region (LCR) (Figure 1.6). The early region contains 6 
open reading frames (ORF) that encode the early (E) proteins, E1, E2, E4, E5, E6 and 
E7. The late region contains 2 ORF which encode the late (L) proteins, L1 and L2. 
The LCR (also known as the upstream regulatory region, URR) is a non-coding 
region, which contains enhancer elements, a promoter and binding sites for many 
transcription factors (Zheng & Baker, 2006). 
 
The high-risk HPV types contain 2 major viral promoters. The early promoter lies 
upstream of the E6 ORF and is responsible for nearly all early gene expression; in 
HPV16 the early promoter is referred to as P97, and in HPV18 it is referred to as 
P105. The second, or late, promoter lies within the E7 ORF and is responsible for late 
gene expression; in HPV16 this is referred to as P670 and there is accumulating 
evidence that a late promoter is also present in HPV18 (Hirochika et al, 1987; Gloss 
& Bernard, 1990; Romanczuk et al, 1990; Grassman et al, 1996; Parker et al, 1997; 
Zheng & Baker, 2006). 
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Figure 1.6 Organisation of the HPV genome. The HPV16 genome (7904bp) is shown as a black 
circle with the early (P97) and late (P670) promoters marked by arrows. The locations of the 8 open 
reading frames (E1, E2, E4, E5, E6, E7, L1 and L2) are shown. The long control region (LCR) is 
enlarged to show the E1 and E2 binding sites, the SP-1 binding sites, the TATA box and the P97 
promoter (from Doorbar, 2006). 
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1.3.1.1 Early proteins 
The E1 and E2 proteins are essential for viral replication (Hebner & Laimins, 2006). 
The E1 protein functions as a helicase, catalysing the unwinding of DNA, and also 
recruits the DNA polymerase alpha-primase to the viral origin of replication 
(Masterson et al, 1998; Conger et al, 1999). The E2 protein helps to recruit E1 to the 
origin of replication, and also functions as a transcription factor, regulating 
transcription of E6 and E7 from the early promoter. The LCR of the high-risk HPVs 
contains four E2-binding sites (see Figure 1.6); at low levels E2 activates viral 
transcription, while at high levels E2 represses expression of the viral oncogenes, by 
displacing basal transcription factors that are essential for promoter activation (Cripe 
et al, 1987; Steger et al, 1997; Hebner & Laimins, 2006).  
 
The E1^E4 and E5 proteins are differentiation-dependent proteins and may play a role 
in viral genome amplification by inducing cell cycle arrest at G2, or by stimulating 
cell cycle progression, respectively (Doorbar et al, 1997; Fehrmann et al, 2003; 
Knight et al, 2006; Conway & Meyers, 2009). In addition, in the stratified epithelium, 
the E1^E4 proteins are believed to cause collapse of the cytoskeleton networks, thus 
allowing release of the virions from these cells (Bryan & Brown, 2000). 
 
The E6 and E7 proteins from high-risk, but not low-risk, HPV types are oncoproteins. 
The high-risk E6 protein binds to the p53 tumour suppressor protein and promotes its 
degradation by forming a trimeric complex with the cellular ubiquitin ligase E6AP 
(Scheffner et al, 1990; Werness et al, 1990). The E6 oncoprotein can also down-
regulate p53 activity by targeting the transcriptional activator CBP/p300 (Patel et al, 
35 
 
Introduction 
1999; Zimmermann et al, 1999). The resulting rapid reduction in the steady-state 
levels of p53 alleviates the restraint on cell cycle progression, enabling viral 
replication. Activation of telomerase is another important function of the E6 
oncoprotein (Klingelhutz et al, 1996). The high-risk E7 protein binds to and degrades 
the Rb tumour suppressor protein and other members of the pocket protein family, 
which releases the E2F transcription factor from Rb inhibition, leading to 
transcription of S-phase genes (Dyson et al, 1989). 
 
1.3.1.2 Late proteins 
The L1 and L2 ORF encode the major (L1) and minor (L2) capsid proteins, 
respectively, and once expressed these proteins assemble into viral capsids. The HPV 
icosahedral capsid is composed of 360 copies of the 55 kDa L1 capsid protein 
arranged as 72 pentameric capsomeres, with 12 copies of the 74 kDa L2 protein, 
possibly associated with the 12 pentavalent capsomeres. (Chen et al, 2000; Modis et 
al, 2002; Finnen et al, 2003).  
 
1.3.2 HPV life cycle 
The human papillomavirus life cycle is tightly linked to differentiation of the host 
epithelial cell, and can be divided into 2 stages, nonproductive and productive (Figure 
1.7) (Doorbar, 2005). HPV can only replicate in basal epithelial cells (Egawa, 2003), 
and the virus is thought to gain access to these cells through micro-abrasions in the 
epithelial tissue (Doorbar, 2005). In the basal cells the virus expresses the early 
proteins E1, E2, E5, E6, and E7 and replicates with the cellular DNA during S-phase, 
maintaining its genome as a low copy number episome (20-100 copies per basal cell) 
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(Stanley et al, 1989; De Geest et al, 1993). This is the non-productive phase of the life 
cycle.  
 
 
     
 
 
Figure 1.7 HPV life cycle. Diagrammatic representation of the skin to reveal the pattern of HPV16 
gene expression as the infected cell migrates towards the epithelial surface. After infection the viral 
genome is maintained as a low copy number episome. During epithelial differentiation the P97 
promoter directs expression of E6 and E7 genes necessary for S-phase entry (red). The P670 promoter 
is up-regulated in the higher epithelial layers, and viral replication proteins (E1, E2, E4, E5) increase in 
abundance (green), facilitating amplification of viral genomes (blue). In the upper epithelial layers the 
viral capsid proteins are found (yellow) (from Doorbar, 2005). 
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As the HPV-infected basal cells divide, the viral episomes are replicated and are 
distributed evenly among the daughter cells. Following mitosis, one cell remains 
attached to the basal layer, while the other cell migrates up through the suprabasal 
layers and begins to differentiate (Lehman & Botchan, 1998; Bastien & McBride, 
2000; Doorbar, 2005). Non-infected cells normally exit the cell cycle once they 
become detached from the basal layer. In contrast, detached HPV-infected epithelial 
cells remain mitotically active due to the expression of the E6 and E7 proteins (Cheng 
et al, 1995; Ruesch & Laimins, 1998; Flores et al, 2000). Hence, HPV infection with 
consequential expression of the E6 and E7 proteins, allows the HPV-infected cell to 
override the normal cell cycle exit that occurs on differentiation, in order to enable 
production of viral progeny (Laimins, 1996). 
 
In the suprabasal cells, the late promoter is activated, the virus expresses the E4, L1 
and L2 proteins and the viral genomes are amplified to a high copy number per cell 
(Laimins, 1996; Doorbar, 2005). This is the productive phase of the life cycle. In the 
uppermost layers of the epithelium, the viral genomes are packaged into the newly 
formed capsids, and the progeny virions are then released from the cell (Doorbar, 
2005). The time from HPV infection to subsequent release of virions is approximately 
3 weeks, which is the time required for the basal cells to undergo complete 
differentiation and desquamation (Stanley, 2006). 
 
1.3.3 Persistence of HPV infection 
Cervical HPV infection is a very common sexually transmitted infection and most 
young women are infected soon after the onset of sexual activity (Collins et al, 2002; 
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Bosch & de Sanjose, 2003). However, the majority of women will spontaneously 
clear their infection within a short period of time, and persistent infection is seen in 
only approximately 15% of women (Ho et al, 1998; Woodman et al, 2001; Stanley et 
al, 2007). Persistent infection with high-risk HPV types is generally considered to be 
a major risk factor for the development of high-grade CIN and cervical cancer (Ho et 
al, 1995; Remmink et al, 1995). However, there is no accepted definition of persistent 
infection (Schiffman et al, 2007). A review of the literature demonstrated that in many 
studies women were considered to have persistent infection if they tested positive for 
HPV on 2 or more occasions, but in these studies the duration of the interval between 
tests ranged from 2 months to 7 years (Woodman et al, 2007). Clearly, the shorter the 
interval between tests, the more likely it is for an infection to be defined as persistent 
(Figure 1.8). Nevertheless, it is now clear that persistent viral infection is not always 
necessary for disease progression; high-grade CIN has been detected soon after 
infection with high-risk HPV (Woodman et al, 2001). 
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Figure 1.8 Persistent HPV infection. The rectangles denote a period of time during which HPV DNA 
sequences could be detected. In many studies, a woman is considered to have a persistent infection if 
she is HPV DNA-positive in two or more consecutive tests, and a transient infection if she is positive 
only once. Panels a) - c) show how the same infection might be considered persistent or transient, 
depending on when the samples were taken. a) The infection is characterized as persistent. b), c) The 
same infection is now characterized as transient merely by changing the sampling times. d) These 
episodes of HPV infection are of identical duration, but began at different, undetermined times before 
entry to the study. Two of these infections would have been considered persistent, and three transient, 
on the basis of when the second test was performed. e) With a definition based on the number of 
positive tests, an infection is more likely to be considered persistent if a woman is tested more 
frequently (from Woodman, 2007). 
 
40 
 
Introduction 
1.3.4 HPV and cervical neoplasia 
Infection with the high-risk types of human papillomavirus is the major cause of 
cervical cancer, and high-risk HPV DNA can be detected in virtually all cervical 
cancers (International Agency for Research on Cancer 1995 and 2007; Walboomers et 
al, 1999). In squamous cell carcinoma HPV16 is the most common type followed by 
HPV18, while in adenocarcinomas HPV18 is the most common type detected. 
Approximately 85% of high-grade CIN lesions also contain high-risk HPV DNA; 
HPV16 is again the most common type detected, but HPV18 is significantly under-
represented (Smith et al, 2007). Infection with HPV18 is associated with an increased 
risk of high-grade CIN, but it has been found that there is a lack of moderate or severe 
cytological changes after an incident HPV18 infection, suggesting that the cytological 
changes detected after infection with HPV18 underestimates the severity of the 
underlying histological abnormality (Woodman et al, 2003; Kovacic et al, 2006). This 
may explain why HPV18 is significantly under-represented in high-grade CIN, as 
women will be referred for colposcopic assessment only if the smear shows moderate 
or severe dyskaryosis. The recent finding that HPV18 tends to integrate early, may 
explain the predominance of minor cytological changes following HPV18 infection; 
early integration of HPV18 was associated with decreased viral load, which in turn is 
known to be associated with less severe cytological abnormalities (Collins et al, 
2009). 
 
1.3.4.1 Integration of HPV 
HPV integration occurs in up to 80% of HPV16-positive and 100% of HPV18-
positive carcinomas (Bosch & de Sanjose, 2003). Viral integration usually leads to the 
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disruption of the E1 and/or E2 open reading frames, with subsequent release of the 
repression of E6 and E7 oncogene expression (Romanczuk et al, 1992). Integration is 
not a normal part of the HPV life cycle - it results in the deletions of genes that are 
essential for the viral synthesis – but it provides cells with a selective growth 
advantage (Jeon et al, 1995). These cells also show increased genomic instability 
which can also contribute to malignant progression (Pett et al, 2004).  
 
Integration of high-risk HPV is known to occur near to common fragile sites 
(Thorland et al, 2000; Wentzensen et al, 2004; Yu et al, 2005), and recently it has 
been shown that this is because these regions are permissive sites for insertion of 
foreign DNA, rather than because it confers a selective growth advantage when 
disrupted (Dall et al, 2008). It was also found that although the majority of integration 
events occur in chromosome bands containing a cancer-associated gene, these genes 
were generally a considerable distance from the integration site, and there was no 
evidence of altered expression of selected candidate genes. This suggests that 
insertional mutagenesis is not a common consequence of HPV16 integration (Dall et 
al, 2008). 
 
Persistent viral infection with constitutive expression of the E6 and E7 genes is 
necessary to maintain the malignant phenotype (Hu et al, 1995). However, in vitro, 
the expression of HPV16 E6 and E7 is only sufficient to immortalise human 
keratinocytes (Hawley-Nelson et al, 1989; Münger et al, 1989; Sedman et al, 1991; 
Dürst et al, 1995). In addition, only a small percentage of women infected with high-
risk HPV will progress to invasive disease, and this is usually after a long latency 
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period (zur Hausen, 2002). Thus infection with HPV is necessary but not sufficient for 
the development of cervical cancer and additional alterations are required for 
progression to cervical cancer. One alteration may be HPV-induced methylation of 
cellular genes and this will be discussed in the next section. 
 
1.3.5 In vitro models to study the role of HPV in cervical carcinogenesis 
There are no animal models available for the study of the interaction between HPV 
and cervical cells in the pathogenesis of cervical neoplasia. However, transfection of 
high-risk HPV types into either primary human keratinocytes derived from neonatal 
foreskins or normal human cervical keratinocytes results in immortalised and 
transformed cell lines, providing useful models for studying the molecular biology of 
HPV in normal epithelia of human origin, and the role of HPV in the initiation of 
cervical neoplasia (Woodworth et al, 1988). For example, cDNA and oligonucleotide 
microarrays have been used to examine the global changes in gene expression in both 
primary human ectocervical keratinocytes and primary human foreskin keratinocytes 
after infection with retroviruses expressing the HPV16 E6 and E7 genes (Nees et al, 
2001; Duffy et al, 2003). Using methylation specific-multiplex ligation-dependent 
probe amplification, a number of candidate genes have also been shown to become 
methylated in primary human foreskin keratinocytes following transfection with 
HPV16 and HPV18 (Henken et al, 2007). However, an assessment of the global 
changes in the methylation of cellular genes that follows infection with high-risk HPV 
has not previously been undertaken. 
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W12 
Another in vitro model that has been used to study the role of HPV during progression 
of early disease is the W12 cell line. W12 is a HPV16-positive cervical keratinocyte 
cell line isolated originally from a young woman with low-grade CIN (Stanley et al, 
1989). In these cells the HPV16 genome is stably maintained, predominantly as viral 
episomes, at a high copy number of 100 copies per cell. During long-term in vitro 
cultivation, loss of episomes and emergence of integrated HPV16 occurs, 
accompanied by an increasing atypia and an accumulation of host cytogenetic 
abnormalities that are similar to those seen in cervical neoplasia in vivo (Stanley et al, 
1989; Alazawi et al, 2002). Thus the W12 cell line is considered to be a model of 
progression of HPV16-associated neoplasia.  
 
Integration of HPV16 in the W12 cell line is associated with loss of transcription of 
the HPV16 E2 gene and increased expression of the HPV16 E7 protein. In turn this is 
associated with both a selective growth advantage, compared to cells harbouring 
episomal forms of HPV16 only, and with the acquisition of numerical and structural 
chromosomal instability (Jeon et al, 1995; Pett et al, 2004). The W12 cell line has 
also been used to assess the changes in cervical keratinocyte gene expression 
associated with integration of HPV16 (Alazawi et al, 2002). More recently, studies 
using the W12 cell line have demonstrated that cervical carcinogenesis requires not 
only integration of the high risk HPV genomes, but also the specific loss of inhibitory 
episomes; in cells containing a mixture of integrated and episomal HPV16, the 
expression of E2 from the episomal forms was sufficient to partially inhibit 
transcription from the coexisting integrated HPV16, and full deregulation of E6 and 
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E7 gene expression was not observed until there was complete loss of E2-expressing 
episomes (Pett et al, 2006). The spontaneous loss of episomes was also found to be 
associated with increased expression of antiviral genes that are inducible by type I 
interferon (IFN), and in a subsequent study, exogenous IFN-β treatment of W12 cells 
resulted in a rapid reduction in the numbers of HPV16 episomes, hastening the 
transition from episomal to integrated HPV16 in these keratinocytes (Herdman et al, 
2006; Pett et al, 2006). This latter study therefore provides strong evidence against the 
routine use of type I interferons in the treatment of HPV16-positive cervical lesions.  
 
An assessment of the changes in the methylation of cellular genes during long term in 
vitro cultivation of the W12 cell line has not previously been undertaken. 
 
1.3.6 HPV vaccination 
Because HPV infection is a necessary cause of cervical neoplasia, prophylactic HPV 
vaccination has thus been investigated as a potential approach to reduce the burden of 
cervical cancer and its precursor lesions. In a proof of principle study, over 2000 
young women aged 16-23, were randomised to 3 doses of a HPV16 L1 virus-like-
particle vaccine or placebo (Koutsky et al, 2002). After a median follow-up of 17 
months a decreased incidence of HPV16 infection and HPV16 related CIN lesions 
was observed among women who tested negative for HPV16 at study entry (Koutsky 
et al, 2002). Several randomised clinical trials have since been performed using either 
a bivalent (HPV types 16 and 18) or quadrivalent (HPV types 6, 11, 16 and 18) L1 
virus-like particle vaccine (Harper et al, 2004; Villa et al, 2005; FUTURE II Study 
Group, 2007; Paavonen et al, 2007). In women who were not infected with HPV16 or 
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HPV18, these studies have all demonstrated that vaccination can reduce the incidence 
of HPV16 or HPV18-associated CIN lesions (~95% efficacy). Additionally 
vaccination may also offer cross-protection against non-vaccine oncogenic HPV 
types. The duration of follow-up of these initial studies was only short (2-3 years), 
however it is encouraging that a sustained effect has been observed after longer 
follow-up (5-6 years) (Harper et al, 2006; Villa et al, 2006; Paavonen et al, 2009). 
Based on early reports, the quadrivalent vaccine (Gardasil, Merck and Company) was 
fast-tracked for approval by the FDA in 2006. In 2009, the bivalent vaccine (Cervarix, 
GlaxoSmithKline Biologicals) was also approved by the FDA, following completion 
of the associated phase 3 randomised clinical trial (Paavonen et al, 2009). As these are 
prophylactic vaccines, cervical screening remains important for the detection of and 
treatment of CIN lesions in women who are already HPV positive and also for lesions 
caused by other oncogenic HPV types. 
 
1.4 Smoking and cervical neoplasia 
In 1950, the first large-scale epidemiological studies linking smoking with lung 
cancer were published (Doll & Hill, 1950; Wynder & Graham, 1950). Since that time, 
cigarette smoking has been causally associated with cancer at most organ sites 
(International Agency for Research on Cancer, 2004).  
 
In the cervix, HPV is known to be necessary but not sufficient for the development of 
cervical cancer; cigarette smoking may be one potential co-factor that modulates 
progression to high-grade CIN and invasive disease. Because smoking is strongly 
correlated with various aspects of sexual behaviour, an association between smoking 
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and cervical neoplasia has actually been difficult to prove. However, smoking is now 
known to be an independent risk factor for cervical neoplasia (International 
Collaboration of Epidemiological Studies of Cervical Cancer, 2006b; Collins et al, 
2010). A recent pooled analysis of 23 case-control and longitudinal studies including 
13,541 women with cervical cancer and 23,017 women without cervical cancer 
revealed that current smokers had a significantly increased risk of cervical SCC 
compared to non-smokers (RR=1.60 95% CI: 1.48-1.73), and this risk increased with 
an increasing number of cigarettes smoked per day and with a younger age at smoking 
initiation (International Collaboration of Epidemiological Studies of Cervical Cancer, 
2006b). This risk persisted when the analysis was restricted to women who tested 
positive for HPV DNA. As previously discussed, smoking was not associated with an 
increased risk of adenocarcinoma (International Collaboration of Epidemiological 
Studies of Cervical Cancer 2006a, 2006b). A longitudinal study has also demonstrated 
that smoking is an independent risk factor for CIN; after controlling for HPV status, 
current smokers were twice as likely to be diagnosed with high-grade CIN compared 
with non-smokers (Collins et al, 2010).  
 
Cigarette smoke contains over 60 known carcinogens including the polycyclic 
aromatic hydrocarbons, N-nitrosamines and aromatic amines (Hecht, 2003; 
International Agency for Research on Cancer, 2004). Nicotine is the major addictive 
agent in tobacco but it is not generally considered to be carcinogenic; however with 
every inhalation, more than 60 carcinogens are simultaneously delivered 
(International Agency for Research on Cancer, 2004). The components of tobacco 
smoke can reach the cervical cells via the bloodstream or by diffusion through tissue. 
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Nicotine and its major metabolite cotinine have been detected in the cervical mucus of 
smokers; the mean nicotine levels were, significantly higher in the smokers compared 
to the passive smokers (p=0.0001), and the non-smokers (p=0.0002) (Sasson et al, 
1985; Jones et al, 1991; McCann et al, 1992). In addition, characteristic smoking-
related DNA adducts have also been detected in normal cervical tissue taken from 
smokers, and a highly significant trend was observed when examining specimens 
taken from normal cervices, compared to histologically normal regions of cervices 
with CIN and invasive cancer (Philips & Ni Shé, 1993; Ali et al, 1994). These studies 
support the biological plausibility of the now proven association between tobacco 
smoke exposure and risk of cervical cancer. 
 
However, it has been found that smoking does not increase the risk of acquiring HPV 
infection, and it does not prolong the duration of HPV infection, thus other 
mechanisms must be involved to account for the association of smoking with cervical 
neoplasia (Collins et al, 2010). One possible mechanism may be smoking-induced 
methylation changes, and this will be discussed in more detail in the next section. 
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In this section I discuss methylation changes following exposure to 2 carcinogens, 
HPV and cigarette smoke, particularly in relation to cervical neoplasia. 
 
1.5 Viruses and methylation 
In 1964, the first human tumour virus - Epstein-Barr virus (EBV) - was discovered 
(Epstein et al, 1964). Since that time, it is now known that approximately 15-20% of 
all human cancers are associated with viral infections (Parkin, 2006; McLaughlin-
Drubin & Munger, 2008). Viral infection may result in activation of the host DNA 
methylation machinery; there are two possible reasons for this. On the one hand, 
methylation of the viral genome may be a host defence mechanism to prevent uptake, 
integration and expression of foreign DNA, such as viruses (Doerfler et al, 2001). On 
the other hand, many oncogenic viruses cause persistent infections, and methylation 
of the viral genome may be the masking mechanism which allows the virus to evade 
detection by the immune system (Fernandez & Esteller, 2010). 
 
In addition to methylation of the viral genome, methylation of cellular genes has also 
frequently been reported in association with viral infection (Li et al, 2005; Flanagan, 
2007). The reason for this remains incompletely understood, but it has been proposed 
that the viral-induced activation of the host DNA methylation machinery may, as a 
by-product, also cause methylation of cellular genes (Li et al, 2005).  Recent reports 
that viral oncogenes can activate the DNA methyltransferases and induce methylation 
of tumour suppressor genes provides direct and compelling evidence linking viral 
infection with aberrant methylation of cellular genes (Tsai et al, 2002; Hino et al, 
2009; Lee et al, 2005; Liu et al, 2006; Arora et al, 2008). For example, the EBV 
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oncogene latent membrane protein 1 (LMP1) induces expression of DNMT1, 3A and 
3B, resulting in hypermethylation of the E-cadherin (CDH1) promoter (Tsai et al, 
2002); in EBV-associated gastric cancer, the EBV oncogene latent membrane 2A 
induces phosphorylation of STAT3 which activates DNMT1, leading to methylation 
of the PTEN promoter (Hino et al, 2009); in hepatocellular carcinoma, methylation of 
the CDH1 promoter follows activation of DNMT1 by the hepatitis B virus oncogenic 
X protein (Lee et al, 2005; Liu et al, 2006) or activation of both DNMT1 and 
DNMT3b by the hepatitis C virus Core protein (Arora et al, 2008).  
 
1.5.1 Methylation of the HPV genome 
Methylation of the human papillomavirus type 1a and the cottontail rabbit 
papillomavirus genomes was reported over 25 years ago, providing the first evidence 
that the papillomaviruses could be targeted by cellular DNA methylation (Danos et al, 
1980; Sugawara et al, 1983; Wettstein & Stevens 1983; Burnett & Sleeman, 1984). 
Despite this, methylation of the high risk HPV16 and HPV18 genomes has only 
recently been reported. The HPV genomes do not code for any gene of the DNA 
methylation machinery and must therefore be methylated by the host DNA 
methylation machinery (Fernandez & Esteller, 2010). The current evidence suggests 
that the genomes of HPV16 and HPV18 can both become methylated but in slightly 
different patterns and in different pathological contexts. However, the causes and the 
consequences of methylation of the HPV genome have yet to be determined in detail. 
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1.5.1.1 HPV16 
The early studies reporting methylation of the HPV16 genome were contradictory. 
Badal et al (2003) initially reported methylation of the long control region (LCR) and 
E6 gene in 52% of normal smears, 22% of precursor lesions and only 6.1% of cervical 
cancers examined. Conversely, in subsequent studies, methylation of the HPV16 LCR 
and part of the L1 gene was found to be highest in invasive cancers and lowest in CIN 
lesions (Kalantari et al, 2004; Ding et al, 2009). This discrepancy may reflect the 
differences in technology used; methylation-sensitive enzyme restriction and 
bisulphite modification followed by direct sequencing, 2 techniques with limited 
resolution, were used in the first study, while bisulphite genomic sequencing (BGS) 
and sequencing of individual clones, was used in the later studies. Indeed BGS has 
demonstrated that even in individual samples, mixtures of differentially methylated 
HPV16 genomes are commonly found (Kalantari et al, 2004).  
 
It has also been shown that the methylation status of the HPV16 genome varies with 
the life cycle; in undifferentiated W12 cells, the episomal HPV16 LCR is heavily 
methylated, but upon differentiation the LCR region becomes hypomethylated (Kim 
et al, 2003; Kalantari et al, 2008). The mechanism for such differentiation linked 
methylation and demethylation remains unknown. Interestingly, differentiation does 
not alter the methylation status of HPV16 genomes that are integrated into 
chromosomal DNA, suggesting that the mechanisms regulating the methylation of 
episomal and integrated HPV16 genomes are different (Kalantari et al, 2008).  
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Recently, it has also been demonstrated that methylation of the E2 binding sites in the 
HPV16 LCR can prevent E2 binding (Thain et al, 1996; Kim et al, 2003; 
Bhattacharjee & Sengupta, 2006). Although viral integration will frequently result in 
disruption of the E2 gene and the consequent loss of E2 protein, in malignant lesions, 
both episomal and integrated HPV16 genomes can co-exist, and in some lesions only 
episomal HPV16 genomes are found (Matsukara et al, 1989). Thus, in the setting of 
intact E2 (ie in presence of episomal HPV16), methylation of the E2 binding sites 
provides an alternative mechanism for the loss of repression of E2, which in turn may 
lead to sustained expression of the E6 and E7 oncogenes (Bhattacharjee & Sengupta, 
2006). 
 
1.5.1.2 HPV18 
The pattern of methylation of the HPV18 genome is slightly different. In 
asymptomatic infections and in low grade CIN lesions the HPV18 L1 gene, the LCR 
and the E6 gene are generally unmethylated. In contrast, in all the cervical carcinomas 
investigated, heavy methylation of the L1 gene was seen while the LCR and E6 gene 
remained unmethylated (Badal et al, 2004; Turan et al, 2006). 
 
Hence in carcinomas, heavy methylation of the L1 region is common to both the 
HPV16 and the HPV18 genomes. There are 2 possible reasons for this. Firstly, as the 
high-risk HPV genomes are usually integrated in cervical carcinoma, the high level of 
methylation observed may be part of the genome defence of the host cell against a 
chromosomally integrating virus (Doerfler et al, 2001). Secondly, following 
integration of HPV16 or 18 into the host genome, the L1 gene now lies upstream of 
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the viral LCR and is therefore unlikely to be transcribed, and a lack of transcription is 
also known to trigger de novo methylation of any DNA (Fuks, 2005). In fact, the 
finding of increased methylation of parts of the HPV genome in carcinomas would 
initially appear counterintuitive – methylation is generally a repressive modification 
while continued transcription of the HPV genome is essential for carcinogenesis. 
However, it has now been demonstrated that the transforming process is maintained 
by a single unmethylated HPV genome (Van Tine et al, 2004); consistent with this 
most copies of HPV16 are methylated in CaSki, while no methylation was observed 
in SiHa, which contains one copy of HPV16 (Badal et al, 2003; Kalantari et al, 2004). 
It has also been suggested that L1 may become preferentially methylated during 
carcinogenesis, because its product, the L1 capsid protein is not required during 
carcinogenesis (Kalantari et al, 2010). 
 
The marked difference in the methylation of the L1 gene between asymptomatic and 
low grade CIN lesions compared to carcinomas has led to it being investigated as a 
potential biomarker predictive of progression of both HPV16 and HPV18 infections 
(Turan et al, 2007; Kalantari et al, 2010). 
 
1.5.2 HPV-associated methylation of cellular genes 
Following infection of cervical cells with high-risk HPV types, aberrant methylation 
of tumour suppressor genes may be one factor that modulates progression to invasive 
disease. Cross-sectional studies have revealed that methylation of TSGs varies 
between HPV-positive and -negative vulval cancers, HPV-positive and -negative 
penile cancers and HPV-positive and -negative head and neck cancers (O’Nions et al, 
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2001; Gasco et al, 2002; Dong et al, 2003; Ferreux et al, 2003; Marsit et al, 2006; 
Yanagawa et al, 2008). However these studies are not informative to cervical cancer 
almost all of which are HPV-positive at diagnosis. Although aberrant methylation of a 
number of TSG has been commonly reported in women with CIN and those with 
invasive disease (Table 4.2, Woodman et al, 2007), the contribution of TSG 
methylation to the initiation or progression of cervical neoplasia has not been defined. 
 
HPV-induced upregulation of the DNA methyltransferases has been reported in a few 
studies, and this may contribute to the aberrant methylation of TSG. Gene expression 
profiling has revealed increased DNMT1 expression in organotypic raft cultures of 
human foreskin keratinocytes transfected with HPV18 E6 and E7 genes, and in short 
term primary cervical cancer cultures (HPV16- or HPV18-positive) compared with 
normal cervical keratinocytes cultures (Garner-Hamrick et al, 2004; Santin et al, 
2005). Genome-wide microarray-based comparative genomic hybridisation, followed 
by fine mapping analysis of 20q, has demonstrated increased DNMT3B copy number 
in all four human HPV-immortalised keratinocytes cell lines and in most of the 
cervical cancers analysed, and this was associated with increased mRNA expression 
in 79% of cases (Wilting et al, 2006). In addition, it has also been shown that HPV16 
E7 can bind directly to DNMT1, stabilising the protein and increasing its 
methyltransferase activity (Burgers et al, 2006). So far for HPV, activation of the 
DNA methyltransferases by a HPV oncogene which subsequently induces 
methylation of a tumour suppressor gene has not been demonstrated. Although the 
HPV16 E7 protein has recently been reported to downregulate CDH1 gene 
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expression, through upregulation of DNMT1 activity, this was independent of DNA 
methylation (Laurson et al, 2008). 
 
To determine the spectrum of epigenetic changes associated with HPV infection, I 
have investigated the methylation and transcriptional changes in both primary human 
foreskin keratinocytes following transfection with HPV18, and those which occur 
during long term cultivation of the W12 cell line, a disease progression model.  
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1.6 Smoking-associated methylation changes 
Currently, there is no direct evidence that smoking induces CpG methylation. 
However, such DNA methylation has been observed following exposure to tobacco 
carcinogens in both in vitro and animal studies. For example, in human oesophageal 
squamous epithelial cells (HEEC), methylation of the fragile histidine triad (FHIT) 
gene promoter was observed following short-term exposure to high dose nicotine (100 
μM), in association with de novo expression of DNMT3A (Soma et al, 2006). 
Similarly, in the human lung carcinoma cell line, A549, treatment with cigarette 
smoke extract for 6 days increased methylation of the promoters of 2 TSGs, RASSF1A 
and MGMT (Liu et al, 2007). 
 
Many animal studies have also demonstrated an association between DNA 
methylation and exposure to tobacco carcinogens (Swafford et al, 1997; Belinsky et 
al, 1998; Vuillemenot et al, 2004; Pulling et al, 2004; Watson et al, 2004; Hutt et al, 
2005; Bachman et al, 2006; Vuillemenot et al, 2006). In F344/N rats, a high frequency 
of de novo methylation of CDKN2A was observed in primary lung tumours induced 
following exposure to several carcinogens including cigarette smoke, and the tobacco 
specific carcinogen 4-methylnitrosamino-1-(3-pyridyl)-1-butanone (NNK) (Swafford 
et al, 1997; Belinsky et al, 1998). Similarly, using mice models, aberrant methylation 
of the retinoic acid receptor beta (RARB) gene has been detected in virtually all 
(>85%) primary lung tumours induced by cigarette smoke or NNK, and methylation 
of the death-associated protein kinase (DAPK) gene has been reported in 43% and 
52% of primary lung tumours induced by cigarette smoke or NNK respectively 
(Pulling et al, 2004; Vuillemenot et al, 2004). Methylated forms have also been 
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detected in precursor lesions suggesting that smoking-induced methylation of these 
genes is an early event in lung carcinogenesis (Belinsky et al, 1998; Pulling et al, 
2004; Vuillemenot et al, 2004).  
 
In humans, cross-sectional surveys restricted to patients with cancer have revealed 
that aberrant methylation of TSGs is associated with various aspects of smoking 
exposure (summarised in Table 1.2). However such studies cannot distinguish those 
epigenetic changes which are a consequence of the disease process from those which 
are directly attributable to smoking.  
 
More compelling evidence of smoking-induced epigenetic changes is dependent upon 
demonstrating, in disease-free individuals, that the onset of smoking precedes the 
detection of such changes. To determine the temporal relationship between cigarette 
smoking and the detection of CDKN2A methylation in cervical cytological samples, 
I have used a unique cohort of young women who were recruited soon after they first 
had sexual intercourse.  
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Site of cancer Gene Smoking-related variable Reference 
Bladder 
 
CDKN2A 
 
current and ex-smokers compared with never 
smokers 
Marsit 2007 
 
Bladder RUNX3 smokers compared with non-smokers Wolff 2008 
Cervix CDKN2A current smokers compared with non-smokers  Lea 2004 
Gastric 
 
MLH1 
 
smokers compared with non-smokers, pack-years 
smoked 
Nan 2005 
 
Head &Neck CDH1 pack-years smoked  Hasegawa 2002 
Head & Neck CDKN2A younger age at initiation Hasegawa 2002 
Lung 
 
APC, 
CDKN2A 
ever smokers compared with never smokers 
 
Toyooka 2003 
 
Lung 
 
CDKN2A 
 
smoking history of >20 pack-years compared 
with smoking history <20 pack-years  
Nakata 2006 
 
Lung 
 
CDKN2A, 
ESR1 
smoking history 
 
Suga 2008 
 
Lung CDKN2A former smokers compared with current smokers Jarmalaite 2003 
Lung 
 
CDKN2A 
 
current smokers, pack-years smoked, duration of 
smoking, and inversely with time since quitting 
smoking 
Kim 2001 
  
Lung CDKN2A pack-years smoked, duration Kim 2003 
Lung CDKN2A smokers compared with non-smokers (male) Wu 2005 
Lung 
 
CDKN2A, 
MGMT 
ever smokers compared with never smokers 
 
Liu 2006 
 
Lung 
 
FANCF 
 
former smokers compared to current smokers, 
inversely with number of years smoked 
Marsit 2004 
 
Lung 
 
FHIT 
 
current smokers compared with never smokers, 
pack-years smoked 
Kim 2004 
 
Lung HIC1 current smokers compared with never smokers Eguchi 1997 
Lung 
 
MTHFR 
 
current and ex-smokers compared with never 
smokers 
Vaissiere 2009 
 
Lung RARB ever smokers compared with non-smokers Tomizawa 2004 
Lung RASSF1A duration of smoking Dammann 2005 
Lung RASSF1A younger age at smoking initiation  Kim 2003 
Lung RASSF1A younger age at smoking initiation  Marsit 2005 
Lung 
 
TSLC1 
 
pack-years smoked and number of cigarettes per 
day 
Kikuchi 2006 
 
Oesophageal 
 
FHIT 
 
current smokers compared with non-smokers, 
pack-years smoked 
Lee 2006 
 
Prostate 
 
 
"M-score" 
APC, 
GSTP1, 
MDR1 
current smokers compared with never smokers, 
pack-years smoked 
 
Enokida 2006 
 
 
 
 
Table 1.2 TSG methylation associated with smoking exposure: Studies which report a significant 
positive association between the prevalence of methylated TSG and some aspect of smoking exposure 
in patients with invasive disease. (Note: There are also many studies which have found no significant 
association between the prevalence of methylated TSG and smoking exposure in patients with invasive 
disease (data not shown)). 
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Thesis Aim and Objectives 
2.1 Aim 
 
To assess the contribution of cigarette smoking and human papillomavirus infection to 
the epigenetic modulation of cellular genes in cervical epithelium. 
 
2.2 Objectives 
 
• To investigate the association between smoking status and CDKN2A methylation 
in cervical smears from disease-free women. 
 
o To determine the prevalence and incidence of CDKN2A methylation in 
smokers and never smokers. 
 
o To determine if CDKN2A methylation becomes undetectable following 
smoking cessation. 
 
• To investigate the spectrum of methylation changes associated with human 
papillomavirus (HPV) infection. 
 
o To describe and validate the changes in DNA methylation which follow 
the transfection of primary human foreskin keratinocytes (isolated from a 
single donor) with episomal HPV18, and which follow long term 
cultivation of the W12 disease progression model. 
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o To determine how often changes in DNA methylation observed using 
these models are recapitulated in cervical neoplasia. 
 
o To investigate possible determinants of virus-associated methylation 
changes. 
 
o To describe and validate the transcriptional changes which follow the 
transfection of PHFK (isolated from a single donor) with episomal HPV18 
which follow long-term cultivation of the W12 disease progression model. 
 
o To compare these transcriptional changes with those reported in published 
gene expression arrays using similar in vitro models, and to determine how 
often these changes are recapitulated in cervical neoplasia. 
 
o To examine the relationship between methylation and transcriptional 
changes in these models. 
 
o To investigate possible HPV18-induced ‘epigenetic switching’, using a 
candidate gene approach. 
 
 
 
 
 
 
 
61 
 
Materials and Methods 
 
 
 
 
 
 
Chapter 3 
 
 
MATERIALS AND METHODS 
 
62 
 
Materials and Methods 
 
63 
3.1 Cell culture 
All the cell cultures were incubated at 37°C in 5% CO2. 
 
3.1.1 Cervical cancer cell lines 
The cervical cancer cell lines CaSki (HPV16 positive), SiHa (HPV16 positive), HeLa 
(HPV18 positive) and C33A (HPV negative) were grown in Dulbeccco’s modified 
Eagle’s medium (DMEM) (Sigma-Aldrich) supplemented with 10% foetal bovine 
serum (FBS), 2% L-glutamine and 1% penicillin-streptomycin. The medium was 
changed every 2-3 days. When the cells reached 90% confluence, they were either 
passaged on or harvested. 
 
3.1.2 W12 cell line 
W12 keratinocytes were grown on mitomycin C-treated J2 3T3 fibroblast feeder cells 
in E-medium (Table 3.1) supplemented with 5 ng/ml mouse epidermal growth factor 
(EGF) and 2% L-glutamine, in our laboratory. The medium was changed every 2-3 
days, with fresh mitomcyin C-treated feeder cells added every 5-6 days. When the 
cells reached 80% confluence they were either passaged onto a fresh feeder layer or 
harvested. Prior to harvesting, 2 ml of ethylenediaminetetraacetic acid (EDTA) were 
added per dish to remove the J2 3T3 feeder cells. DNA, RNA and protein has been 
extracted from every passage (P) between P11-P56; I have performed some of the 
extractions.  
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Reagent Volume    
DMEM 300 ml  100x Cocktail:  
F12 medium 160 ml  Adenine (0.18 M) 20 ml 
Penicillin/streptomycin 10 ml  Insulin (5 mg/ml) 20 ml 
100x Cocktail 5 ml  Transferrin (5mg/ml) 20 ml 
Hydrocortisone (0.5 µg/ml) 0.5 ml  Tri-iodothyronine (2x10-8 M) 20 ml 
Cholera Toxin (0.1 nM) 0.5 ml  PBS 120 ml 
FBS 25 ml  Total volume 200ml 
Total volume 500 ml    
 
Table 3.1 Composition of E-medium 
 
3.1.3 Primary human foreskin keratinocytes transfected with HPV18 
Primary human foreskin keratinocytes (PHFK) transfected with HPV18 have 
previously been established in the laboratory of Dr Sally Roberts (Senior Lecturer, our 
Institute) (Wilson et al, 2007). In brief, PHFK have been isolated from the foreskin of 
a single neonatal donor (#1) and were maintained in keratinocyte-SFM growth 
medium (Invitrogen). Prior to transfection, a plasmid containing the wildtype HPV18 
genome was digested with EcoRI to release the HPV18 genomes, and the genomes 
were re-circularised in the presence of T4 DNA ligase. At passage 3 (see Figure 3.1) 
PHFK from donor (#1) were co-transfected with the re-circularised wildtype HPV18 
genome and a plasmid containing a neomycin resistance gene. The transfected cells 
were then selected in G418- and serum containing medium (E-medium) for 8 days. 
The selected clones were pooled (passage 4/2, Figure 3.1) and were grown on 
mitomycin C-treated J2 3T3 fibroblast feeder cells in E-medium. 
 
For the purposes of experiments performed in this thesis, I have taken frozen aliquots 
of cells from untransfected PHFK (passage 4), PHFK transfected with HPV18 at an 
early (passage 4/3) and a later (passage 4/8) (Figure 3.1). The untransfected 
keratinocytes were grown in keratinocyte-SFM growth medium, while PHFK 
transfected with HPV18 were grown on mitomycin C-treated J2 3T3 fibroblast feeder 
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cells in E-medium supplemented with 5 ng/ml EGF and 2% L-glutamine. The 
medium was changed every 2 days. All the cells were cultivated for one passage only, 
and when the cells reached 80% confluence they were harvested, once J2 3T3 feeder 
cells had been removed with EDTA treatment. DNA, RNA and protein extractions 
were performed immediately. 
 
3.1.4 J2 3T3 feeder cells 
J2 3T3 fibroblast feeder cells were grown in DMEM supplemented with 10% bovine 
serum. When the cells reached 80% confluence they were either passaged on or 
harvested for mitomycin C treatment.  
 
3.1.4.1 Mitomycin C treatment 
The medium was first removed from each dish and the cells washed with 10 ml 
phosphate-buffered saline (PBS). Five ml of DMEM supplemented with 5% bovine 
serum were then added per dish. One hundred μl of mitomycin C (0.4 mg/ml) (Roche) 
were then added and the cells were incubated for 2-4 hours at 37°C; the medium was 
mixed at 30 minutes intervals. Following mitomycin C treatment the medium was 
removed and the cells were washed 3 times with 10 ml PBS. The cells were then 
incubated with 1 ml of trypsin-EDTA at 37°C for 3-5 minutes. Once the cells were 
separated from the dish, the trypsin was neutralised with 1 ml of E-medium and all the 
suspended cells were transferred to a universal container. Ten μl of the cell 
suspension were removed for cell counting (section 3.1.6). The suspended cells were 
centrifuged at 1000 rpm for 5 minutes to pellet the cells, and then re-suspended in 1ml 
of E-medium for every 1.5 x 106 cells. 1 ml of re-suspended cells (1.5 x 106 cells) was 
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then added drop wise to each new culture dish containing 10 ml of E-medium. The 
mitomycin C treated J2 3T3 feeder cells were incubated at 37°C for at least one hour 
before keratinocytes were added. 
 
3.1.5 Cultivation of cell lines 
Once the cells reached 80-90% confluence, the medium was removed and the 
adherent cells were washed with 10 ml of PBS. Two-three ml of trypsin-EDTA were 
added and the cells were incubated at 37°C for 3-5 minutes. Once the cells were 
separated from the dish, the trypsin was rapidly neutralised using an equal volume of 
serum-containing medium and all the suspended cells were transferred to a universal 
container. The suspended cells were centrifuged at 1500 rpm for 5 minutes to pellet 
the cells, and then re-suspended in fresh medium. Cells were then plated out onto new 
culture dishes in a total volume of 10ml, for further cultivation. 
 
3.1.6 Cell counting 
Ten μl of cell suspension were introduced into a counting chamber containing 10 
large squares. Light microscopy was used to count the number of cells in 5 large 
squares, which was then divided by 5 to give the average number of cells x 104 per 
ml. The average number of cells per ml was then multiplied by the total volume the 
cells were suspended in to provide the total number of cells present. 
 
3.1.7 Harvesting of cell lines 
Once the cells reached 80-90% confluence, the medium was removed and the 
adherent cells were washed with 10 ml of PBS. Two-three ml of trypsin-EDTA were 
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added and the cells were incubated at 37°C for 3-5 minutes. Once the cells were 
separated from the dish, the trypsin was rapidly neutralised using an equal volume of 
serum-containing medium and all the suspended cells were transferred to a universal 
container. Ten μl of the cell suspension were removed for cell counting (section 
3.1.6). The suspended cells were centrifuged at 1500 rpm for 5 minutes to pellet the 
cells. Ten ml of PBS were added to wash the cells, and the cells were centrifuged at 
1500 rpm for a further 5 minutes. This was repeated twice. The cells were then re-
suspended in PBS and divided into 3 aliquots for DNA, RNA and protein extraction.  
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Figure 3.1 Transfection of primary human foreskin keratinocytes with HPV18. PHFK were isolated from a single neonatal donor. At passage 3, PHFK 
were either co-transfected with re-circularised wildtype HPV18 and a plasmid containing a neomycin resistance gene and grown on J2 3T3 fibroblast feeder 
cells, or maintained in culture as untransfected cells again on J2 3T3 feeder cells. Following transfection with HPV18, the cells underwent G418 selection and 
the selected cells were then pooled at passage 4/2. DNA, RNA and protein were extracted from the 3 passages highlighted in green. 
 
PHFK from donor #1 
P1 
P2 
P3 
P4 
P5 
 
 P4/9
Transfection with HPV18 and pcDNA G418 resistance 
P4/1 
P4/2 
P4/4
P4/3
G418 selection process 
Untransfected
Pooling of selected clones All cells 
grown on J2 
3T3 cells 
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3.2 In vivo model (Longitudinal cohort) 
Cytological samples are available from a completed prospective cohort study that was 
conducted to determine the natural history of early cervical neoplasia in young 
women (Woodman et al, 2001). 
 
3.2.1 Study population 
2,011 women aged 15 to 19 years were recruited from a single family planning clinic 
(a Brook Advisory Centre) in Birmingham, United Kingdom, between 1988 and 1992. 
Women were asked to re-attend at intervals of six months: follow-up ended on 31st 
August 1997. The study was approved by the appropriate ethical committee. 
 
At recruitment, a standardised interview questionnaire was used to construct a 
detailed social, sexual, and behavioural risk-factor profile, including smoking. Sexual 
and smoking histories were updated at each follow-up visit. In addition, at each visit 
two cytological samples were taken using the same Ayres spatula: the first was used 
to prepare a smear for cytological evaluation; the second was placed into 10 ml of 
PBS and stored at -80°C for subsequent virological examination.  
 
All women in whom a cytological abnormality was identified were immediately 
referred to a dedicated research clinic for histological examination, irrespective of the 
severity of that abnormality. Colposcopic and cytological surveillance were 
maintained in these women and treatment postponed until there was histological 
evidence of high-grade CIN (CIN2 or CIN3), at which point women left the study.  
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3.2.2 Analysis of HPV DNA 
After all clinical follow-up had ended, cervical samples have been tested for the 
presence of HPV DNA using a general primer (GP5+/GP6+) mediated polymerase 
chain reaction (PCR) and further PCR tests have been performed with type-specific 
primers on samples that were HPV positive (Woodman et al, 2001). 
 
3.2.3 Smoking history 
Smoking quantity was recorded as a categorical variable, with categories 0 cigarettes 
smoked per day, 1-9, 10-19, 20-29, 30-39, and 40 or more. Cumulative smoking 
exposure was measured using pack-years, estimated as the midpoint of each smoking 
category (with the final category set to 45), multiplied by the length of the interval 
during which this quantity applied, and accumulated over the lifetime of the woman. 
 
3.2.4 Analysis of smoking and CDKN2A methylation 
The study populations for all analyses performed in this thesis comprise subsets of the 
1,075 women who were cytologically normal and tested negative for HPV DNA in 
the cervical smear taken at study entry (incident cohort). Three analyses were 
performed (Chapter 4): 
 
• For the analysis comparing the prevalence of CDKN2A methylation in smokers 
with that in never-smokers, the study population was restricted to women who had 
normal cervical smears, and who tested negative for HPV DNA of any type in 
cervical samples, throughout follow-up.  
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• For the analysis comparing the risk of CDKN2A methylation in incident smokers 
with that in never-smokers, all women who began to smoke during follow-up were 
potentially available for inclusion, but only follow-up time prior to the first 
detection of HPV DNA of any type, or of cytological abnormality, in cervical 
samples, was included. 
 
• For the analysis examining the time to disappearance of methylated forms of 
CDKN2A in ex-smokers, all women who quit smoking during follow-up were 
potentially available for inclusion, but only follow-up time prior to the first 
detection of HPV DNA of any type, or of cytological abnormality, in cervical 
samples, was included.  
 
3.3 DNA ANALYSIS 
 
3.3.1 DNA extraction 
DNA was isolated from cell lines and cervical samples.  
 
3.3.1.1 Lysis 
Four hundred μl of freshly prepared lysis buffer (40 µl 10x PCR buffer, 2 µl Tween 
20, 358 μl nuclease-free water and 13 μl of proteinase K) were added to each sample. 
Each sample was vortexed and incubated overnight at 55°C. Phenol-chloroform 
extraction was then performed. 
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3.3.1.2 Phenol-chloroform extraction 
To remove the protein, an equal volume of phenol (400 μl) was added to each sample, 
vortexed and centrifuged at 13,000 rpm for 5 minutes. The supernatant was then 
transferred to a fresh tube, avoiding aspiration of the interlayer and the organic phase, 
and one volume (400 μl) each of phenol and chloroform was added. The sample was 
again vortexed and then centrifuged at 13,000 rpm for 5 minutes. The supernatant was 
then transferred to a fresh tube, again avoiding aspiration of the interlayer and the 
organic phase, and one volume of chloroform (400 μl) was added, to remove phenol. 
The sample was vortexed and centrifuged again at 13,000 rpm for 5 minutes. The 
supernatant was then transferred to a fresh tube, again avoiding aspiration of the 
interlayer and the organic phase. Two-and-a half volumes of 100% ethanol (1000 μl), 
0.1 volume of 3M sodium acetate (40 μl) and 1 μl of glycogen were added, and the 
sample was vortexed and then precipitated at -80°C overnight. 
 
3.3.1.3 Clean up 
The precipitated sample was centrifuged at 13,000 rpm at 0°C for 30 minutes. The 
supernatant was discarded and 1000 μl of cold 70% ethanol were added, and the 
sample was centrifuged at 13,000 rpm at 4°C for 30 minutes. The supernatant was 
again discarded and 500 μl of 70% ethanol were added, and the sample was 
centrifuged at 13,000 rpm at 4°C for 10 minutes. The pellet was allowed to air-dry at 
room temperature for 30 minutes and then re-suspended in 50 μl of nuclease-free 
water. Extracted DNA samples were then stored at -20°C until use. 
 
 
72 
 
Materials and Methods 
The NanoDrop ND-100 Spectrophotometer (Thermo Scientific) was used to measure 
DNA concentration, according to the manufacturer’s instructions.  
 
3.3.2 Bisulphite modification 
Genomic DNA was modified by treatment with sodium bisulphite. In this reaction, all 
unmethylated cytosines will be converted to uracil, while methylated cytosines will be 
resistant to this modification (Wang et al, 1980). The methylated cytosines can then 
be detected using techniques such as methylation specific polymerase chain reaction 
(MSP), and bisulphite genomic sequencing (BGS). 
 
3.3.2.1 Bisulphite modification (cell lines – traditional method) 
Ten micrograms of cell line DNA in a volume of 10 μl were denatured by adding 1 μl 
of freshly prepared 3M sodium hydroxide, and incubating at 37°C for 15 minutes. 
Five hundred μl of freshly prepared 3.12M sodium bisuphite/5mM hydroquinone (pH 
5.0) were added to the denatured DNA and the samples were placed in a thermocycler 
for 20 cycles of 99°C for 15 seconds and 50°C for 15 minutes. Bisulphite modified 
DNA was then purified using the Wizard DNA Clean-up System (Promega), 
according to the manufacturer’s protocol and eluted using 50 μl of nuclease-free 
water. Five μl of freshly prepared 3M sodium hydroxide were added for 
desulphonation and the mixture was incubated at room temperature for 10 minutes. 
Two-and-a half volumes of 100% ethanol (125 μl), 0.1 volume of 3M sodium acetate 
(5 μl) and 1 μl of glycogen were added, the sample was vortexed and precipitated at -
80°C for at least 1 hour. 
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The precipitated bisulphite modified DNA was centrifuged at 13,000 rpm at 4°C for 
30 minutes. The supernatant was discarded and 1000 μl of cold 70% ethanol were 
added, and the sample was centrifuged at 13,000 rpm at 4°C for 5 minutes. The 
supernatant was discarded and the pellet was allowed to air-dry at room temperature 
for 30 minutes and then re-suspended in 50 μl of nuclease-free water. Bisulphite 
modified DNA samples were stored at -20°C until use. 
 
3.3.2.2 Bisulphite modification using the EZ DNA Methylation-Gold KitTM 
The EZ DNA Methylation Gold KitTM (Zymo Research) allows bisulphite 
modification to be completed in less than 3 hours. The kit has also been designed to 
minimise template degradation, loss of DNA during treatment and clean-up, and to 
provide complete conversion of unmethylated cytosines; all of which are potential 
limitations of standard bisulphite modification. In addition the kit is designed to 
bisulphite modify much smaller quantities of DNA from 500 pg to 2 μg, with the 
optimal amount of DNA being 200-500 ng. This is an important consideration with 
our cervical samples where the total amount of DNA extracted was small 
 
Cervical samples 
Two hundred nanograms of DNA isolated from each cervical cytological sample were 
subjected to bisulphite modification using the EZ DNA Methylation-Gold KitTM 
according to the manufacturer’s protocol. The converted DNA was eluted in a final 
volume of 50 μl and stored at -20°C until use. 
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Cell Lines 
Five hundred nanograms of DNA isolated from each cell line were subjected to 
bisulphite modification using the EZ DNA Methylation-Gold KitTM according to the 
manufacturer’s protocol. The converted DNA was eluted in a final volume of 50 μl 
and stored at -20°C until use. 
 
3.3.3 Methylation specific PCR 
Methylation specific PCR (MSP) is a sensitive and specific PCR-based technique 
which can detect the methylation of a block of CpG sites. It takes advantage of the 
sequence differences following bisulphite modification, using primers designed to 
recognise methylated or unmethylated DNA in a bisulphite modified sample (Herman 
et al, 1996). The sensitivity of MSP has been reported to be 1:1000; 0.1% of 
methylated DNA can be detected in an otherwise unmethylated sample (Herman et al, 
1996). 
  
Five μl of bisulphite modified DNA solution (section 3.3.2.1) were amplified in a 25 
μl volume using 12.5 μl of GoTaq Green Master Mix (Promega) and 0.6 μmol/L 
primer mix. Each sample was amplified using primers that recognise methylated 
DNA, and primers that recognise unmethylated DNA, in parallel. Amplification was 
performed using a Px2 Thermal Cycler (Thermo Scientific) and the following cycle 
conditions: 95ºC for 5 minutes, followed by 40 cycles of 95ºC for 45 seconds, 
annealing temperature for 1 minute, 72ºC for 2 minutes, and a final extension of 72ºC 
for 10 minutes. Table 3.2 lists the primer sequences and the corresponding annealing 
temperatures used. CpGenome Universal methylated and unmethylated DNA 
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(Millipore) were used as positive controls of the methylated and unmethylated 
reactions, respectively. Unmodified DNA was used as a negative control of the 
completeness of bisulphite modification. Water was used as a template-free control. 
All the PCR products were analysed using 2% agarose gel electrophoresis and 
ethidium bromide staining (section 3.3.5). 
 
Name Primer sequence 5'-3' 
Product 
size (bp) 
Annealing 
temperature (°C) 
CDKN2A MF TTATTAGAGGGTGGGGCGGATCGC 
CDKN2A MR GACCCCGAACCGCGACCGTAA 
150 62 
CDKN2A UF TTATTAGAGGGTGGGGTGGATTGT 
CDKN2A UR CAACCCCAAACCACAACCATAA 
151 62 
DAPK1 MF GGATAGTCGGATCGAGTTAACGTC 
DAPK1 MR CCCTCCCAAACGCCGA 
99 60 
DAPK1 UF GGAGGATAGTTGGATTGAGTTAATGTT 
DAPK1 UR CAAATCCCTCCCAAACACCAA 
106 60 
 
Table 3.2 Primer sequences used for MSP analysis. 
 
3.3.3.1 Designing primers for MSP 
The Methprimer primer design program was used to design primers for MSP 
(http://www.urogene.org/methprimer/index1.html). The UCSC genome browser 
website (http://genome.ucsc.edu/index.html) was used to obtain the genomic sequence 
of the gene of interest; the upstream genomic sequence (by 1000 base pairs, bp) and 
the first exon were selected and copied into the Methprimer design program. The 
options ‘pick MSP primers’ and ‘use CpG island prediction’ were selected and the 
following parameters for primer design were used: product size 100-300 bp, primer 
annealing temperature 55-60°C, primer size between 15-30 bp. A pair of methylated 
and unmethylated primers was selected with annealing temperatures within 1-2°C of 
each other. Primers were ordered from Alta Bioscience, UK. 
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3.3.4 Nested MSP 
Nested methylation-specific PCR (MSP) is a 2-stage PCR approach that has been 
reported to have a 50-fold improved sensitivity to detect methylated alleles compared 
to standard MSP; one methylated allele can be detected among 50,000 unmethylated 
alleles (Palmisano et al, 2000). The stage 1 primers recognise the bisulphite-modified 
template but do not discriminate between methylated and unmethylated alleles; the 
stage 2 primers are standard MSP primers. Nested MSP allows the investigation of 
low numbers of cells without needing to use excess PCR cycles (which can generate 
false positive results). Nested MSP was thus used to detect methylated forms of the 
CDKN2A gene in cervical cytological samples. Table 3.3 lists the primer sequences 
and the corresponding annealing temperatures used. 
 
Name Primer sequence 5'-3' 
Product 
size (bp) 
Annealing 
temperature (°C) 
CDKN2A Ext F GAAGAAAGAGGAGGGGTTGG 
CDKN2A Ext R CTACAAACCCTCTACCCACC 
273bp 56 
CDKN2A MF TTATTAGAGGGTGGGGCGGATCGC 
CDKN2A MR GACCCCGAACCGCGACCGTAA 
150bp See Table 3.2 
CDKN2A UF TTATTAGAGGGTGGGGTGGATTGT 
CDKN2A UR CAACCCCAAACCACAACCATAA 
151bp 62 
DAPK1 Ext F GAGGAGGATAGTYGGATYGAGTTAA 
DAPK1 Ext R ACRAAAACACAACTAAAAAATAAATAAAAAAC 
141bp 56 
DAPK1 MF GGATAGTCGGATCGAGTTAACGTC 
DAPK1 MR CCCTCCCAAACGCCGA 
99bp See Table 3.2 
DAPK1 UF GGAGGATAGTTGGATTGAGTTAATGTT 
DAPK1 UR CAAATCCCTCCCAAACACCAA 
106bp 60 
 
Table 3.3 Primer sequences used for nested MSP analysis. 
 
3.3.4.1 Stage 1 PCR 
Five μl of bisulphite-modified DNA solution were amplified in a 25 μl volume using 
12.5 μl of GoTaq Green Master Mix (Promega), and 0.6 μmol/L of primer mix. 
Amplification was performed using a Px2 Thermal Cycler and the following cycle 
conditions: 95ºC for 10 min, followed by 40 cycles of 95ºC for 30 seconds, annealing 
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temperature for 30 seconds, 72ºC for 30 seconds, and a final extension of 72ºC for 10 
minutes.  
 
3.3.4.2 Stage 2 PCR 
The stage 2 PCR was performed on 5 μl of diluted stage 1 PCR product using primers 
specific for methylated and unmethylated template. Amplification was performed in a 
25 μl volume, using 12.5 μl of GoTaq Green Master Mix and 0.6 μmol/L of primer 
mix. Amplifications were performed as in section 3.3.4.1 but all cycling times were 
reduced to 15 seconds. All stage 2 amplifications were performed in duplicate. 
CpGenome Universal methylated and unmethylated DNA (Millipore) were used as 
positive controls of the methylated and unmethylated reactions, respectively. Water 
was used as a template-free control. Stage 2 PCR products were analysed using 2% 
agarose gel electrophoresis and ethidium bromide staining (section 3.3.5). 
 
3.3.4.3 Optimising nested MSP 
Prior to performing nested MSP in cervical cytological samples from our in vivo 
model, nested MSP was repeated using a series of different PCR conditions in order to 
optimise the sensitivity and specificity of this method:  
 
a) Increasing the number of PCR cycles. The sensitivity of the technique will 
increase with the number of PCR cycles used in the nested MSP reaction. 
However false positives can arise when a high number of PCR cycles are utilised 
due to 2 reasons. Firstly, mispriming of the methylation specific primers can lead 
to false positive results either from mispriming in the same region but with just a 
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C/T mismatch, or in a different region with some areas of similarity to the primer 
sequence. Secondly, if there is a low level of methylation in the “normal” 
counterparts of a mixed cell population, this will amplify up with a high number 
of PCR cycles, but the positive result is not actually arising from the “abnormal” 
counterpart. This is particularly a problem if a large amount of DNA is taken into 
the stage 2 PCR step. Thus to maintain a high sensitivity but to minimise the 
occurrence of false positives two further adjustments were made: 
 
b) Increasing the annealing temperature of the methylated primer in the stage 2 
PCR.  Mispriming can occur more readily at lower annealing temperatures. By 
increasing the annealing temperature for the methylated primer, this will ensure 
the highest specificity of amplification of only methylated alleles in the sample.  
 
c) Diluting the stage 1 PCR product. False positives can occur more readily if too 
much template is taken forward to the stage 2 PCR. The stage 1 PCR product was 
thus diluted 1:50 and 5 μl of this was used in the stage 2 PCR.  
 
3.3.5 Agarose gel electrophoresis 
Agarose gel electrophoresis is a technique used to separate DNA and RNA molecules 
based on their size. DNA and RNA are negatively charged molecules and will migrate 
towards the cathode when an electrical current is applied. Shorter molecules will 
migrate more easily through the pores in the agarose gel compared to longer 
molecules. Adjusting the concentration of the agarose gel enables visualisation of 
molecules of varying sizes, for example, increasing the concentration of the agarose 
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gel will reduce the migration speed and enables separation of smaller DNA molecules. 
Ethidium bromide is commonly added to the agarose gel; this intercalates double-
stranded DNA and RNA, fluoresces under ultraviolet (UV) light and thus enables the 
separated nucleic acids to be visualised. 
 
Agarose powder was dissolved in 1x Tris-Borate-EDTA (TBE) buffer (Sigma) by 
heating in a microwave oven on high power for 2-3 minutes. A 2% gel (for example, 
2 g of agarose in 100 ml of TBE) was used to analyse DNA fragments below 1 kb in 
length. Ethidium bromide was added for a final concentration of 0.5 μg/ml, and the 
solution was poured into a gel tray and allowed to set. A suitable comb was inserted 
before setting. For the electrophoresis, the agarose gel was placed into an 
electrophoresis tank which was filled with 1x TBE buffer. Loading buffer (30% 
glycerol, 0.25% bromphemol blue) was mixed with every sample (1:5 dilution); a 
molecular weight marker (100 bp DNA ladder, Promega) was loaded into the first 
well and the PCR samples were loaded into the remaining wells. An electric voltage 
of 100V was applied and once separated the nucleic acids were visualised under UV 
light using a transilluminator (Bio-Rad). 
 
3.3.6 Bisulphite genomic sequencing 
Bisulphite genomic sequencing (BGS) involves amplification of bisulphite modified 
DNA followed by cloning of the amplified fragments then sequencing analysis of 
individual clones, and this provides detailed information of the methylation status of 
all the CpG sites within an amplified region (Frommer et al, 1992). 
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3.3.6.1 PCR amplification 
Five µl of bisulphite modified DNA were amplified in a 25 μl volume using 12.5 μl of 
PCR Master Mix (Promega) and 0.6 μmol/L primer mix. The primers for BGS were 
designed to recognise the bisulphite-modified template but did not discriminate 
between methylated and unmethylated alleles ie there were no CpG sites located in 
the primer sequence. Amplification was performed using a Px2 Thermal Cycler and 
the following cycle conditions: 95ºC for 10 minutes, followed by 40 cycles of 95ºC 
for 1 minute, annealing temperature for 45 seconds, 72ºC for 2 minutes, and a final 
extension of 72ºC for 10 minutes. Five µl of the PCR product were analysed using 2% 
agarose gel electrophoresis and ethidium bromide staining (section 3.3.5). If a single 
band of the expected size was confirmed, the remaining PCR product (20 µl) was 
purified using the QIAquick PCR Purification Kit (Qiagen) according to the 
manufacturer’s protocol. The purified PCR product was eluted in 50 µl of EB buffer. 
 
 
Name 
 
Primer sequence 5’-3’ 
Product 
size 
Annealing 
temperature 
SOCS3 BGSF GTTTAAGGGATTTAGGAGATTTTTGTTT 339bp 60°C 
SOCS3 BGSR CAAATACAACCACCAACAATAACAAC   
MARK1 BGSF AAGTGTGAGGAAGTTATTTGGAAGAG 331bp 60°C 
MARK1 BGSR TCAAAATCACCCTCAAAATTTAACA   
RARB BGSF TTAGATTAGTTGGGTTATTTGAAGGTTAGT 451bp 60°C 
RARB BGSR AAATAATAATCTCTTTCCCAACCCC   
WT1 BGSF AGTGGTTATGATTTTGGGGTTATT 250bp 60°C 
WT1 BGSR AAAAAATTAAATATTCCTCACTAAAAAAAA   
CDKN2A BGSF TTGTGGTTTTATTTTTTTAATTAGGTTATT 463bp 60°C 
CDKN2A BGSR CCTTCCTCCTTTTCCAACTAAAA   
ATM BGSF GTTTTTTATTGTGGTTTTTGTTGTG 147bp 60°C 
ATM BGSR AAAACCTTTAACCTCAAAAATCCTT   
CDH13 BGSF AAGGGAGGTTAGAGAAATTGGATAG 331bp 60°C 
CDH13 BGSR ACTTAACAACAAAAACACAAATATAAATCA   
ROBO3 BGSF TGTGTGTTTATGTGTGGGGTATATTA 283bp 60°C 
ROBO3 BGSR ACCTCCTAAAAATCTAAAAAAATCAAAA   
 
Table 3.4 Primer sequences used for bisulphite genomic sequencing 
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3.3.6.2 Cloning 
Cloning of the PCR products was performed using the pGem T Easy Vector system II 
(Promega), according to the manufacturer’s protocol. To analyse the transformants, 10 
white colonies were selected and each one amplified in a 25 µl volume using 12.5 μl 
of PCR Master Mix (Promega) and 0.6 μmol/L M13 primer mix. Amplification was 
performed as in section 3.3.6.1 but for 30 cycles only. Five µl of the PCR product 
were analysed using 2% agarose gel electrophoresis and ethidium, bromide staining 
(section 3.3.5). If a single band of the expected size was confirmed, the remaining 
PCR product (20 µl) was purified using the QIAquick PCR Purification Kit (Qiagen) 
according to the manufacturer’s protocol, prior to sequencing. 
 
3.3.6.3 Sequencing 
Only clones with the correct insert were selected for sequencing. The sequencing 
reaction was performed in a 20 µl volume and included 10 ng of purified PCR 
product, 3.2 pmol of M13 primer (forward or reverse), 1.5 µl BigDye® Terminator 
v3.1 Ready Reaction Mix (Applied Biosystems), and 3.5 µl Sequencing Buffer 
(Applied Biosystems). Cycle sequencing was performed using the following cycle 
conditions: Rapid thermal ramp (1°C per second) to 96°C, then 96°C for 1 minute, 
followed by 25 cycles of rapid thermal ramp to 96°C, 96°C for 10 seconds, rapid 
thermal ramp to 50°C, 50°C for 5 seconds, rapid thermal ramp to 60°C and 60°C for 4 
minutes. The extension products were then purified using ethanol/EDTA 
precipitation: One µl of 0.5M EDTA and 64 µl of 95% ethanol were added to each 
reaction, and incubated at room temperature for 15 minutes, followed by 
centrifugation at 13,000 rpm for 20 minutes. The supernatant was discarded and 250 
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µl of 70% ethanol were added, followed by centrifugation at 13,000 rpm for 10 
minutes. The supernatant was again discarded and the pellet was allowed to air-dry at 
37°C for 20 minutes. Ten µl of Hi-Di™ Formamide (Applied Biosystems) were 
added to re-suspend the DNA. The samples were denatured at 100°C for 5 minutes, 
and then immediately placed on ice, prior to loading onto a 96-well plate. Automated 
sequencing was performed using the ABI 3100 prismTM capillary sequencer (Applied 
Biosystems), according to the manufacturer’s protocol. Following sequencing, the 
extracted data files were analysed using the ABI sequencing analysis program 
(version 3.6.1). 
 
3.3.7 Gel band extraction and direct sequencing 
A subset of methylated products visualised using 2% agarose gel electrophoresis and 
ethidium bromide staining were excised from the gel using the GFX PCR DNA and 
Gel Band Purification Kit (Amersham), according to the manufacturer’s protocol. Ten 
ng of the purified PCR product were then sequenced directly. The sequencing reaction 
was performed as described in section 3.3.6.3 but the reverse primer of the gene of 
interest was used instead of the M13 primer. The remainder of the purification and 
sequencing steps were performed as described in section 3.3.6.3. 
 
3.3.8 Pyrosequencing methylation analysis 
Pyrosequencing is a sequencing-by-synthesis method based on the luminometric 
detection of pyrophosphate release during nucleotide incorporation (Ronaghi et al, 
1998). The DNA fragment of interest is firstly immobilised onto a solid support and 
converted into single-stranded form. A sequencing primer is hybridised onto the 
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single-stranded DNA and incubated with 4 enzymes, DNA polymerase, ATP 
sulphurylase, firefly luciferase and apyrase (a nucleotide-degrading enzyme). 
Repeated cycles of deoxynucleotide addition are performed. A deoxynucleotide will 
only be incorporated into the growing DNA strand if it’s base is complimentary to the 
base on the template strand. The release of inorganic pyrophosphate during DNA 
synthesis is detected by ATP sulphurylase and luciferase in a coupled reaction; the 
inorganic pyrophosphate is converted to ATP by ATP sulphurylase, and the amount of 
ATP is then determined by the luciferase assay. The amount of light generated by the 
luciferase-catalysed reaction is proportional to the number of pyrophosphate 
molecules released, and can be detected using a suitable light-sensitive device such as 
a luminometer. Unincorporated deoxynucleotides and the produced ATP are degraded 
between each cycle by apyrase. 
 
The technology has been applied to genotyping and haplotyping of single nucleotide 
polymorphisms and microbial typing. More recently it has been extensively used to 
assess DNA methylation. Pyrosequencing methylation analysis (PMA) offers the 
following advantages. It is a high-throughput, quantitative method which allows for 
the simultaneous examination of up to 25 CpG sites. It also provides an inbuilt 
internal control for the adequacy of bisulphite modification, and its reproducibility is 
reported to be close to 100%. (Colella et al, 2003; Tost et al, 2003). 
 
3.3.8.1 Designing primers for pyrosequencing 
The PSQ Assay Design software v1.0 (Qiagen) was used to design primers for 
pyrosequencing. The genomic sequence of the gene of interest was obtained from the 
 
84 
 
Materials and Methods 
UCSC genome browser website (http://genome.ucsc.edu/index.html), and the 
sequence was then bisulphite modified in silico: CG dinculeotides were converted to 
YG, and the remaining cytosines (C) bases were then converted to thymidine (T). This 
modified sequence was then copied into the PSQ Assay Design software. Primers 
were designed using the “allele quantification” assay type setting and the following 
parameters: product size 50-200 bp, primer annealing temperature 55-60°C and 
primer size between 18-24 bp. For each gene 3 primers were generated; a biotinylated 
forward primer, a non-biotinylated reverse primer (or vice versa) and a sequencing 
primer. In order to enable the quantitative detection of the level of methylation in a 
given sample, pyrosequencing primers were designed to avoid CpG sites. If this was 
not possible in the region of interest then a maximum of 2 “Y” or “R” wobble bases 
were allowed in the primer sequence. Primers were ordered from Biomers.net.  
 
3.3.8.2 Pyrosequencing PCR 
For pyrosequencing analysis, all bisulphite modifications were performed using the 
EZ DNA Methylation Gold KitTM (Zymo Research) (see section 3.3.2.2). Five μl of 
bisulphite modified DNA were amplified in a 50 μl volume using 25 μl of 2x Thermo-
Start® High Performance PCR Master Mix (ABgene), 10 pmol non-biotinylated 
primer, and 5 pmol biotinylated primer. Amplifications were performed using a Px2 
Thermal Cycler and the following cycle conditions: 95ºC for 15 minutes, followed by 
50 cycles of 95ºC for 30 seconds, annealing temperature for 45 seconds, 72ºC for 30 
seconds, and a final extension of 72ºC for 10 minutes. Ten µl of the PCR product 
were analysed using 2% agarose gel electrophoresis and ethidium bromide staining 
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(section 3.3.5). If a single band of the expected size was confirmed, the remaining 
PCR product (40 µl) was taken forward for pyrosequencing. 
 
3.3.8.3 Pyrosequencing 
Forty μl of PCR product were used for each sequencing reaction. The PCR products 
were loaded into 96 well plates, and purification using Streptavidin Sepaharose beads 
(Amersham) followed by co-denaturation of the biotinylated PCR product with the 
sequencing primer (15 pmol/reaction) were performed using the PyroMark Q96 
Vacuum Prep Workstation (Qiagen), according to the manufacturer’s protocol. 
Pyrosequencing was then performed using PyroGold SQA reagents (Qiagen) on the 
PyroMark™Q96 ID system (Qiagen), according to the manufacturer’s protocol. 
Following pyrosequencing, data were analysed using the Pyro Q-CpG software 
(Qiagen). 
 
3.3.9 Differential methylation hybridisation 
Differential methylation hybridisation (DMH) is an array-based method that enables 
genome-wide assessments of changes in DNA methylation patterns (Huang et al, 
1999). The technique uses a methylation-sensitive restriction endonuclease to identify 
differentially methylated DNA present in a test sample compared to the reference 
sample. 
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Figure 3.2 Differential methylation hybridisation. Schematic flowchart for the preparation of 
fluorescent labelled amplicons (see text for details, adapted from Yan et al, 2001). 
Cut with MseI
Ligate linker primers
Divide into 2 equal aliquots
Test sample Reference sample
McrBC cut McrBC mock-cut
No product
Linker-PCR
Label Cy5 Label Cy3
Co-hybridise both samples to microarray
Genomic DNA
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3.3.9.1 Preparation of fluorescently labelled targets (Figure 3.2) 
Fluorescently labelled targets were first prepared. 
 
3.3.9.1.1 MseI restriction 
Firstly, 2 μg of genomic DNA were digested with the restriction enzyme MseI (New 
England Biolabs). This endonuclease restricts genomic DNA into small fragments 
(<200 bp), but its recognition sequence TTAA rarely occurs within GC-rich regions, 
leaving most CpG islands intact following digestion (Huang 1999). The digestion mix 
included 5 μl 10x NE Buffer 2, 5 μl MseI (10 U/μl) and water to a total volume of 50 
μl. The digestion was allowed to proceed overnight at 37°C, using a Px2 Thermal 
Cycler. The digested product was then purified using the QIAquick PCR Purification 
Kit (Qiagen) according to the manufacturer’s protocol; the final elution step was 
repeated to produce a final volume of 80 μl. The purified digested product was then 
concentrated in a SpeedVac concentrator to a volume of 10 μl. 
 
3.3.9.1.2 Ligation to linkers 
The cleaved ends of DNA were then ligated to unphosphorylated linkers. The linker 
sequences used were: H12 5’-TAATCCCTCGGA-3’ and H24 5’-
AGGCAACTGTGCTATCCGAGGGAT-3’. The use of universal linkers enables the 
subsequent amplification of all methylated fragments in ligated DNA samples (Yan et 
al, 2002). The purified digested DNA (10 μl) was mixed with 5 μl each of H12 and 
H24 linkers (100 μM) and incubated at 50°C for 10 minutes. To allow the linkers to 
anneal, the mixture was then allowed to cool gradually to room temperature (25°C), 
by a 1°C drop every 2 minutes using a Px2 Thermal Cycler. The annealed linker-
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primers were then ligated to the purified DNA with the addition of 1 μl of T4 DNA 
ligase (400 U/μl), 3 μl of T4 DNA ligase buffer and 6 μl of nuclease-free water to 
bring the reaction volume to 30 μl. This ligation reaction was allowed to proceed 
overnight at 16°C using a Px2 Thermal Cycler.   
 
To test the efficiency of ligation a test PCR was performed. Ten μl of water were 
added to each ligated sample to bring the volume up to 40 μl. One μl of ligated DNA 
was then amplified in a 25 μl volume using 12.5 μl of GoTaq Green Master Mix 
(Promega), and 1 μl of 10 μM H24 primer. Amplification was performed using the 
following cycle conditions: 72ºC for 3 minutes, to allow the protruding ends of the 
ligated DNA to be filled in, followed by 25 cycles of 95ºC for 1 minute, 66ºC for 1 
minute, 72ºC for 2 minutes, and a final extension of 72ºC for 10 minutes. The PCR 
products were analysed using 2% agarose gel electrophoresis and ethidium bromide 
staining. A diffuse smear between 200-900 bp indicated a successful MseI digestion 
and linker ligation. Once the optimal smear pattern was achieved, the remaining 39 μl 
of ligated DNA were purified using the QIAquick PCR Purification Kit (Qiagen) 
according to the manufacturer’s protocol. The purified ligated DNA was then 
concentrated in a SpeedVac concentrator to a volume of 24 μl. 
 
3.3.9.1.3 Methylation-sensitive restriction 
The purified ligated DNA sample was divided into 2 equal aliquots of 12 μl. One 
aliquot was restricted with the methylation-sensitive restriction enzyme, McrBC (New 
England Biolabs). This endonuclease cleaves DNA containing methylcytosine on one 
or both strands, but will leave unmethylated DNA intact. The recognition site for 
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McrBC consists of 2 half-sites of the form (G/A)mC, which can be separated by up to 
3 kb. The digestion mix contained 2 μl McrBC (10 U/μl), 2 μl 10x NE Buffer 2, 2 μl 
10X BSA, 2 μl 10X GTP (10 mM) in a total volume of 20 μl. The second aliquot was 
mock-digested, with nuclease-free water substituting McrBC in the digestion mix. 
The digestions were allowed to proceed overnight at 37°C, using a Px2 Thermal 
Cycler. 
 
3.3.9.1.4 Linker PCR 
The McrBC digested and the mock-digested samples were each divided into 4 
aliquots (5 μl each) for PCR amplification. Five μl of digested (or mock-digested) 
DNA were amplified in a 100 μl volume using 50 μl of GoTaq Green Master Mix 
(Promega), and 2.5 μl of 10 μM H24 primer. This was performed in quadruplicate for 
all 4 aliquots per digested and mock-digested sample. Amplification was performed 
using the following cycle conditions: 72ºC for 3 minutes, to allow the protruding ends 
of the ligated DNA to be filled in, followed by 20 cycles of 95ºC for 1 minute, 66ºC 
for 1 minute, 72ºC for 2 minutes, and a final extension of 72ºC for 10 minutes. PCR 
amplification was conducted for only 20 cycles to ensure that the PCR was still in the 
linear range. Five μl of the PCR products were analysed using 2% agarose gel 
electrophoresis and ethidium bromide staining to check the diffuse smear between 
200-900 bp as above was still present. The amplified samples were then purified using 
the QIAquick PCR Purification Kit (Qiagen) according to the manufacturer’s 
protocol, with the exception that only 11 μl of nuclease-free water were used to elute 
the DNA in the final step. The four replicates per sample were combined for a total 
volume of 44 μl each for both the digested and the mock-digested samples. The 
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NanoDrop ND-100 Spectrophotometer was then used to measure DNA concentration, 
according to manufacturer’s instructions. 
 
3.3.9.1.5 Fluorescent dye labelling 
The McrBC-digested and mock-digested amplified samples were labelled with the 
fluorescent dyes Cy5 and Cy3 respectively, using the Mirus Label IT Kit (Mirus Bio). 
The labelling mix included 5 μg of the amplified samples, 5 μl of 10x labelling buffer 
A, and 1 μl of the fluorescent dye (Cy5 or Cy3) in a total volume of 50 μl. Both 
samples were incubated at 37°C for 3 hours, and the labelled samples were then 
purified together using the Cyscribe GFX purification kit (Amersham). 
 
3.3.9.2 Microarray hybridisation 
A hybridisation solution mix was prepared comprising 80μl DIG Easy Hyb solution 
(Roche), 4 μl calf thymus DNA (10 mg/ml) (Sigma-Aldrich) and 4 μl yeast total RNA 
(10 mg/ml) (Invitrogen). To denature the calf thymus DNA and the yeast total RNA, 
the hybridisation solution mix was incubated at 65°C for 3 minutes and allowed to 
cool to room temperature. The combined purified Cy3 and Cy5 labelled samples were 
then added to the hybridisation solution mix, and mixed gently by pipetting.  
 
The hybridisation solution mix containing the combined labelled samples was 
hybridised to a University Health Network Human CpG Island 12K (HCGI12K) 
array. This array contains 12,192 CpG Island clones printed onto Corning 
UltraGAPS™ slides; the clones were originally derived from a CpG island library 
established at the Wellcome Trust Sanger Institute, Cambridge in the 1990s (Cross et 
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al, 1994). The CpG Island clones are single-spotted in 48 grids arranged in a 12 x 4 
format (Figure 3.3); each grid comprises 16 columns and 17 rows of spots. PCR 
products of Arabidopsis, SA1 and SA2 (SpotReportTM AlienTM cDNA Array 
Validation System, Stratagene) have also been spotted onto the array as controls. 
 
 
 
Figure 3.3 Layout of the UHN HCGI12K array. 
 
Hybridisation was performed at 42°C for 16 hours, using the Advalytix SlideBooster 
hybridisation station (Advalytix), according to the manufacturer’s protocol. The 
SlideBooster uses acoustic wave transducers below the microarray to continuously 
agitate the solutions on the slide surface, which greatly improves hybridisation and 
reproducibility of the results. The post-hybridisation wash steps were performed using 
the Advawash wash station (Advalytix), which provides an automated wash facility 
for consistent slide washing. The microarray slides were first washed in 2x SSC/0.1% 
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SDS at 42°C for 5 minutes, followed by 0.1x SSC/0.1% SDS at room temperature for 
5 minutes, and finally in 0.1x SCC at room temperature for 5 minutes. The slides were 
then dried by centrifuging at 1800 rpm for 5 minutes. 
 
3.3.9.3 Data acquisition 
After washing and drying, the slides were scanned immediately using a GenePix 
4000A scanner (Axon) according to the manufacturer’s protocol, and the acquired 
images were analysed using the GenePix Pro 3.0 software (Axon). The GenePix 
4000A scanner contains a dual laser scanner which has been optimised for use with 
Cy3 and Cy5, and acquires data at these 2 wavelengths (532nm (green) and 635nm 
(red)) simultaneously. Each spot was defined by the positioning of a grid of circles 
over the array image. The median pixel intensity within each circle and of the local 
background (see below) were determined; the net signal for each spot was calculated 
by subtracting the local background from the corresponding median intensity of that 
spot. The data were then exported into an Excel spreadsheet for subsequent analyses. 
 
3.3.9.3.1 Computing local background intensities 
The local background is calculated using a circular region that is centred on each 
individual spot (“feature”) (Figure 3.4). This region is 3 times the diameter of the 
corresponding spot. All the pixels in this circular region are used to calculate the 
median local background pixel intensity unless the pixel is within the spot of interest, 
or is not completely outside a 2-pixel wide region around each array spot, or unless it 
lies within a neighbouring array spot.  
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Figure 3.4 Defining background pixels. The black region represents the pixels used for computing 
background, the dark grey region represents the pixels used to calculate the median intensity of the 
array spot, and the light grey region represents excluded pixels (from GenePix Pro 3.0 User Manual). 
 
3.3.9.4 Data processing 
Prior to data analysis, array spots of low quality were first filtered: Array spots are 
marked “Not Found” (flag value -50) if the array spot contains fewer than 6 pixels, or 
if the diameter of the array spot is not within 80-120% of the theoretical spot size, or 
if the array spot is found in a location than would overlap with an adjacent spot. In 
addition, for the mock-digested sample, array spots with fluorescent signals close to 
the background signal (<25), reflecting PCR or printing failures were also excluded 
from subsequent data analysis. 
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3.3.9.5 Data normalisation 
Because the Cy3 and Cy5 fluorescent labels are known to have different labelling 
efficiencies, the array data were normalised using a set of mitochondrial clones. 
Mitochondrial DNA is known to be completely unmethylated so the cut/mock-cut 
ratio of the signal intensities for the mitochondrial clones should equal one. There are 
120 mitochondrial clones spotted on the UHN HCGI12K array. The median Cy3 and 
Cy5 signal intensities of all the mitochondrial clones on each array were first 
calculated. To enable comparison of data between different arrays, the Cy3 and Cy5 
mitochondrial signal intensities were normalised to a value of 1000 on each array, ie 
the Cy3 signal intensity of each mitochondrial clone was multiplied by the median 
mitochondrial Cy3 signal intensity on that array, and then divided by 1000. This was 
performed for both the Cy3 and the Cy5 signal intensities. These normalisation factors 
were then applied to all the probes on the array.  
 
3.3.9.6 Array annotation 
Each CpG island clone on the UHN HCGI12K array may be associated with three 
possible genes located either within the same strand (W), upstream (U), or 
downstream (D) by a variable distance. To simplify the data analysis Dr Wenbin Wei 
(Head of Bioinformatics, our Institute) has re-annotated the UHN HCGI12K array - 
using the chromosome start and end position for each CpG island clone; each clone 
was allocated the nearest gene using the criteria, “mid-point of the CpG island clone is 
within 7.5kb upstream of 5’ transcriptional start site of that gene through to 100bp 
downstream of the transcriptional end site.” Following this re-annotation the UHN 
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HCGI12K array now covers 3379 unique genes only. This re-annotation has been 
used for all the data analyses described in this thesis. 
 
3.3.9.7 Data analysis 
A fluorescent ratio was calculated for all the array spots on each array with the mock-
cut signal intensity (Cy3) as denominator and the cut signal intensity as numerator 
(Cy5). The resulting ratio reflects the degree of methylation of each CpG island clone; 
a ratio approaching zero indicates a methylated CpG island, and a ratio approaching 1 
indicates an unmethylated CpG island. 
 
Differentially methylated genes 
A t-test was used to compare the individual cut/mock-cut ratios of all the replicates 
performed between 2 different time-points. A CpG island was considered to be 
differentially methylated if the p value was <0.05. 
 
3.4 RNA ANALYSIS 
 
3.4.1 RNA Extraction 
Total RNA from cell lines was extracted using the RNeasy Mini Kit (Qiagen) 
according to the manufacturer’s protocol. The extracted RNA was then stored at -
80°C until use. The quality and concentration of the RNA were measured using the 
NanoDrop ND-100 Spectrophotometer, according to the manufacturer’s protocol. The 
ratio of the absorbance at 260 and 280 nm (A260/280) of all the RNA samples was 
required to be between 1.9 and 2.1. 
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3.4.2 Reverse transcription-PCR 
Reverse transcription-PCR (RT-PCR) was used to analyse the expression of genes. 
One hundred ng of total RNA from each cell line were reverse transcribed to cDNA 
using the Quantitect kit (Qiagen), according to the manufacturer’s protocol. Fifty ng 
of cDNA from each cell line were then amplified in a 25 μl volume using 12.5 μl of 
GoTaq Green Master Mix (Promega), and 12.5 pmol of each primer. Amplification 
was performed using a Px2 Thermal Cycler and the following cycle conditions: 95ºC 
for 10 minutes, followed by 40 cycles of 95ºC for 45 seconds, annealing temperature 
for 1 minute, 72ºC for 2 minutes, and a final extension of 72ºC for 10 minutes. PCR 
products were analysed using 2% agarose gel electrophoresis and ethidium bromide 
staining. 
 
3.4.2.1 Designing primers for RT-PCR 
The Primer 3 primer design program was used to design primers for RT-PCR 
(http://www.frodo.wi.mit.edu/primer3/). The pubmed website (http://pubmed.com) 
was used to obtain the mRNA sequence of the gene of interest, and the sequence was 
then copied into the Primer 3 program. The options ‘pick left primer’ and ‘pick right 
primer’ were selected and the following parameters for primer design were used: 
product size 100-300 bp, primer annealing temperature 55-60°C, primer size between 
15-25 bp and a GC content between 40-80%. Primers were ordered from Alta 
Bioscience, UK. 
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3.4.3 Quantitative-RT-PCR 
Quantitative-PCR (Q-PCR) measures PCR amplification as it occurs; data are 
collected during the exponential phase of the PCR when the quantity of PCR product 
is directly proportional to the amount of template present, and is therefore more 
precise. In comparison, standard PCR measures the amount of accumulated PCR 
product at the end of the PCR cycles, during the plateau phase. 
 
Q-PCR using TaqMan chemistry requires specific PCR primers and a fluorogenic 
probe for the PCR reaction. The probe contains a reporter dye on the 5’ end (FAM or 
VIC) and a quencher dye on the 3’ end (TAMRA or MGB), and anneals downstream 
to one of the primer sites. When the probe is intact, the proximity of the quencher dye 
to the reporter dye reduces the amount of fluorescence emitted by the reporter dye. 
During PCR amplification, the probe is cleaved by the 5’ nuclease activity of Taq 
DNA polymerase, which separates the reporter dye from the quencher dye, and 
increases the reporter fluorescence signal. Hence the increase in fluorescence intensity 
is directly proportional to the number of PCR amplicons produced. 
 
Fifty ng of cDNA from each cell line were amplified in a 25 μl volume using 12.5 μl 
of TaqMan Universal PCR Master Mix (Applied Biosystems), 1.25 μl of 20x TaqMan 
Gene Expression Assay primer and probe mix for the target gene of interest (Applied 
Biosystems), and 1.25 μl of 20x TaqMan Gene Expression Assay primer and probe 
mix for the house-keeping gene (Applied Biosystems). Amplifications were 
performed in triplicate in a 96 well plate using the ABI PRISMTM 7700 Sequence 
Detection System (Applied Biosystems) and the following cycle conditions: 50°C for 
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2 minutes, followed by 95°C for 10 minutes, followed by 40 cycles of 95°C for 15 
seconds and 60°C for 1 minute.  
 
Data were analysed using the ABI PRSIMTM 7700 SDS Software 1.9.1 (Applied 
Biosystems); fold changes in gene expression between 2 samples were measured 
using the comparative Ct method for relative quantitation (ddCt). Here the difference 
between the Ct value of the target gene of interest and the house-keeping gene is 
designated dCt. One sample is then selected as the reference sample. The difference 
between the dCt values between different samples compared to the reference sample 
is then designated ddCt. The absolute fold change in gene expression between each 
sample compared to the reference sample can then be calculated using the arithmetic 
formula, 2-(ddCt). 
 
3.4.3.1 Designing primers and probes for Q-RT-PCR 
Applied Biosystems have already pre-designed primers and probe sequences for many 
target genes. The target gene of interest and the house-keeping gene were selected and 
ordered from Applied Biosystems, UK. 
 
3.4.4 Gene expression profiling 
Gene expression profiling was performed using the Affymetrix GeneChip® Human 
Genome U133 Plus 2.0 array (Affymetrix). This array comprises 54,675 probe sets 
which analyses the expression level of approximately 47,400 transcripts. 
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3.4.4.1 Synthesis of biotin-labelled, fragmented cRNA 
Prior to array hybridisation, biotin-labelled fragmented cRNA was first generated: 
 
3.4.4.1.1 Preparation of Poly-A RNA controls 
The Affymetrix GeneChip® Human Genome U133 Plus 2.0 array contains probe sets 
for several Bacillus subtilis genes which are not found in eukaryotic samples (lys, phe, 
thr, and dap). These pre-mixed, polyadenylated (poly-A) prokaryotic controls are 
processed together with the RNA sample, and undergo in vitro transcription (IVT) 
followed by amplification and labelling. Following hybridisation, the signal 
intensities of these controls then serve as sensitive indicators of target preparation and 
the labelling reaction efficiency, independent from the quality of the starting RNA 
sample. 
 
The Poly-A Control Stock (Affymetrix) was serially diluted with the Poly-A Control 
Dilution Buffer (Affymetrix) prior to use: Firstly, 2μl of the Poly-A Control Stock 
was added to 38 μl of the Poly-A Control Dilution Buffer (1:20 dilution);  2μl of this 
first dilution was then added to a further 98 μl of the Poly-A Control Dilution Buffer 
(1:50 dilution); 2 μl of this second dilution was then added to 18μl of the Poly-A 
Control Dilution Buffer (1:10 dilution) and 2 μl of this final dilution was added to the 
cDNA reaction below. 
 
3.4.4.1.2 cDNA synthesis 
Total RNA from each cell line was reverse transcribed to generate first-strand 
complementary DNA (cDNA) followed by converson to double-stranded cDNA, 
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using the Affymetrix One-Cycle cDNA Synthesis Kit (Affymetrix). All incubation 
steps were performed in a Px2 Thermal Cycler.  
 
(i) First-strand cDNA synthesis 
Firstly, 1 μg of total RNA, 2 μl of diluted poly-A RNA controls (from 3.4.4.1.1) and 1 
μl of T7-Oligo(dT) primer (100 pmol/μl), in a total volume of 12 μl, were incubated at 
65°C for 10 minutes, followed by 4°C for 2 minutes. Four μl of First Strand Buffer 
(5x), 2 μl of DTT (0.1M) and 1 μl of dNTPs (10 mM) were then added and the 
reaction was incubated at 42°C for 2 minutes. One μl of Superscript II Reverse 
Transcriptase (200 U/μl) was then added and the whole reaction was incubated at 
42°C for 1 hour. 
 
(ii) Second-strand cDNA synthesis 
130μl of the second-strand master mix (Table 3.5) were then added to each first-
strand synthesis sample from (i) for a total volume of 150 μl, and the reaction 
incubated at 16°C for 2 hours. Two μl of T4 DNA Polymerase (5 U/μl) were added 
and the reaction was incubated at 16°C for a further 5 minutes. Ten μl of 0.5 M EDTA 
were then added, and the newly synthesised double-stranded cDNA was immediately 
purified using the Affymetrix Sample Cleanup Module (Affymetrix) according to the 
manufacturer’s protocol. The purified eluted double-stranded cDNA (12 μl) was used 
immediately in the in vitro transcription (IVT) reaction. 
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Reagent Volume 
RNase-free Water  91 μl 
5X Second- Strand Reaction Mix  30 μl 
dNTPs (10 mM)  3 μl 
E. coli DNA ligase (10 U/μl) 1 μl 
E. coli DNA Polymerase I (10  U/μl) 4 μl 
RNase H (2 U/μl) 1 μl 
Total Volume  130 μl 
 
Table 3.5 Second-strand master mix. 
 
3.4.4.1.3 In vitro transcription 
Double-stranded cDNA was in vitro transcribed to cRNA and labelled with biotin 
using the Affymetrix IVT Labelling Kit (Affymetrix). Twenty eight μl of IVT mix 
(Table 3.6) was added to each of the 12 μl of eluted double-stranded cDNA samples, 
and the reaction was incubated at 37°C overnight. 
 
Reagent Volume 
RNase-free Water  8 μl 
10X IVT Labelling Buffer  4 μl 
IVT Labelling NTP Mix  12 μl 
IVT Labeling Enzyme Mix  4 μl 
Total Volume  40 μl 
 
Table 3.6 IVT master mix. 
 
The biotin-labelled cRNA was then purified using the Affymetrix Sample Cleanup 
Module (Affymetrix) according to the manufacturer’s protocol. One μl of the eluted 
purified cRNA was used to quantify the cRNA using the NanoDrop ND-100 
Spectrophotometer. The absorbance at 260 nm and 280 nm was measured and the 
sample was considered of sufficient quality only if the A260/280 ratio was between 1.9 
and 2.1. 
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3.4.4.1.4 Fragmentation of cRNA 
Prior to hybridisation onto the GeneChip arrays, fragmentation of cRNA has been 
shown to be critical in obtaining optimal assay sensitivity. Thus, 25 μg of each 
purified biotin-labelled cRNA sample were incubated with 10 μl of 5x Fragmentation 
Buffer in a total volume of 50 μl, at 94°C for 35 minutes. The Fragmentation Buffer 
has been optimized to break down full length cRNA to 35-200 base fragments by 
metal-induced hydrolysis. The undiluted fragmented biotin-labelled cRNA was stored 
at -80°C until array hybridisation. 
 
The quality of the labelled cRNA and the fragmented cRNA was assessed using 1.2% 
agarose gel electrophoresis and ethidium bromide staining; 500ng to 1μg of cRNA 
should show a smear between 100 bp to 2 kb with most fragments between 500 bp to 
1kb, and 1-2μg of fragmented cRNA should show a smear between 35 to 200 bp. 
 
3.4.4.2 Microarray hybridisation 
Twenty μg of each fragmented biotin-labelled cRNA sample were hybridised to an 
Affymetrix GeneChip® Human Genome U133 Plus 2.0 array according to standard 
Affymetrix protocols at our Institute. Post-hybridisation staining and washing were 
performed according to the manufacturer's protocol (Affymetrix). 
 
3.4.4.3 Data analysis 
Scanned images of the microarray chips were analysed using the Affymetrix 
GeneChip Operating Software (GCOS) with the default settings except that the target 
signal was set to 100 for all arrays. Prior to data analysis, the quality reports were first 
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assessed. An array was considered acceptable if the following criteria were fulfilled: 
average background <100, percentage of Present calls for all the probe sets on the 
array >40%, and degradation of GAPDH as measured by the 3’/5’ probe set ratio <2. 
Pairwise comparisons were then performed between different samples and 
differentially expressed genes were identified using the GCOS change algorithm. 
 
3.4.4.4 Array annotation 
One of the challenges associated with the analysis of microarray data is that the 
annotation files for the arrays are updated every 3 months. To ensure that different 
datasets are comparable it is clearly important that the datasets are compared using 
genes annotated with the same annotation version. Re-annotation of the larger datasets 
have been undertaken by Dr Wenbin Wei (Head of Bioinformatics, our Institute) and 
Prof Ciaran Woodman (Professor of Cancer Epidemiology, our Institute).   
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3.5 PROTEIN ANALYSIS 
 
3.5.1 Protein extraction 
Protein extraction from cell lines was performed using freshly prepared protein lysis 
solution (Table 3.7). One protease inhibitor cocktail tablet (Roche) was added to 
every 10 ml of protein lysis solution. Five hundred μl of protein lysis solution (with 
protease inhibitor) was added to each cell pellet, pipette-mixed and then incubated on 
ice for 45 minutes. The sample was then centrifuged at 13,000 rpm at 4°C for 30 
minutes. The supernatant containing extracted protein was transferred to a new tube 
and stored at -80°C until use. 
 
Reagent Volume 
1M Tris (pH 8) 2.5 ml 
2M Sodium chloride 3.75 ml 
0.5M EDTA (pH 8) 100 μl 
1% NP40 500 μl 
Nuclease-free water 43.15 ml 
Total volume 50ml 
 
Table 3.7 Protein lysis solution 
 
3.5.2 Western blotting 
Western blot analysis was used to assess protein expression. In this technique, sample 
proteins are first separated according to their molecular weight using SDS-
polyacrylamide gel electrophoresis, followed by transfer of the proteins to 
nitrocellulose membranes, where they are then probed using antibodies specific to the 
target protein. 
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3.5.2.1 Measuring protein concentration 
Following protein extraction (section 3.5.1), proteins were first quantified using the 
Bradford protein assay. The Bradford assay is a colorimetric assay, based on the 
differential colour change of the Coomassie dye following binding of various 
concentrations of proteins; without protein the solution is red-brown, when protein 
binds, the pKa of the dye shifts causing the dye to become blue.  
 
A series of bovine serum albumin (BSA) standards was first prepared (Table 3.8).  
 
BSA standard Volume of water  Volume of BSA stock (1 mg/ml) Final concentration (mg/ml) 
0 100 μl 0 μl 0 
100 90 μl 10 μl 0.1 
200 80 μl 20 μl 0.2 
300 70 μl 30 μl 0.3 
400 60 μl 40 μl 0.4 
500 50 μl 50 μl 0.5 
 
Table 3.8 BSA standards used for the Bradford protein assay. 
 
Ten μl of each standard was added to duplicate wells in a 96 well plate (flat-bottom). 
An aliquot of each protein sample was then diluted 1:10 and 10 μl was also added in 
duplicate wells to the plate. The Bradford reagent (Bio-Rad Protein Assay Solution) 
was diluted 1:5 and then 200 μl was carefully added to each standard and sample well. 
The reaction was incubated at room temperature for 5 minutes before the absorbance 
at 595nm was read using an ELISA plate reader. A standard curve was then plotted 
and the protein concentration of the samples was calculated. 
 
3.5.2.2 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
A polyacrylamide gel was first prepared. For the DNMT1 protein (mwt=183kDa) an 
8% polyacrylamide gel was prepared, comprising a lower 8% resolving gel and an 
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upper 5% stacking gel (Table 3.9). The polyacrylamide gel was allowed to polymerise 
for at least one hour prior to use. 
 
Reagent 8% Resolving Gel 5% Stacking Gel 
Water 9.3 ml 4.1 ml 
30% ProtoGel*  5.3 ml 1.0 ml 
1.5M Tris HCl 5.0 ml (pH 8.8) 750 μl (pH 6.8) 
10% SDS 0.2 ml 60 μl 
10% ammonium persulphate 0.2 ml 60 μl 
TEMED 12 μl 6 μl 
Total volume 10 ml 5 ml 
 
*ProtoGel is a 37.5:1 ratio of acrylamide/methylene bisacrylamide solution (National Diagnostics) 
 
Table 3.9 Reagents required for preparing an 8% polyacrylamide gel. 
 
 
The polyacrylamide gel was placed into the Bio-Rad Mini-Protean 3 Electrophoresis 
Cell and the tank was filled with running buffer (0.25M Tris base, 1.92M Glycine, 1% 
SDS). 2x Laemmli loading buffer (4% SDS, 10% 2-mercaptoethanol, 20% glycerol, 
0.004% bromophenol blue, 0.125M Tris HCl pH 6.8) was added in a 1:1 ratio to 15 
μg of protein from each sample. The samples were then heated at 100°C for 5 minutes 
to denature the proteins and then allowed to cool to room temperature. Ten μl of the 
Precision Plus Protein Kaleidoscope molecular weight marker (Bio-Rad) were loaded 
into the first well of the polyacrylamide gel, and the samples were then loaded into the 
remaining wells. An electrical voltage of 135V was applied for 90 minutes to allow 
the proteins to separate, stopping just before the bromophenol blue front reached the 
bottom of the resolving gel. The proteins were then transferred to a nitrocellulose 
membrane (Invitrogen) in transfer buffer (0.25M Tris base, 1.92M Glycine and 20% 
methanol), at 90V for 90 minutes.  
 
 
 
 
107 
 
Materials and Methods 
3.5.2.3 Immunoblotting 
Following protein transfer, the nitrocellulose membrane was incubated in 5% 
blocking solution (5% non-fat dry milk powder in PBS, 0.01% Tween 20) for one 
hour to prevent non-specific binding of the primary and secondary antibodies to the 
membrane. The membrane was rinsed with Tris Buffer Saline Tween 20 (TBS-
Tween; 1 ml of Tween 20 in 1 l of TBS), and then incubated at 4°C overnight with the 
primary antibody, diluted to the appropriate concentration with the blocking buffer; 
specifically DNMT1 (clone 60B1220, mouse monoclonal diluted 1:250; Abcam) or 
beta-actin (clone-2, mouse monoclonal diluted 1:4000; Santa Cruz). The membrane 
was then washed in TBS-Tween for 5 minutes with agitation to remove residual 
primary antibody, followed by incubation with the secondary peroxidase-labelled 
antibody, again diluted to the appropriate concentration with the blocking buffer, at 
room temperature for 1 hour. The membrane was then washed with TBS-Tween for 5 
minutes with agitation 5 times. Proteins were visualised using the enhanced 
chemiluminescence system (ECL, Amersham), according to the manufacturer’s 
protocol. 
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3.5.3 Chromatin Immunoprecipitation 
Chromatin proteins have important roles in DNA repair, replication and transcription. 
Chromatin immunoprecipitation (ChIP) is a technique used to assess the interaction of 
specific proteins with defined genomic regions. 
 
3.5.3.1 Preparation of cross-linked chromatin 
For chromatin immunoprecipitation, untransfected PHFK (passage 3) and PHFK 
transfected with HPV18 (passage 4/3 and passage 4/8) were grown on J2 3T3 feeder 
cells in E-medium as described in section 3.1.3. At sub-confluence, the J2 3T3 feeder 
layer was first removed by EDTA treatment, and the keratinocytes were then isolated 
by scraping the petri dish and transferred to a universal container. Three volumes of 
ice-cold PBS/5mM sodium butyrate were added, and the cells were centrifuged at 400 
g for 5 minutes at 4°C. The supernatant was discarded and the keratinocytes were re-
suspended in 500 μl of cold PBS/5mM sodium butyrate for every 5x105 cells. Native 
protein-DNA complexes were then cross-linked by treatment with 1% formaldehyde 
for 8 minutes, followed by the addition of 1.25M glycine to stop the cross-linking. 
The cells were then centrifuged at 470 g for 5 minutes at 4°C and the supernatant 
discarded. 
 
3.5.3.2 Sonication 
The cells were washed twice with cold PBS/5mM sodium butyrate and then re-
suspended in 130 μl of lysis buffer (50 mM Tris-HCl pH 7.5, 10 mM EDTA, 1% 
SDS, PMSF, 5 mM sodium butyrate) for every 5x105 cells. The keratinocytes were 
then sonicated in 500 μl aliquots using the Biorupter Sonicator (Diagenode) set to 
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‘HIGH’ for 15 minutes, with 30 seconds on/off. Following sonication the samples 
were centrifuged at 10,000 g for 10 minutes at 4°C. The supernatant (which contains 
the chromatin) was removed and stored at -20°C until use. The NanoDrop ND-100 
Spectrophotometer was used to measure the chromatin concentration. 
 
To check the adequacy of sonication, a sample of chromatin was de-cross-linked; 2 μg 
of chromatin was made up to 500 μl with lysis buffer, and 50 μg/ml of proteinase K 
was added. This mixture was incubated on a thermo-mixer at 68°C overnight at 1300 
rpm. The de-cross-linked chromatin was then extracted by phenol/chloroform and 
precipitated by ethanol (section 3.3.1.2). Following clean up (section 3.3.1.3), the 
pellet was re-suspended in 30 μl of nuclease-free water. One μg of DNA was run on a 
2% agarose gel; a smear between 200-1000 bp was expected, with most fragments 
around 400 bp. Immunoprecipitation was only performed if sonication was adequate. 
 
2.5.3.3 Immunoprecipitation 
One hundred μl of Dynabeads Protein G (Invitrogen) were transferred into a 1.5 ml 
tube. Using the Dynal Magnetic Particle Concentrator magnet (Invitrogen), the beads 
were captured and the supernatant was removed. The beads were re-suspended and 
washed with 500 μl of RIPA buffer (10 mM Tris-HCl pH 7.5, 1 mM EDTA, 0.5 mM 
EGTA, 1% Triton, 0.1% SDS, 0.1% sodium deoxycholate, 150 mM sodium chloride), 
and this wash step was repeated twice. The beads were then re-suspended in 90 μl of 
RIPA buffer, 2.4 μg of antibody (DNMT1, H3K27me3, or control IgG - Abcam) were 
added to each tube and this bead-antibody mixture was incubated on a rotator at 4°C 
for 2 hours.  
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The antibody-bound beads were then captured using the magnet and the supernatant 
discarded. Ten μg of chromatin made up to 100 μl with RIPA buffer were added to 
each tube and the chromatin and antibody-bound beads were incubated on a rotator at 
4°C for 2 hours. Following immunoprecipitation, the beads were again captured and 
washed 3 times with RIPA buffer. The beads were then re-suspended in 100 μl of TE 
(pH 8). 
 
3.5.3.4 Reversal of cross-links 
To remove cross-links, the chromatin-antibody-bound beads were captured, the 
supernatant discarded, and  150 μl of elution buffer with SDS (20 mM Tris-HCl pH 
7.5, 5 mM EDTA, 5 mM sodium butyrate, 50 mM sodium chloride, 1% SDS) and 50 
μg/ml of proteinase K were added. This was incubated on a thermo-mixer at 68°C 
overnight at 1300 rpm. The immunoprecipitated DNA was then extracted by 
phenol/chloroform and precipitated by ethanol (section 3.3.1.2). Following clean up 
(section 3.3.1.3), the pellet was re-suspended in 30 μl of nuclease-free water and 
stored at -20°C until use. 
 
3.5.3.5 Detection 
The immunoprecipitated DNA was then analysed by PCR or Q-PCR. For PCR 
analysis, 50 ng of each immunoprecipiated DNA sample were amplified in a 25 μl 
volume using 12.5 μl of GoTaq Green Master Mix (Promega) and 0.3 μmol/L primer 
mix. Amplification was performed as described in section 3.3.3 but for only 30 cycles. 
The specificity of the binding was assessed by performing PCR of the region of 
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interest, and also a downstream region. Table 3.10 lists the primer sequences and the 
corresponding annealing temperatures used.  
 
Name Primer sequence 5'-3' 
Product 
size (bp) 
Annealing 
temperature (°C) 
RARB F TCCTGGGAGTTGGTGATGTCAG 
RARB R AAACCCTGCTCGGATCGCTC 
230 62 
RARB down F TCAAAGTCAGGATTAGGGGACTAC 
RARB down R GTCACACTCGTTATTTCACCAAAG 
229 60 
 
Table 3.10 Primer sequences used for ChIP-PCR analysis 
 
For Q-PCR analysis, 30 ng of each immunoprecipitated DNA sample were amplified 
in a 25 μl volume using 12.5 μl SYBRTM Green PCR Master Mix and 0.3 μmol/L 
primer mix. Amplifications were performed in duplicate in a 96 well plate using the 
ABI PRISMTM 7700 Sequence Detection System (Applied Biosystems) and the 
following cycle conditions: 95°C for 15 minutes, followed by 40 cycles of 95°C for 
30 seconds, annealing temperature for 1 minute, and 72°C for 2 minutes. The 
incorporation of SYBR green into double-stranded DNA was measured during each 
elongation step. The Ct value for the control IgG antibody immunoprecipitated DNA 
was selected as the reference sample. The absolute fold change between each antibody 
compared to the control IgG antibody was then calculated using the arithmetic 
formula, 2-(Ct[sample]-Ct[IgG]).  
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Chapter 4 
 
 
RESULTS 1: 
ASSOCIATION BETWEEN SMOKING 
AND CDKN2A METHYLATION 
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4.1 Restatement of Objectives 
To investigate the association between smoking status and CDKN2A methylation in 
cervical smears from disease-free women: 
 
• To determine the prevalence and incidence of CDKN2A methylation in 
smokers and never smokers. 
 
• To determine if CDKN2A methylation becomes undetectable following 
smoking cessation. 
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4.2 Selection of candidate genes for inclusion in the study of smoking-induced 
epigenetic changes in cervical material 
This has to be informed by an assessment of: 
a) which genes are methylated as a consequence of tobacco exposure and, 
b) how often these genes are methylated in women with cervical intraepithelial 
neoplasia (CIN). 
 
Table 4.1 describes the prevalence with which methylated forms of a number of TSG 
are found in cancer-free samples taken from current or former smokers and non-
smokers. This analysis was performed by Professor Ciaran Woodman (Professor of 
Cancer Epidemiology, our Institute). 
 
TSG Non-smokers Smokers Significance 
APC - 42% (68; 1) - 
CDH1 0% (5; 1) 27% (22; 1) NS 
CDH13 4% (47; 2) 15% (301; 3) NS 
CDKN2A 3% (110; 5) 14% (1049; 13) p=0.0007 
CDKN2B 8% (37; 1) 68% (22; 1) p=0.0000 
DAPK1 0% (25; 2) 21% (249; 4) p=0.0121 
FHIT 0% (37; 2) 30% (182; 2) p=0.0000 
MGMT 0% (25; 2) 15% (371; 5) p=0.0401 
PAX5 - 12% (118; 1) - 
RARB 11% (47; 2) 32% (295; 3) p=0.0032 
RASSF1A 0% (47; 2) 4% (479; 5) NS 
TMS1 - 2% (85; 1) - 
 
Table 4.1 Smoking-associated cancers: prevalence of methylated forms of TSG in cancer-free 
subjects by smoking status. Pooled analysis reporting as a percentage the detection of methylated 
forms in cell samples taken from cancer-free smokers and non-smokers. The table includes the number 
of cases contributing to each estimate and the number of studies from which they are derived in 
brackets. 
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The studies from which these estimates were derived were identified using the search 
terms “methylation”, “smokers”, “smoking”, “non-smokers” and “tobacco”. Sixteen 
studies were identified: 12 studies reported the prevalence of methylated forms in 
bronchial epithelial cells which were obtained from induced or un-induced sputum 
samples, bronchial lavages or bronchial aspirates; in 3 studies samples were taken 
from the oral mucosa using either buccal smears or mouth and throat rinsings; and in 
one study cervical smears were taken (Kersting et al, 2000; Palmisano et al, 2000; 
Belinsky et al, 2002; Gilliland et al, 2002; Zöchbauer-Müller et al, 2003; Chang et al, 
2004; Grote et al, 2004; Kim et al, 2004; Kulkarni et al, 2004; Lea et al, 2004; von 
Zeidler et al, 2004; Belinsky et al, 2005; de Fraipont et al, 2005; Russo et al, 2005; 
Cirincione et al, 2006; Machida et al, 2006). 
 
A pooled analysis revealed that methylated forms of CDKN2A, CDKN2B, DAPK1, 
FHIT, MGMT and RARB are more commonly detected in smokers than in non-
smokers (Table 4.1). However, there are a number of caveats: 
 
• The number of non-smokers is small, and in only 2 of these studies was there a 
significant difference in the prevalence of methylated forms (Chang et al, 2004; 
Kim et al, 2004). The small number of healthy non-smokers reflects the difficulty 
in obtaining a sputum sample in the absence of lung disease, and the reluctance of 
healthy non-smokers to undergo more invasive procedures.  
 
• None of these studies reported an association between the detection of methylated 
forms and measures of smoking intensity or duration. Some studies comment on 
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the absence of an association, others do not appear to have explored this 
possibility. However, none of the studies was designed to explore such a 
relationship. Furthermore, almost invariably, the study population includes older 
individuals who have smoked for many years. Therefore, the failure to reveal a 
disease-exposure relationship may merely reflect the lack of heterogeneity in the 
distribution of the exposure variables. 
 
• Given that many of the “healthy” smokers included in these studies were either 
participating in secondary prevention programmes, or had some form of benign 
lung disease, it is possible that some already had a cancer which was unrecognised 
at the time the sample was taken. For example, in only one of these studies was 
the “cancer-free” status of healthy smokers confirmed by a prolonged period of 
follow-up during which they were regularly reviewed (Palmisano et al, 2000).  
 
There has only been one study which has related the prevalence of methylated forms 
of a TSG in cervical material to smoking status: methylated forms of CDKN2A were 
detected in 12% (4/34) of smokers with normal smears, compared to 5% (2/38) of 
non-smokers with normal smears (Lea 2004). However in women with CIN, and in 
those with invasive cancer, the prevalence of methylated forms was significantly 
higher in cervical smears taken from smokers than from a non-smoker (Lea et al, 
2004). 
 
Table 4.2 describes the prevalence with which methylated forms of a number of TSG 
are found in cervical tissue or exfoliated cells taken from disease-free women, women 
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with CIN and those with invasive disease. This analysis was again undertaken by 
Professor Ciaran Woodman. These estimates were generated from 52 studies 
identified using the search terms “methylation”, “cervix”, and “cervical”. A pooled 
analysis revealed that 11 genes (APC, CCNA1, CDH1, CDKN2A, DAPK1, HIC1, 
IGSF4, RARB, ROBO1, SLIT1 and SLIT2) are more likely to be methylated in HGCIN 
compared to disease-free controls. 
 
Thus 3 genes, CDKN2A, DAPK1 and RARB are more commonly methylated both in 
cancer-free smokers compared to cancer-free non-smokers, and in HGCIN compared 
to disease-free controls. Two of these genes (CDKN2A and DAPK1) were selected for 
further study. 
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Table 4.2 Epigenetic changes in cervical neoplasia: prevalence of methylated forms in relation to 
disease severity and histological type. Pooled analysis of 52 studies reporting the detection of 
methylated forms in cervical material. Listed are those genes for which methylated forms in tissue or 
exfoliated cells taken from women with invasive disease were significantly more frequent (p<0.05) 
than in disease-free controls or when these were unavailable, women with LGCIN. Genes numbered 1-
11 are also more likely to be methylated in HGCIN, whereas those numbered 12-19 are not. The 
presence of methylated forms in HGCIN and in disease-free controls tissue has yet to be established for 
genes numbered 20-26 and 27-31 respectively. *Estimates significantly different from baseline. The 
table includes the number of cases contributing to each estimate and the number of studies from which 
they are derived in brackets. "Cervical cancer" refers to cases of invasive disease with unspecified 
histological type (from Woodman et al, 2007). 
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 4.3 Detection of methylated forms in cervical cell lines 
Methylation specific PCR (MSP) and nested MSP of CDKN2A and DAPK1 were first 
optimised using DNA extracted from 4 cervical cancer cell lines (CaSki, SiHa, HeLa 
and C33A) and normal human foreskin keratinocytes (NHFK). The MSP and nested 
MSP primers used are published primers which have previously been well validated 
in several tumour sites (Table 3.3, Materials and Methods) (Herman et al, 1996; 
Palmisano et al, 2000; Esteller et al, 2001; Belinsky et al, 2002). 
 
4.3.1 Using methylation specific PCR 
Using MSP, the CDKN2A promoter was found to be methylated in CaSki, but not in 
NHFK, SiHa, HeLa or C33A (Figure 4.1a). Some unmethylated forms were also 
present in CaSki. Whilst for the DAPK1 promoter, methylated forms were detected in 
SiHa, but not in NHFK, CaSki, HeLa or C33A (Figure 4.1b). Some unmethylated 
forms were also detected in SiHa.  
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Figure 4.1a MSP for CDKN2A in cervical cell lines. The CDKN2A promoter was found to be methylated in 
CaSki, but not in normal human foreskin keratinocytes (NHFK), SiHa, HeLa or C33A. Unmethylated forms of 
the CDKN2A promoter were detected in all 5 cell lines. Expected product size: unmethylated primer (U) = 151bp, 
methylated primer (M) = 150bp.  
U MU MU M
Water
Unmethylated
Control
Methylated
ControlNHFK
U M U M U MU M U M
CaSki SiHa HeLa C33A
150bp
Figure 4.1b MSP for DAPK1 in cervical cell lines. The DAPK1 promoter was found to be methylated in SiHa, 
but not in NHFK, CaSki, HeLa or C33A. Unmethylated forms of the DAPK1 promoter were detected in all 5 cell 
lines. Expected product size: unmethylated primer (U) = 106bp, methylated primer (M) = 99bp.
NHFK
U M U M U MU M U M
CaSki SiHa HeLa C33A
U M
Unmethylated
Control
U MU M
Water
Methylated
Control
100bp
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4.3.2 Using nested MSP 
Nested MSP was performed in all 5 samples. Figure 4.2 shows that a single band of 
the correct size was obtained for all samples after the stage 1 PCR. Using nested MSP, 
methylation of the DAPK1 promoter was detected in all 5 samples (Figure 4.3). Some 
methylated forms were also detected using the unmethylated control; this could be 
due to the increased sensitivity of the nested MSP technique or a consequence of false 
priming secondary to a high number of PCR cycles. 
 
4.3.3. Using lower concentrations of DNA 
To determine if lower quantities of DNA could be used for bisulphite modification, 
different concentrations of HeLa (1 μg, 500 ng, 100 ng, 50 ng and 10 ng) were subject 
to standard bisulphite modification. The bisulphite modified DNA was then eluted in 
50 μl of nuclease-free water in all cases, and 5 μl were used in the MSP reaction. 
Figure 4.4 shows that following MSP for DAPK1, the unmethylated band could be 
detected even using 10ng of starting DNA for bisulphite modification (ie 1 ng in the 
MSP), although at this concentration the band was faint compared to higher 
concentrations of DNA. One hundred ng was thus selected as the starting 
concentration for bisulphite modification of cervical samples. 
 
4.4 Detection of methylated forms in cervical smears  
Next, we wanted to see if we could detect methylation of the promoters of CDKN2A 
and DAPK1 in cervical smears. A nested MSP method was chosen to investigate 
methylated forms of TSGs in these cytological samples, as the number of abnormal 
cells present in the samples was expected to be very low. 
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Figure 4.2 Nested MSP for DAPK1 in cervical cell lines – stage 1 PCR. A single band of the correct size 
was observed following the stage 1 PCR in all the cervical cell lines and controls. UC, unmethylated 
control. MC, methylated control.
146bp
NHFK CaSki SiHa HeLa C33A WaterUC MC
DNA
Ladder
Figure 4.3 Nested MSP for DAPK1 in cervical cell lines. The DAPK1 promoter was found to be 
methylated in all 5 cervical cell lines. Expected product size: unmethylated primer (U) = 106bp, methylated 
primer (M) = 99bp. W1, template-free control from both stages of PCR. W2, template-free control from 
stage 2 PCR only.
NHFK
U M U M U MU M U M
CaSki SiHa HeLa C33A
100bp
U M
Unmethylated
Control
U MU M
W1
Methylated
Control
100bp
U M
W2
Figure 4.4 MSP for DAPK1 in HeLa. Bisulphite modification of different starting concentrations of HeLa 
DNA was performed followed by MSP for DAPK1. An unmethylated band could be detected even using 10ng 
of starting DNA for bisulphite modification.  Expected product size: unmethylated primer (U) = 106bp, 
methylated primer (M) = 99bp.
1μg
U M U M U MU M U M
500ng 100ng 50ng 10ng
100bp
U M
Unmethylated
Control
U MU M
Water
Methylated
Control
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4.4.1 Detection of methylated forms in cervical smears from women with HGCIN 
DNA extraction was first performed on all available cytological samples from 11 
women with prevalent HGCIN ie present on first biopsy following study entry.  One 
hundred ng of the DNA from the cervical sample corresponding to the diagnosis of 
HGCIN (Table 4.3), were then subject to bisulphite modification, followed by nested 
MSP analysis 
       
Tube No. Study No. 
2 138.2 
6 170.2 
11 557.2 
27 702.2 
31 876.2 
36 878.3 
40 888.2 
48 1371.2 
56 1448.2 
59 1466.2 
66 1878.2 
  
Table 4.3 Cervical cytological samples from 11 women who were found to have HGCIN in the 
cervical biopsy taken at the same visit. 
 
 
Using nested MSP, methylation of the DAPK1 promoter was found in 5/11 HGCIN 
samples (Figure 4.5a). An unmethylated band was detected with all 11 samples. For 
CDKN2A, 5 samples (11, 31, 48, 56 and 66) were non-evaluable, producing no band 
with either the methylated or the methylated primers. Of the remaining 6 HGCIN 
samples, methylation of the CDKN2A promoter was detected in 1 sample (Figure 
4.5b). 
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Figure 4.5a Nested MSP for DAPK1 in 11 HGCIN cervical smear samples. The DAPK1 promoter was found 
to be methylated in 5 samples with HGCIN (2, 27, 36, 40, 59). Unmethylated forms of the DAPK1 promoter was 
detected in all 11 smear samples. Expected product size: unmethylated primer (U) = 106bp, methylated primer 
(M) = 99bp. W1, template-free control from both stages of PCR. W2, template-free control from stage 2 PCR 
only.
2
U M U M U MU M U M
6 11 27 31
U M
36
UU M
4840
100bp
U M
Unmethylated
Control
U MU M
W1
Methylated
Control
100bp
U M
W248
M U M U MU M
56 59 66
Figure 4.5b. Nested MSP for CDKN2A in 11 HGCIN cervical smear samples. 5 HGCIN samples were non-
evaluable (11, 31, 48, 56, 66). Of the remaining 6 HGCIN samples, methylation of the CDKN2A promoter was 
found in 1 sample (36). Unmethylated forms of the CDKN2A promoter was detected in 6 smear samples (2, 6, 
27, 36, 40 and 59). Expected product size: unmethylated primer (U) = 151bp, methylated primer (M) = 150bp. 
W1, template-free control from both stages of PCR. W2, template-free control from stage 2 PCR only.
2
U M U M U MU M U M
6 11 27 31
U M
36
UU M
4840
150bp
U M
Unmethylated
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4.4.2 Detection of methylated forms in cervical smears from disease-free women 
Ten women with serial smear samples, who remained cytologically normal and tested 
negative for HPV DNA throughout follow-up were selected. To ensure the “disease-
free” status of the sample, 1 cervical smear from the middle of the range of all the 
available cytological samples for each woman was selected for DNA extraction, and 
bisulphite modification.  
 
Using nested MSP, methylation of the CDKN2A promoter was not detected in any of 
the 5 evaluable normal smear samples (Figure 4.6a). For DAPK1, of 9 evaluable 
samples, methylation was detected in 1 sample (Figure 4.6b). 
 
4.4.3 Validation of bisulphite modification using the EZ DNA Methylation-Gold 
KitTM 
One of the limitations of standard bisulphite modification is that it is a laborious 
technique, which is impractical if multiple samples require modification. Thus the EZ 
DNA Methylation-Gold KitTM was tested to see if this could be used for all further 
cervical smear samples (section 3.3.2.2, Materials and Methods).  
 
Previously, using MSP, I have shown methylation of the TFPI2 promoter in CaSki, 
SiHa and HeLa cervical cell lines, but not in C33A. Methylation was complete in 
SiHa but some unmethylated forms were also present in CaSki and HeLa (Figure 4.7). 
The results for NHFK, SiHa, HeLa and the methylated control have also been 
validated using bisulphite genomic sequencing (Figures 4.8a, 4.8b and 4.8c). 
 
 
126 
 
Results 
 
 
Figure 4.6a Nested MSP for CDKN2A in cervical smear samples from 10 disease-free women. 5 samples 
were non-evaluable (1, 3, 4, 6, 9). Of the remaining 5 normal smear samples, methylation of the CDKN2A
promoter was not detected in any of the samples. Unmethylated forms of the CDKN2A promoter were present in 
5 normal smear samples (2, 5, 7, 8, 10). Expected product size: unmethylated primer (U) = 151bp, methylated 
primer (M) = 150bp. W1, template-free control from both stages of PCR. W2, template-free control from stage 2 
PCR only. 
150bp
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Methylated
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U M U MU M
W1
U M
W2
U M U MU M
8 9 10
150bp
1
U M U M U MU M U M
2 3 4 5
U M
6
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7
1
U M U M U MU M U M
2 3 4 5
U M
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7
100bp
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Figure 4.6b Nested MSP for DAPK1 in cervical smear samples from 10 disease-free women. 1 sample was 
non-evaluable (4). Of the remaining 9 normal smear samples, methylation of the DAPK1 promoter was found 1 
sample (6). Unmethylated forms of the DAPK1 promoter were detected in 9 smear samples (1, 2, 3, 5, 6, 7, 8, 9, 
10). Expected product size: unmethylated primer (U) = 106bp, methylated primer (M) = 99bp. W1, template-free 
control from both stages of PCR. W2, template-free control from stage 2 PCR only.
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Control
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U M U MU M
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Figure 4.7 MSP for TFPI2 in cervical cell lines. The TFPI2 promoter was found to be methylated in CaSki, 
SiHa and HeLa, but not in C33A. Methylation was complete in SiHa, but some unmethylated forms were also 
present in CaSki and HeLa. The absence of a product with the wild-type primers confirms the completeness of 
bisulphite modification. Expected product size: unmethylated primer (U) = 261bp, methylated primer (M) = 
256bp, wild-type primer (W) = 222bp.
Figure 4.9 MSP for TFPI2 in cervical cell lines (using EZ DNA Methylation Gold kit). MSP for TFPI2 using 
EZ modified DNA produced similar results to conventional bisulphite modification. The TFPI2 promoter was 
found to be methylated in CaSki, SiHa, HeLa and C33A. Methylation was complete in CaSki and SiHa, but 
some unmethylated forms were also present in HeLa and C33A. The absence of a product with the wild-type 
primers confirms the completeness of bisulphite modification. Expected product size: unmethylated primer (U) = 
261bp, methylated primer (M) = 256bp, wild-type primer (W) = 222bp.
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Transcription start site
5’ 3’
I II III IV V
CpG Islands: 1 2 3 4 5
MSP primers
CpG Number:
6-23 36-66 67-96 97-10626-352-5
●●●●-●●●●●●●●●●●●●●●●●●-○●●○○○○○○○-○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○-○○○○○○○○○○○○○○○○○    ○○○○○○○○○○-○○○○○○○○○○ 
●●●●-●●●●●●●●●●●●●○●●●●-●○○●○○○○○○-○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○-○○○○○○○○○○○○○○○○○○○○○○○○○●●○○○-○○○○○○○○○○ 
●●●●-●●●●●●●●●●●●●●●●●●-○○○○○○○○○○-○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○-○○○○○○○○○○○○○○○○○○○○○○○○○○●○○○-○○○○○○○○○○ 
●●●●-●●●●●●○●●●●●●●●○●●-○○●○○○○○○○-○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○-○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○-○○○○○○○○○○ 
○●●●-●○●●●●●●●●●●●●●●●●-●○○●○○○○○○-○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○-○○○○○○○○○○○○○○○○○○○○○○○○○●●○○○-○○○○○○○○○○ 
●○○●-●●●●●●●●●●●●●●○●●●-○○○○○○○○○○-○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○-○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○-○○○○○○○○○○ 
●●●○-●●●●●●●●●●●●●●●●●●-○○○○○○○○○○-○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○-○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○-○○○○○○○○○○ 
●●●●-●●●●●●●●●○●●●●●●●○-            -○○○○○○○○○○○○○○○○○○○○●○○○○○○○○○○-○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○-○○○○○○○●○○ 
Figure 4.8a BGS of the TFPI2 promoter in NHFK. The methylation status of all 106 CpGs located in the TFPI2 promoter in NHFK was 
assessed using bisulphite genomic sequencing (BGS). ○ = unmethylated CpG, ● = methylated CpG. The region covered by the MSP 
primers is indicated in red.
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Transcription start site
5’ 3’
I II III IV V
CpG Islands: 1 2 3 4 5
MSP primers
CpG Number:
6-23 36-66 67-96 97-10626-352-5
○●●●-●○●○○●○●●●●●●●●●●●-●●●●●●●●●●-●●●●●●●○●●●●○●●●●●●○●○●●●●●●●●○-●●●●●●○●●●●●●●●●●●●●●○●●●●●●●●-●●●●●●●●●● 
●●● -●●●●●●●●●●●●●●●●●●-●●●●●●●●●●-●●●●●●●●○●●●●●●●●●●●●○○○●●●●●●●-●●●●●●○●●●●●●●●●●●●●●○●●●●●●●●-●●●●●●●●●● 
●●●●-●●●●○○○●●●●●●●●●●●-●●○●●●●●●●-●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●-●●●●●●●○●●●●●●●●●●●○●●●○●○●●●●-●●●●●●●●●● 
●●●●-●●●●○○○●●●●●●●○●●●-●●●●○●●○●●-●●●●●●●●○●●●○●●○●●●●●●●○●○●○○●●-●●●●●●○●●●●●●●●●●●●●●○●●●●●●●●-●●●●●●●●●● 
●●●●-●●●●○●○●●●●●○●●●●●-●●●●○●●●●●-●●●●●●●●●●○●●●●●●●●○●●●●●○●●●○●-●●●●●●●○●●●●●●●●●●●●●●●○●○●●●●-●●●●●●●●●● 
●●●●-●●●●○●○●●●●●●●●●●●-○●●●●●●●●●-●●●●●●●●○●●●●●●●●●●●●○○○●●●●●●●-●●●●●●●●●●●●●●●●●●○●●●      -●●●●●●●○●● 
●●● -●●●●●●●●●●●●●●●●●●-●●●●●●●●●○-●●●●○●●●●●●●●●●●●○●●●○●●●●○●●●●-●●●●●●●●●●●●●●●●●      -●●●●●●●●●● 
●●●●-                                -●●●●●○●●●●●●●●●●●○●●●○●●●●○●●●●-●●●●●●●○●●●●●●●●●                -●●●●●●●●●● 
Figure 4.8b. BGS of the TFPI2 promoter in SiHa. The methylation status of all 106 CpGs located in the TFPI2 promoter in SiHa cells 
was assessed using bisulphite genomic sequencing (BGS). ○ = unmethylated CpG, ● = methylated CpG. The region covered by the MSP 
primers is indicated in red.
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Transcription start site
5’ 3’
I II III IV V
CpG Islands: 1 2 3 4 5
MSP primers
CpG Number:
6-19 36-66 67-96 97-10626-292-5
●●●●-●●●●●●●●●●●●●●-●●●○-●●●●-●●●○●●-○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○-○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○-●●●●●●●●●● 
●●●●-●●●●●●●●●●●●●●-●●●○-●●●●-○○○○○○-○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○-●●●●●●●●●●○●●○●●●●●●●●●●●●●●●●-●●●●●●●●○● 
●●●●-●●●●●●●●●●●●●●-●●●●-○●●●-○●●○○○-○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○-●●●●●●●●●●○●●○●●●●●●●●●●●●●●●●-●●●●●●●●●● 
●●●●-●●●●●●●●●●●●●●-●●●●-●●●●-○○○○○○-○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○-○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○-○○○○○○○○○○ 
●●●●-●●●●●●●●●●●●●●-●●●○-○○●○-●●○●●●-○○○○○○○●○○○○○○○○○○○○○○○○○○○○○○○-○○●○○○○○○●●○○●●●●○○●○●●●○●●●●●-●●●●●●●●●○ 
●●●●-●●●●●●●●●●●●●●-●●●●-     -○○●●●●-○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○-○○●●●○○○○○○○○○●○●●●●○●○○●●●●●●-○○○○○○○○○○ 
●●●●-●●●●●●●●●●●●●○-●●●●-     -●●●●●●-○○○○●○○○○○○○○○○○○○○○○○○○○○○○○○○-●●●●●●●●●●●●●●●●●●●●●●○●●●●●●●-●●●●●●●●●● 
●●●●-●●●●●●●●●●●●●●-●●●●-     -●●●●●●-○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○-○○●○○○○○○○○○○○○○○○○○○○○○○○○○○○-●●●●●●●○●● 
                         -●●●●●●●●●●●●●●●●●●○●●○●●●●●●●●- 
20-23 30-35
Figure 4.8c BGS of the TFPI2 promoter in HeLa. The methylation status of all 106 CpGs located in the TFPI2 promoter in HeLa cells 
was assessed using bisulphite genomic sequencing (BGS). ○ = unmethylated CpG, ● = methylated CpG. The region covered by the MSP 
primers is indicated in red.
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To show that these results could be replicated using the EZ DNA Methylation-Gold 
KitTM 500 ng of DNA from CaSki, SiHa, HeLa and C33A were bisulphite modified 
using the kit. The bisulphite modified DNA was eluted in 20 μl, and 2 μl was used in 
the MSP reaction. Using MSP, methylation of the TFPI2 promoter was found in 
CaSki, SiHa, HeLa and C33A (the latter had previously only been unmethylated) 
(Figure 4.9). No product was seen with the wild-type primers confirming the 
completeness of bisulphite modification using the kit. As the MSP results using DNA 
bisulphite modified using the kit were comparable to those obtained following 
standard bisulphite modification, all subsequent samples were bisulphite modified 
using the kit. 
 
4.4.4 Optimising nested MSP conditions in cervical smears  
Nested MSP of CDKN2A and DAPK1 in cervical smear samples was optimised using 
the 11 HGCIN and the 10 normal cervical samples; nested MSP was repeated using a 
series of different PCR conditions, using DNA bisulphite modified using the kit (see 
section 3.3.4.3 Materials and Methods):  
 
• Increasing the number of PCR cycles. To increase the sensitivity of the 
technique. 
 
• Increasing the annealing temperature (Tm) of the methylated primer in the 
stage 2 PCR. To ensure the highest specificity of amplification of only 
methylated alleles in the sample (mispriming can occur more readily at lower 
annealing temperatures).  
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PCR cycles stage 1: 20 20 30 40 40 40 40 40 40 40 40 
PCR cycles stage 2: 25 30 25 30 30 30 30 30 30 30 30 
M primer Tm (°C) 60 60 60 60 65 66 68 70 65 66 70 
Diluting stage 1 PCR product No No No No No No No No 1:50 1:50 1:50 
             
HGCIN 
(n=11) 
0  
(0%) 
0 
 (0%) 
2  
(18%) 
9  
(82%) 
4  
(36%) 
2  
(18%) 
1  
(9%) 
0  
(0%) 
4  
(36%) 
4  
(36%) 
0  
(0%) 
 
No. with 
methylation Normal 
(n=10) 
1  
(10%) 
3  
(30%) 
5  
(50%) 
7  
(70%) 
3  
(30%) 
3  
(30%) 
0  
(0%) 
0  
(0%) 
3 
(30%) 
3  
(30%) 
0  
(0%) 
 
Table 4.4 Summary of nested MSP for DAPK1 in HGCIN and normal smears using different PCR conditions. 
 
 
 
 
PCR cycles stage 1: 40 40 40 40 
PCR cycles stage 2: 30 40 40 40 
Stage 2 PCR cycling times 30s 15s 15s 15s 
M primer Tm (°C) 68 68 70 70 
Diluting stage 1 PCR product No No No 1:50 
      
HGCIN 
(n=11) 3 (27%) 3 (27%) 4 (36%) 4 (36%) 
 
No. with 
methylation Normal 
(n=10) 2 (20%) 2 (20%) 3 (30%) 1 (10%) 
 
Table 4.5 Summary of nested MSP for CDKN2A in HGCIN and normal smears using different PCR conditions.
 
Results 
• Diluting the stage 1 PCR product prior to amplification in the stage 2 PCR. 
False positives can occur more readily if too much template is taken forward 
to the stage 2 PCR. 
 
Tables 4.4 and 4.5 summarise the results of nested MSP for CDKN2A and DAPK1 
using different PCR conditions. The optimal PCR conditions for nested MSP in 
cervical smear samples for CDKN2A and DAPK1 are shown in Table 4.6: 
 
Conditions CDKN2A DAPK1 
No of PCR cycles: Stage 1 40 40 
No of PCR cycles: Stage 2 40 30 
Annealing temp of methylated primer (°C) 70 66 
Dilution of stage 1 PCR product 1:50 1:50 
 
Table 4.6 Optimal nested MSP conditions for CDKN2A and DAPK1 in cytological samples. 
 
As no case-control difference was observed between the cytological samples taken 
from women with HGCIN compared to those from disease-free women for DAPK1 
(Table 4.4), only CDKN2A was taken forward for the study of smoking-induced 
methylation changes in cervical material.  
 
4.5 Association between smoking status and CDKN2A methylation in cervical 
smears from disease-free women 
To demonstrate an association between smoking and methylation in disease-free 
women, nested MSP for CDKN2A was performed using cervical smear samples from 
a longitudinal cohort of 2,011 women (see 3.2.1 Materials and Methods). 
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Results 
4.5.1 Study population 
A cohort of 2,011 women aged 15 to 19 years were recruited from a single family 
planning clinic (a Brook Advisory Centre) between 1988 and 1992.  These women 
were seen every 6 months when a cervical smear was taken and the smoking history 
was updated. The study populations for all analyses described below comprise subsets 
of the 1,075 women who were cytologically normal and tested negative for HPV 
DNA in the cervical smear taken at study entry (incident cohort) (see section 3.2.4 
Materials and Methods).  
 
4.5.2 Sensitivity of nested MSP for CDKN2A 
Many attempts were made to determine the sensitivity of the nested MSP assay using 
serial dilutions of the methylated control mixed with a fixed amount of the CpGenome 
Universal unmethylated control (vial B). However, the reproducibility of the result 
was poor and we believed that this was probably because the sensitivity of the assay 
was functioning at the limits of detection. The minimal reproducible sensitivity was 
1:1000; however at this level the methylated PCR product was always a very strong 
band when visualised using agarose gel electrophoresis and ethidium bromide 
staining, while positive methylation PCR products from cytological samples were 
frequently faint bands, suggesting that the sensitivity of my assay was greater then 
1:1000. A pragmatic decision was therefore made that a sample would be considered 
positive only if a methylated band was obtained on 2 replicates. 
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Results 
4.5.3 Prevalence of CDKN2A methylation in smokers and never smokers 
I first wanted to conduct a cross-sectional analysis to determine if there was a 
difference in the prevalence of methylation of the CDKN2A promoter in smokers 
compared to never smokers. This analysis was restricted to women who had normal 
cervical smears and who tested negative for HPV DNA in cervical samples 
throughout follow-up (disease-free women).  
 
Within the entire cohort of 2,011 young women, 1,022 had smoked at some point 
during follow-up (Figure 4.10):  
719
232
54 14 1 1 1
0
100
200
300
400
500
600
700
800
No. of 
women
0-2 2-4 4-6 6-8 8-10 10-12 12-14
Pack-years smoked at the end of follow-up
 
Figure 4.10 Chart showing the distribution of pack-years smoked for all smokers within the 
entire cohort of 2,011 young women. 
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Results 
Women were categorised as light, moderate or heavy smokers according to whether 
their cumulative number of pack-years smoked at the end of follow-up fell in the 
lower (0-0.76 pack-years), middle (0.76-1.83 pack-years) or upper third (1.83-12.11 
pack-years) of the distribution of pack-years smoked in the entire cohort of 2011 
young women.  
 
Never smokers 
25 women who had never smoked before study entry and who remained non-smokers 
throughout follow-up (never smokers), were randomly selected from the pool of 
disease-free never smokers (Table 4.7, n=534). To ensure the “disease-free” status of 
the sample, 1 cervical smear from the middle of the range of all the available 
cytological samples for each woman was selected for DNA extraction, and bisulphite 
modification. 
 
 
Ever smokers 
before study 
entry 
Smoking 
status at first 
interview 
Smoking 
status after 
first interview 
Gave up at some 
point during 
follow up 
No. of 
women   
Incident 
smokers 
Ex-
smokers 
N N N - 534    
N N Y N 66  66  
N N Y Y 31  31 31 
Y N N - 46    
Y N Y N 34    
Y N Y Y 11   11 
Y Y N - 22   22 
Y Y Y N 253    
Y Y Y Y 78   78 
   Total 1075   97 142 
 
 
Table 4.7 Smoking status of the 1075 young women who were cytologically normal and HPV-
negative at study entry. 
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Results 
Smokers 
25 disease-free women who smoked throughout follow-up were randomly selected 
from the category of heavy smokers. The last cervical smear for each of the smokers 
was selected for DNA extraction and bisulphite modification. 
 
Nested MSP for CDKN2A was performed on the selected cervical smear of these 50 
women. The stage 2 PCR was performed in duplicate. A sample was considered: 
positive for CDKN2A methylation when a methylated band was seen in both stage 2 
PCR replicates using the methylated primers; negative when only an unmethylated 
band was detected; and non-evaluable when no band was seen using either the 
methylated or the unmethylated primers. 
 
Methylation of the CDKN2A promoter was detected in 2/21 (9%) evaluable disease-
free never smokers (Figure 4.11) and in 7/21 (33%) evaluable disease-free heavy 
smokers (Figure 4.12) (p=0.06).  
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Figure 4.11 Nested MSP for CDKN2A in never smokers. Using nested MSP, methylation of 
the CDKN2A promoter was detected in 2 replicates in 2/21 (9%) evaluable smears taken from 
disease-free never smokers (NNN1 AND NNN15). Expected product size: unmethylated primer 
(U) = 151bp, methylated primer (M) = 150bp. UCA (CpGenome Universal unmethylated DNA 
(vial A)) and UCB (CpGenome Universal unmethylated DNA (vial B)) were used as positive 
controls for unmethylated DNA, and MC (methylated control) was used as a positive control for 
methylated DNA. W1, template-free control from both stages of PCR. W2, template-free control 
from stage 2 PCR only
.
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151bp
S1 S2 S3 S4 S5 S6 S7 S8 S9 S10 UCA UCB MC W1 W2
U primers 2
150bp
S1 S2 S3 S4 S5 S6 S7 S8 S9 S10 UCA UCB MC W1 W2
M primers 2
151bp
S11 S12 S13 S14 S15 S16 S17 S18 S19 S20 S21 S22 S23 S24 S25
U primers 1
150bp M primers 1
S11 S12 S13 S14 S15 S16 S17 S18 S19 S20 S21 S22 S23 S24 S25
151bp
S11 S12 S13 S14 S15 S16 S17 S18 S19 S20 S21 S22 S23 S24 S25
U primers 2
150bp M primers 2
S11 S12 S13 S14 S15 S16 S17 S18 S19 S20 S21 S22 S23 S24 S25
Figure 4.12 Nested MSP in 25 heavy smokers. Using nested MSP, methylation of the CDKN2A
promoter was detected in 2 replicates in 7/20 (33%) evaluable smears taken from disease-free 
heavy smokers (S1, S3, S6, S7, S8, S12, S15). Expected product size: unmethylated primer (U) = 
151bp, methylated primer (M) = 150bp. UCA (CpGenome Universal unmethylated DNA (vial 
A)) and UCB (CpGenome Universal unmethylated DNA (vial B)) were used as positive controls 
for unmethylated DNA, and MC (methylated control) was used as a positive control for 
methylated DNA. W1, template-free control from both stages of PCR. W2, template-free control 
from stage 2 PCR only
150bp
150bp
S1 S2 S3 S4 S5 S6
S7 S8 S9 S10 UCA UCB MC W1 W2
M primers 1
150bp
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U primers 1
 
Results 
We next wanted to see if we could detect a dose-response relationship. A further 25 
disease-free women were randomly selected from each of the categories of light and 
moderate smokers. Again the last cervical smear was selected for DNA extraction and 
bisulphite modification. Using nested MSP, methylation of the CDKN2A promoter 
was detected in 7/21 (33%) evaluable disease-free light smokers (Figure 4.14), and in 
9/20 (45%) evaluable disease-free moderate smokers (Figure 4.13). Thus the 
prevalence of CDKN2A methylation did not vary with smoking category; however the 
range of values of pack-years smoked was not extensive in this population of young 
women.  
 
Overall, methylation of the CDKN2A promoter was detected more frequently in 
disease-free smokers than in disease-free never smokers; 23/62 (37.1%) evaluable 
samples taken from smokers, compared to only 2/21 (9.3%) evaluable samples taken 
from never smokers (Fisher’s exact p-value=0.03). 
 
Although this cross-sectional survey did suggest an association between smoking 
status and the detection of methylated forms of CDKN2A, inferences based on such 
surveys may be confounded by extraneous factors which are associated with both 
smoking and the detection of CDKN2A methylation. Therefore, I next set out to 
determine if smoking preceded the first detection of TSG methylation, using a subset 
of women from the incident cohort who first began to smoke after they were enrolled 
on study (incident smokers). 
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150bp
S26 S27 S28 S29 S30 S31 S32 S33 S34 S35 S36 S37 S38 S39 S40
M primers
150bp
S41 S42 S43 S44 S45 S46 S47 S48 S49 S50
M primers
150bp M primers
150bp M primers
S26 S27 S28 S29 S30 S31 S32 S33 S34 S35 S36 S37 S38 S39 S40
S41 S42 S43 S44 S45 S46 S47 S48 S49 S50
Figure 4.13 Nested MSP in 25 moderate smokers. Using nested MSP, methylation of the 
CDKN2A promoter was detected in 2 replicates in 9/20 (45%) evaluable smears taken from 
disease-free moderate smokers (S26, S27, S32, S34, S40, S41, S43, S49). Expected product 
size: unmethylated primer (U) = 151bp, methylated primer (M) = 150bp. 
151bp U primers
151bp U primers
151bp U primers
151bp U primers
S26 S27 S28 S29 S30 S31 S32 S33 S34 S35 S36 S37 S38 S39 S40
S41 S42 S43 S44 S45 S46 S47 S48 S49 S50
S26 S27 S28 S29 S30 S31 S32 S33 S34 S35 S36 S37 S38 S39 S40
S41 S42 S43 S44 S45 S46 S47 S48 S49 S50
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150bp M primers
150bp M primers
150bp M primers
150bp M primers
Figure 4.14 Nested MSP in 25 light smokers. Using nested MSP, methylation of the CDKN2A
promoter was detected in 2 replicates in 7/21 (33%) evaluable smears taken from disease-free 
light smokers (S52, S53, S56, S60, S66, S68, S71). Expected product size: unmethylated primer 
(U) = 151bp, methylated primer (M) = 150bp. 
151bp U primers
151bp U primers
151bp U primers
151bp U primers
S51 S52 S53 S54 S55 S56 S57 S58 S59 S60 S61 S62 S63 S64 S65
S66 S67 S68 S69 S70 S71 S72 S73 S74 S75
S51 S52 S53 S54 S55 S56 S57 S58 S59 S60 S61 S62 S63 S64 S65
S66 S67 S68 S69 S70 S71 S72 S73 S74 S75
S51 S52 S53 S54 S55 S56 S57 S58 S59 S60 S61 S62 S63 S64 S65
S66 S67 S68 S69 S70 S71 S72 S73 S74 S75
S51 S52 S53 S54 S55 S56 S57 S58 S59 S60 S61 S62 S63 S64 S65
S66 S67 S68 S69 S70 S71 S72 S73 S74 S75
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 4.5.4 Incidence of CDKN2A methylation in smokers and never smokers 
Next, we compared the incidence of methylation of the CDKN2A promoter in disease-
free incident smokers with that in disease-free never smokers. From the incident 
cohort of 1,075 women who were cytologically normal and who tested negative for 
HPV DNA at study entry, 97 women began smoking during follow-up (Table 4.7 ) 
and 60 of these remained cytologically normal and HPV-negative throughout follow-
up. All the cervical samples from these 60 women were selected for DNA extraction 
and bisulphite modification followed by nested MSP for CDKN2A. Women were 
excluded from subsequent analyses when the last sample taken before smoking 
initiation was unavailable or not evaluable (n=10), when it tested positive for 
methylated forms of CDKN2A (n=3), or if no smoking sample was available or 
evaluable (n=9) (Table 4.8).  
 
Incident smokers from 1075 97   
Subsequent test positive for HPV or CAB  37 
Pre-smoking smear missing  8 
Pre-smoking smear non-evaluable  2 
Pre-smoking smear methylated  3 
Smoking smears missing  3 
Smoking smears non-evaluable  6 
Disease-free incident smokers evaluable 38   
 
Table 4.8 Breakdown of all incident smokers excluded from subsequent analyses. 
 
Of the remaining 38 women who tested negative for CDKN2A methylation in the 
sample taken immediately before they began to smoke, 8 subsequently tested positive 
for methylated forms of CDKN2A after smoking initiation (Table 4.9); the median 
time to first detection of methylation of the CDKN2A promoter was 266 days (range 
153-824). 
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Each of the 38 women contributing to this incidence analysis was matched, on length 
of follow-up (within 30 days), with two randomly selected disease-free never 
smokers. For the 8 women who first tested positive for methylated forms after 
smoking initiation, the follow-up period was defined as the interval between the last 
unmethylated sample taken before smoking initiation and the first cervical sample to 
test positive for methylated forms during that smoking episode. For the remaining 30 
women who did not test positive for methylated forms after they started to smoke, the 
follow-up period was defined as the interval between the last unmethylated sample 
taken before smoking initiation and the last cervical sample taken during that smoking 
episode. Nested MSP for CDKN2A was performed on the first and last matched 
sample from each never smoker control. Three controls were excluded from 
subsequent analyses because of the presence of methylated forms in the first of their 
two samples (n=2) or when one of the two samples was not evaluable (n=1). Of the 
remaining 73 controls who tested negative for methylated forms of CDKN2A in their 
first sample, 5 tested positive for these forms in their second sample. Compared with 
disease-free never smokers, disease-free women who first started to smoke during 
follow-up had an increased risk of acquiring methylation of the CDKN2A promoter 
(odds ratio=3.67; 95% CI 1.09 to 12.33; χ2=4.42; 1 df: p=0.04).  
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Smoking smears 
  
Study no. Pre-smoking 
smear 1 2 3 4 5 6 7 
1 235 U M       
2 322 U M       
3 731 U M       
4 814 U M       
5 1500 U M       
6 1565 U M       
7 571 U M U M     
8 804 U U - - M -   
9 30 U U       
10 131 U U       
11 147 U U       
12 184 U U       
13 338 U U       
14 634 U U       
15 811 U U       
16 882 U U       
17 949 U U       
18 1352 U U       
19 1362 U U       
20 1391 U U       
21 1580 U U       
22 1843 U U       
23 1845 U U       
24 1856 U U       
25 1922 U U       
26 2080 U U       
27 1912 U - U      
28 1915 U - U      
29 4 U U U      
30 756 U U U      
31 1020 U U U      
32 1581 U U U      
33 1759 U U U      
34 1679 U U U U     
35 1330 U U U U -    
36 231 U U - - U    
37 1151 U U U - U U   
38 277 U U U U U - - U 
 
 
Table 4.9 Nested MSP results for the 38 incident smokers who tested negative for CDKN2A 
methylation in their last pre-smoking smear. Nested MSP for CDKN2A was performed on all the 
smears taken following smoking initiation, whilst the women remained cytologically normal and HPV-
negative. U; unmethylated for CDKN2A in 2 replicates. M; methylated for CDKN2A in 2 replicates.      
- = non evaluable sample. 
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4.5.5 Loss of CDKN2A methylation following smoking cessation 
Finally, I measured how often CDKN2A methylation was reversible following 
smoking cessation. This analysis was again restricted to disease-free women. From 
the incident cohort of 1,075 women who were cytologically normal and who tested 
negative for HPV DNA at study entry, 142 women stopped smoking during follow-up 
(Table 4.7) and 75 of these remained cytologically normal and HPV-negative 
throughout follow-up. For these 75 women, the final cervical sample whilst they were 
still smoking, and all the subsequent cervical samples following smoking cessation 
were selected for DNA extraction and bisulphite modification. Women were excluded 
from subsequent analyses when the last sample taken before smoking cessation was 
unavailable or not evaluable (n=9), when it tested negative for methylated forms of 
CDKN2A (n=40), or if no ex-smoking sample was available or evaluable (n=7) (Table 
4.10). 
 
Ex-smokers from 1075 142  
Tested positive for HPV or CAB during follow-up  67 
Smoking smear missing  3 
Smoking smear non-evaluable  6 
Not methylated on last smoking smear  40 
Ex-smoking smear missing  5 
Ex-smoking smear non-evaluable  2 
Disease-free ex-smokers evaluable 19  
 
Table 4.10 Breakdown of all ex-smokers excluded from subsequent analyses 
 
Of the remaining 19 women who tested positive for CDKN2A methylation in their last 
cervical sample taken immediately before they stopped smoking, 12 subsequently 
tested negative for CDKN2A methylation in one or more cervical samples after 
smoking cessation; the median time to the first negative sample was 432 days (range 
161-1107) (Table 4.11). Of the 7 women who continued to test positive for 
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methylated forms of CDKN2A following smoking cessation, 6 women provided one 
further sample and 1 woman provided two further samples. However, as the range of 
follow-up times for these women was only 190 to 893 days (median 266), it would be 
unwise to conclude that their epigenetic marks were in any meaningful sense “fixed”.  
 
 
 
Ex-smoking smears 
  
Study 
no. 
Final 
smoking 
smear 1 2 3 4 
1 250 M U    
2 706 M U    
3 751 M U    
4 828 M U    
5 1363 M U    
6 1433 M U    
7 1458 M U U -  
8 1500 M U U   
9 733 M M U   
10 949 M M U   
11 439 M - M U U 
12 977 M - M - U 
13 1053 M M M   
14 329 M M    
15 411 M M    
16 606 M M    
17 973 M M    
18 1353 M M    
19 1727 M M       
 
 
Table 4.11 Nested MSP results for the 19 ex-smokers who tested positive for CDKN2A 
methylation in their last smoking smear. Nested MSP for CDKN2A was performed on all the smears 
taken following smoking cessation, whilst the women remained cytologically normal and HPV-
negative. U; unmethylated for CDKN2A in 2 replicates. M; methylated for CDKN2A in 2 replicates.      
- = non evaluable sample. 
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4.5.6 Specificity of nested MSP assay 
To exclude false priming, ie amplification of unmethylated alleles by the methylated 
primers, a subset of methylated products was analysed by direct sequencing (n=21): 
methylation of all CpGs within the CDKN2A primer sites was observed in every case 
(Figure 4.12).  
 
 
       F primer      R primer   Sample tube no: 
●●●●●●●●●●●●●●●●●●   Methylated control 
●●●○○○○○○○○○○○●●●●   C2 
●●●○○○○○○○○○○○●●●●   C6 
●●●○○○○○○○○○○○●●●●   C10 
          ○○○○○○○○○○○●●●●   E4 
          ●●●●●●●●●●●●●●●     E12 
                ○○○○○○○○●●●●   E14 
●●●○○○○○○○○○○○●●●●   M7 
●●●○○○○○○○○○○○●●●●   M171 
●●●○○○○○○○○○○○●●●●   M219 
●●●○○○○○○○○○○○●●●●   M237 
    ●●○○○○○○○○○○○    P28 
●●●○○○○○○○○○○○    P38 
         ○○○○○○○○○○○●●●●   P39 
         ○○○○○○○○○○○●●●●   S3 
          ○○○○○○○○○○○●●●●   S23 
           ○○●●●○●●●●●●●●●   S26 
●●●●○○●●●●○●○●●●●●   S53 
●●●○●○●●●●○●●●●●●●    S58 
            ○○○○○○○○○○○●●●●   S78 
               ○○○○○○○○○○○●●●●   S86 
 
 
Figure 4.12 Specificity of nested MSP. Summary of direct sequencing results for the extracted 
methylated band from 21 samples. Methylation of all CpGs within the CDKN2A primer sites was 
observed in every case. The CDKN2A forward (F) primer sequence contains 3 CpGs. The CDKN2A 
reverse (R) primer sequence contains 4 CpGs. ○ = unmethylated CpG, ● = methylated CpG.
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5.1 Restatement of Objectives 
To investigate the spectrum of methylation changes associated with human 
papillomavirus (HPV) infection: 
• To describe and validate the changes in DNA methylation which follow the 
transfection of PHFK (isolated from a single donor) with episomal HPV18, 
and which follow long term cultivation of the W12 disease progression model. 
 
• To determine how often changes in DNA methylation observed using these 
models are recapitulated in cervical neoplasia. 
 
• To investigate possible determinants of virus-associated methylation changes. 
 
• To describe and validate the transcriptional changes which follow the 
transfection of PHFK (isolated from a single donor) with episomal HPV18 and 
which follow long-term cultivation of the W12 disease progression model. 
 
• To compare these transcriptional changes with those reported in published 
gene expression arrays using similar in vitro models, and to determine how 
often these changes are recapitulated in cervical neoplasia. 
 
• To examine the relationship between methylation and transcriptional changes 
in these models. 
 
• To investigate possible HPV18-induced ‘epigenetic switching’, using a 
candidate gene approach. 
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In this section, I report the results of a pilot study designed to evaluate the use of the 
UHN HCGI12K arrays in the cervical cancer cell line, HeLa. I first describe the steps 
involved in data processing, normalisation and analysis before reporting for a panel of 
candidate genes, how often the methylation status predicted by the array could be 
confirmed using bisulphite genomic sequencing. Finally, I determine how often genes 
which were predicted to be methylated on the array have previously been reported to 
be methylated in cervical neoplasia.  
 
 
5.2 Assessment of the methylation status of CpG islands in HeLa cells 
At the time of this study, the UHN HCGI12K array was the only array-based platform 
commercially available for the measurement of methylation changes. The technique 
was first optimised in HeLa cells.  
 
Differential methylation hybridisation (DMH) was performed in HeLa cells with 4 
technical replicates as described in section 3.3.9 (Materials and Methods). The HeLa 
samples restricted with McrBC were labelled with Cy5, and the mock-digested 
samples were labelled with Cy3. 
 
5.2.1 Data processing  
The Cy3 and Cy5 fluorescent intensities were obtained for each hybridised spot (see 
3.3.9.3). Prior to data analysis, array spots of low quality were first filtered as 
described in section 3.3.9.4. After this filtering step, the number of remaining array 
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spots contributing to the data analysis for all 4 replicates of HeLa is shown in Table 
5.1. 
 
Array No. of spots 
“Not Found” 
No. with signal intensities 
near background (<25) 
Remaining 
spots 
HeLa 1 1601 805 9786 
HeLa 2 768 12 11412 
HeLa 3 1710 7 10475 
HeLa 4 294 3 11895 
 
Table 5.1 Filtering - spots of low quality were first removed prior to data analysis. 
 
5.2.2 Normalisation 
The median Cy3 and Cy5 signal intensities of all the mitochondrial clones on each 
array were used to calculate a normalisation factor as described in section 3.3.9.5, and 
this was then applied to all the probes on each corresponding array. 
  
5.2.3 Confirmation of the adequacy of the normalisation step 
The log ratios of the mitochondrial clones were plotted for each array. Following 
normalisation the log ratio should equal zero. Figure 5.1 shows that the log ratios for 
the mitochondrial clones for each replicate were close to zero.  
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HeLa 1: Normalised log ratios for mitochondrial clones
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HeLa 2: Normalised log ratios for mitochondrial clones
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HeLa 4: Normalised log ratios for mitochondrial clones
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Figure 5.1 Normalised log ratios of the mitochondrial clones for all 4 replicates of HeLa. 
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The log (mock-cut) vs the log (cut) was plotted to check that the mitochondrial clones 
cover the full range of the signal intensities. Figure 5.2 shows that the mitochondrial 
clones on each array cover most of the range of the signal intensities. Graphs of log 
ratio (M) vs mean log intensity (A) (MA graphs) were then plotted for each array 
individually. Based on the assumption that most genes will be unchanged, the 
majority of points on the y axis (log ratio) will be located at zero. Figure 5.3 shows 
that the log ratio for all probes on each array was located around zero following 
normalisation. 
 
5.2.4 Data analysis 
Having shown that the technical quality of each individual array was adequate, the 4 
replicates were then analysed together. Only clones that were informative in all 4 
replicates were selected. Any clone with a low quality result in any of the 4 replicates 
was removed from further analysis: 2932 clones were filtered leaving 9260 common 
informative clones on all 4 arrays, corresponding to 2804 unique genes. 
 
A fluorescent ratio was calculated for all the remaining spots with the mock-cut signal 
intensity (Cy3) as denominator and the cut signal intensity (Cy5) as numerator. The 
resulting ratio reflects the degree of methylation of each CpG island clone; a ratio 
approaching 0 indicates a methylated CpG island, and a ratio approaching 1 indicates 
an unmethylated CpG island. Average fluorescent ratios were then calculated using 
the normalised ratios from each of the 4 technical replicates. 
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Figure 5.2 Log (mock-cut) vs log (cut) plots for all 4 replicates of HeLa showing that the 
mitochondrial clones (in pink) cover most of the range of the signal intensities on each array. 
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a) HeLa 1  Pre      Post 
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c) HeLa 3 
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Figure 5.3 Graphs of log ratio (M) vs mean log intensity (A) (MA plots) pre and post-
normalisation for all 4 replicates of HeLa. 
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To further categorise the data, I have used the method published by Nouzova et al 
(2004), in which the methylation status is classified using the cut/mock-cut ratios: 
  <0.5   = heavily methylated (HM) 
 
  0.5-0.67  = methylated (M) 
  0.68-0.87 = partially methylated (PM) 
  >0.87   = not methylated (NM) 
 
Table 5.2 and Figure 5.4 show the number of informative clones and the 
corresponding genes in each of these methylation categories. Genes that were 
represented more than once on the array were re-allocated to the category with the 
highest methylation status.  
 
Category No. of clones No. of genes  
Heavily methylated (<0.5) 163 (2%) 85 
Methylated (0.5-0.67) 652 (7%) 298 
Partially methylated (0.68-0.87) 3897 (42%) 1366 
Not methylated (>0.88) 4548 (49%) 1055 
 
Table 5.2 Distribution of the methylation status of the common informative clones in HeLa cells 
and their corresponding genes. 
49%
  
Figure 5.4 Graph showing the distribution of the methylation status of the common informative 
clones in HeLa cells. 
2% 
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5.2.5 Validation using bisulphite genomic sequencing 
To determine if these arbitrary cut-off values accurately predicted methylation status, 
the CpG islands corresponding to 2 genes from each of the four categories were 
selected for validation by bisulphite genomic sequencing (BGS) (Table 5.3). The 
primer sequences used are listed in Table 3.4 (Materials and Methods). The primers 
were designed to cover all the CpGs present in each CpG island clone selected for 
analysis by BGS 
 
Category UHN ID Gene symbol Cut/mock-cut ratio 
Heavily methylated (<0.5) UHNhscpg0000969 MARK1 0.46 
 UHNhscpg0000007 SOCS3 0.39 
Methylated (0.5-0.67) UHNhscpg0002561 RARB 0.56 
 UHNhscpg0011071 WT1 0.54 
Partially methylated (0.68-0.87) UHNhscpg0006964 ATM 0.84 
 UHNhscpg0010927 CDKN2A 0.81 
Not methylated (>0.88) UHNhscpg0010736 CDH13 0.88 
 UHNhscpg0001366 ROBO3 0.95 
 
Table 5.3 Selection of genes for confirmation by bisulphite genomic sequencing. 
 
Bisulphite genomic sequencing was only successful for five genes (SOCS3, RARB, 
ATM, CDH13 and ROBO3) (Figure 5.5). For SOCS3 and RARB, there was good 
concordance between the methylation status predicted by the array and that observed 
by BGS. However, the array results and the BGS data were discordant for 3 genes. 
Although ATM was predicted to be “partially methylated” using the array (the 
cut/mock-cut ratio was 0.84), it was unmethylated by BGS. Similarly, CDH13 and 
ROBO3 were both predicted to be “not methylated” using the array, but using BGS I 
have shown them both to be partially methylated. Thus the cut-off values do not 
reliably predict methylation status determined by BGS when a gene is not methylated 
or is partially methylated, but do when the gene is methylated or heavily methylated.  
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a)   SOCS3 (“heavily methylated”)   b)   RARB (“methylated”)  
                                                           
●●●●●●●●●●●     ●●●●●●●●●●●●●●●●○ 
○●●○●●●●●●●     ●●●●●●●●●●●●●●●●○ 
●●●●●●●●●●●     ●●○●●●●●●●●●●●●●● 
●●●●●●●●●●●     ●●●●●●●●●●●●●●●●● 
●●●●●●●●●●●     ●●●●●●●●●●●●●○●●○ 
●●●●●●●●●●●     ●●●●●●●●●●●●●●●●○ 
●●●●●●●●●●●      
○●●○●●●●●●●      
 
4503bp downstream  
 
c) ATM (“partially methylated”)   d)   CDH13 (“not methylated”)  
 
○○○○○○○○      ●●○● 
○○○○○○○○      ○●○○ 
○○○○○○○○      ●●○● 
○○○○○○○○      ●●○● 
○○○○○○○○      ○●○● 
○○○○○○○○      ●●○○ 
○○○○○○○○       
○○○○○○○○       
  
 
      247bp upstream 
e) ROBO3 (“not methylated”) 
 
●●○●●●● 
●●●○●●● 
○●○○●●● 
○○●○●●● 
○○○●●●● 
●●○●●○● 
●○○●○○○ 
●●○●●●○ 
 
 
 
   1005bp upstream 
Figure 5.5 Bisulphite genomic sequencing results for HeLa. Each circle represents a CpG site. 
●=methylated CpG. ○=unmethylated CpG. Below each set of BGS result is a diagrammatic 
representation of the location of the CpG island in relation to the transcriptional start site (arrow) of the 
gene; the vertical lines represent CpG sites. The methylation status predicted by the array is shown in 
inverted commas. 
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 5.2.6 External validation 
A review of the literature has previously identified 31 genes that are methylated 
significantly more frequently in women with invasive cervical cancer compared with 
disease-free controls or women with low-grade CIN (see section 4.2 and Table 4.2). 
This analysis has recently been updated by Professor Ciaran Woodman, and the 
number of genes reported to be hypermethylated in cervical neoplasia has now 
increased to 58. Of these 58 genes, 15 are represented on the UHN HCGI12K arrays 
in HeLa cells post-filtering (see section 5.2.4). Table 5.4 shows the number of genes 
predicted in HeLa cells to be “heavily methylated” or “methylated” using the UHN 
HCGI12K arrays, which have previously been reported to be methylated in cervical 
neoplasia. 
 
Methylated in cervical neoplasia Methylation status in 
HeLa cells Yes No 
Odds ratio 
(95% CI) 
“Not methylated” 
(n=1055) 
 
 
2 
 
1053 
1 
(reference) 
“Heavily methylated” or 
“methylated” 
(n=383) 
 
8 
 
375 
11.3 
(2.4-53.3) 
p=0.0001 
 
Table 5.4 Frequency with which genes classified as “heavily methylated” or “methylated” in 
HeLa cells are known to be methylated in cervical neoplasia. 
 
 
This comparison revealed that compared to genes predicted to be “not methylated” in 
HeLa cells, those genes which were classified as “heavily methylated” or 
“methylated” were found to be enriched significantly (11-fold) for genes previously 
reported to be methylated in cervical neoplasia; these 8 genes are listed in Table 5.5. 
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Genes Reference 
CDH13 Widschwendter 2004; Feng 2005; Henken 2007 
HOXA11 Apostolidou 2009 
NKX6-1 Lai 2008 
ONECUT1 Lai 2008 
RARB Virami 2001; Narayan 2003; Gustafson 2004; 
Feng 2005; Wisman 2006; Henken 2007 
ROBO1 Narayan 2006 
SLIT2 Narayan 2006 
SOCS3 Shivapurkar 2007 
 
 
Table 5.5 List of 8 genes predicted to be “heavily methylated” or “methylated” in HeLa cells and 
also known to be methylated in cervical neoplasia.  
 
 
In summary, in this section I have shown that using the UHN HCGI12K array in 
HeLa cells, 2 candidate genes predicted to be “heavily methylated” or “methylated” 
were confirmed as such using BGS. Furthermore, compared with genes predicted to 
be “not methylated” in HeLa cells, genes predicted to be “heavily methylated” or 
“methylated” were also significantly more likely to be known to be methylated in 
cervical neoplasia. The UHN HCGI12K array was therefore taken forward for use in 
our 2 in vitro models, primary human foreskin keratinocytes following transfection 
with HPV18 and the W12 disease progression model. 
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In this section, I describe how the UHN HCGI12K arrays were used to assess the 
methylation status of cellular genes in untransfected PHFK, and how this changed 
following transfection of these cells with HPV18. I first describe and compare using 
the methods outlined in the preceding section, the methylation changes seen at an 
early (P4) and later passage (P9) before investigating how often changes in 
methylation status predicted on the array could be confirmed by pyrosequencing. 
Finally, I determine whether genes which were predicted to have increased 
methylation following HPV18 transfection were enriched for those previously 
reported to be methylated in cervical neoplasia. 
 
 
5.3 Methylation changes following transfection of PHFK with HPV18 
The UHN HCGI12K arrays were used to assess the methylation status of cellular 
genes in untransfected PHFK from a single neonatal donor (#1), and the methylation 
changes following transfection with HPV18 at an early (P4) and later passage (P9). 
 
Prior to data analysis, arrays spots of low quality were first filtered as described in 
section 3.3.9.4 (Table A1, Appendix). The data were then normalised using the subset 
of mitochondrial clones on each array as described in section 3.3.9.5.  
 
For the data analysis all 9 arrays were analysed together. Only clones that were 
informative in all 9 arrays were selected: 3534 clones were filtered leaving 8658 
common informative clones on all 9 arrays, corresponding to 2612 unique genes.  
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In untransfected PHFK (#1), <1% (35) of the clones were classified as “heavily 
methylated”, 4% “methylated” (352), 20% “partially methylated” (1758) and 75% 
“not methylated” (6513) (Figure 5.6a). 
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Figure 5.6a Graph showing the distribution of the methylation status of the common informative 
clones in untransfected PHFK (#1). 
 
At passage 4, in PHFK (#1) transfected with HPV18, 2% (160) of the clones were 
classified as “heavily methylated”, 15% “methylated” (1296), 43% “partially 
methylated” (3765) and 40% “not methylated” (3437) (Figure 5.6b). 
 
2%
15%
43%
40%
0%
10%
20%
30%
40%
50%
60%
% Clones
Heavily methylated Methylated Partially methylated Not methylated
Methylation status
 
Figure 5.6b Graph showing the distribution of the methylation status of the common informative 
clones in PHFK (#1) transfected with HPV18 – passage 4. 
 
164 
 
   Results 
At passage 9, in PHFK (#1) transfected with HPV18, 2% (181) of the clones were 
classified as “heavily methylated”, 10% “methylated” (843), 48% “partially 
methylated” (4141) and 40% “not methylated” (3493) (Figure 5.6c). 
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Figure 5.6c Graph showing the distribution of the methylation status of the common informative 
clones in PHFK (#1) transfected with HPV18 – passage 9. 
 
 
These graphs show that at passage 4 of PHFK (#1) transfected with HPV18, the 
distribution of the methylation status of the common informative clones showed an 
increase in the number of clones classified as “methylated” and “partially 
methylated”, and a decrease in the number of clones classified as “not methylated”. 
However there were no substantial changes in these proportions between passage 4 
and passage 9. 
 
5.3.1 Differentially methylated genes 
A gene was considered to be differentially methylated if the cut/mock-cut ratios of the 
associated clone between untransfected PHFK (#1) and PHFK (#1) transfected with 
HPV18 at passages 4 or 9, were found to be significantly different (p<0.05) using the 
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t-test (see section 3.3.9.6). Table 5.6 shows the number of clones and their 
corresponding genes found to be differentially methylated at an early and later 
passage of PHFK (#1) following transfection with HPV18. 
 
Comparison Methylation change No. of clones No. of genes  
hypermethylated 1546 667 
hypomethylated 83 30 
PHFK(#1)/HPV18 P4 vs 
untransfected PHFK 
both* - 6 
hypermethylated 1698 556 
hypomethylated 103 56 
PHFK(#1)/HPV18 P9 vs 
untransfected PHFK 
both* - 7 
hypermethylated 564 172 
hypomethylated 574 291 
PHFK(#1)/HPV18 P9 vs 
PHFK(#1)/HPV18 P4 
both* - 9 
 
Table 5.6 Number of clones and corresponding genes differentially methylated in PHFK (#1) 
following transfection with HPV18. 
*Both = genes identified as both hypermethylated and hypomethylated in non-overlapping regions 
 
At both an early and late passage of PHFK (#1) following transfection with HPV18, it 
can be seen that more genes became hypermethylated than hypomethylated compared 
to untransfected PHFK (#1). In total 986 unique genes became significantly more 
methylated at early or late passages, or both, while 51 unique genes became 
significantly less methylated. 
 
5.3.2 De novo methylated genes 
I also undertook an analysis to identify genes which became methylated de novo 
following transfection of PHFK (#1) with HPV18. A CpG island clone was classified 
as methylated de novo if it was “not methylated” in untransfected PHFK (#1) (>0.87) 
and then became “methylated” (0.5-0.67) or “heavily methylated” (<0.5) following 
transfection with HPV18 (early or late passage). Table 5.7 shows the number of 
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clones and their corresponding genes which became de novo methylated following 
transfection of PHFK (#1) with HPV18 at passages 4 and 9. 
 
De novo methylation No. of clones No. of genes 
Heavily methylated Early 4 4 
Methylated Early 290 167 
Both* - 0 
Heavily methylated Late 28 18 
Methylated Late 287 136 
Both* - 2 
 
Table 5.7 Number of clones and corresponding genes which became de novo methylated following 
transfection of PHFK (#1) with HPV18. 
*Both = genes identified as both “heavily methylated” and “methylated” in non-overlapping regions in 
cells from the same passage 
 
In total 566 unique CpG island clones became methylated de novo following 
transfection of PHFK with HPV18 at early or late passage, corresponding to 294 
unique genes. 
 
Interestingly, most of the genes which became methylated de novo at early and late 
passages did not overlap: only 29 genes were common to both groups (Figure 5.7).  
 
Figure 5.7 Number of genes which 
became de novo methylated in PHFK 
transfected with HPV 18 compared to 
untransfected keratinocytes. 
  
29 123 142 
Late vs controlEarly vs control  
 
142 unique genes which became “methylated” or “heavily methylated” for the first 
time at early passage (P4) were found to be less methylated at passage 9. Of the 29 
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genes which were found to be de novo methylated at both early and late passages, 
only 3 of these showed an increase in methylation between early and late passage – 
from “methylated” to “heavily methylated”. The remaining 26 genes became 
“methylated” at early passage and their methylation status remained unchanged at 
passage 9. 123 unique genes became de novo methylated for the first time at late 
passage. 
 
5.3.3 Validation of methylation changes using pyrosequencing 
Pyrosequencing was used to validate some of the methylation changes observed in 
PHFK (#1) following transfection with HPV18, using DNA harvested from the same 
passages used to probe the UHN HCGI12K arrays. All the pyrosequencing analyses 
were performed twice.  
 
5.3.3.1 Criteria used to select genes for validating methylation changes in PHFK 
following transfection with HPV18: 
Twelve genes (CDH13, NKX6-1, NOL4, RARB, SLIT2, SOX1, COL5A3, GAP43, KIT, 
NR2F1, PLXDC2, and UNC5B) were selected which fulfilled both of the following 
criteria (Table A3, Appendix): 
• Not methylated in untransfected PHFK (#1) 
• Became “methylated” or “heavily methylated” following transfection of 
PHFK (#1) with HPV18 at early or late passages (ie de novo methylated) 
 
Six of these genes have also previously been reported to be methylated in cervical 
neoplasia (CDH13, NKX6-1, NOL4, RARB, SLIT2, SOX1).  
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5.3.3.2 Pyrosequencing results 
The sequence provided in the annotation file was used to design pyrosequencing 
primers: one or more primers were designed to cover all (or nearly all) the CpGs 
present in each CpG island probe. The primer sequences used are listed in Table A5 
(Appendix). Pyrosequencing analysis was performed in untransfected PHFK (#1), and 
in PHFK (#1) following transfection with HPV18 at passages 4 and 9. 
 
Of the 12 genes, 1 (SLIT2) could not be analysed further because no CpG sites were 
present in the sequence provided in the annotation file; this must be considered a false 
positive result, the reasons for which will be discussed later. Two genes (SOX1 and 
KIT) repeatedly failed the pyrosequencing run despite producing a single band of the 
correct size following PCR amplification. Pyrosequencing analysis was successful for 
the remaining 9 genes. De novo methylation was confirmed in only 3 genes (NKX6-1, 
PLXDC2 and RARB) (Table 5.8). For NKX6-1, de novo methylation was observed at 
CpG 9 and for PLXDC2, this was observed at CpG 1. For RARB, de novo methylation 
of CpGs 1-3 was found at passage 4 following transfection with HPV18.  In addition, 
in untransfected keratinocytes, 3 CpGs (numbers 13, 18 and 19) in RARB were 
already methylated, and these showed a further increase in methylation at passage 4 
following transfection with HPV18. For all 3 genes (NKX6-1, PLXDC2 and RARB) 
pyrosequencing also demonstrated progressive methylation at all the CpG sites 
described between passages 4 and 9, whilst the UHN HCG12K array predicted no 
further change or a decrease in methylation between these 2 stages.  
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The pyrosequencing results for the remaining 6 genes (CDH13, COL5A3, GAP43, 
NOL4, NR2F1, UNC5B) are shown in Table 5.9; de novo methylation was not 
demonstrated at any CpG site for these 6 genes. Furthermore, although all 6 genes 
were predicted by the array to be not methylated in untransfected keratinocytes, 
pyrosequencing revealed significant methylation at all the CpG sites for 3 genes 
(CDH13, NR2F1 and UNC5B). 
 
   Results 
 
   % Methylation 
Gene Sample Cut/mock-
cut ratio 
CpG 
1 
CpG 
2 
CpG 
3 
CpG 
4 
CpG 
5 
CpG 
6 
CpG 
7 
CpG 
8 
CpG 
9 
CpG 
10 
CpG 
11 
CpG 
12 
CpG 
13 
CpG 
15 
CpG 
16 
CpG 
17 
CpG 
18 
CpG 
19 
Untransfected PHFK#1 0.94 0.0 4.2 16.6 12.2 6.5 0.0 3.6 3.2 0.0 5.9 6.8 10.8 0.0 4.8     
PHFK#1/HPV18 P4 0.67 0.0 1.8 11.3 9.7 5.9 2.3 5.9 3.7 5.0 4.2 5.1 9.9 0.0 0.0     
PHFK#1/HPV18 P9 0.65 2.7 1.8 10.7 5.3 5.5 3.4 4.6 6.1 10.9 4.9 9.5 10.3 0.0 6.4     
 
NKX6-1 
MC - - - - - - 91.3 90.9 89.1 95.0 81.1 96.3 96.8 76.3 98.0     
                     
Untransfected PHFK#1 0.99 7.7 12.0 3.9 2.7 10.8 15.8             
PHFK#1/HPV18 P4 0.58 13.3 12.3 4.6 3.5 10.6 19.5             
PHFK#1/HPV18 P9 0.75 18.9 14.8 6.0 3.4 13.8 24.7             
 
PLXDC2 
MC - 98.8 93.6 97.6 94.6 95.9 88.5             
                     
Untransfected PHFK#1 0.93 3.7 5.1 3.8 3.5 1.9 2.3 3.7 2.4 4.7 2.9 7.0 5.8 9.9 7.0 4.1 4.9 13.0 
 
 
Table 5.8a Pyrosequencing results for selected candidate genes in the PHFK-HPV18 cell line. This table shows the number of CpGs analysed in the selected 
CpG island for each gene, and the methylation percentage at each CpG site using cells from untransfected PHFK (from donor #1), and PHFK from the same donor 
transfected with HPV18 at passage (P) 4 and P9. The corresponding cut/mock-cut ratios using the UHN HCGI12K array are shown. MC, methylated control.  
17.1 
PHFK#1/HPV18 P4 0.56 15.1 16.8 13.7 4.9 4.0 3.5 5.0 2.0 4.7 4.6 14.2 7.0 14.6 7.6 4.3 5.5 24.7 30.3 
PHFK#1/HPV18 P9 0.95 19.6 22.7 17.9 5.1 3.8 4.7 5.1 4.1 9.1 5.2 14.0 10.5 19.6 4.5 3.4 7.0 22.2 34.0 
 
RARB 
MC - 94.8 97.2 95.7 93.1 96.4 60.1 90.4 77.6 92.6 95.2 100.0 91.0 97.0 100.0 100.0 100.0 95.9 91.4 
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   % Methylation 
No. Gene Sample 
Cut/mock-
cut ratio CpG 1 CpG 2 CpG 3 CpG 4 CpG 5 CpG 6 CpG 7 CpG 8 CpG 9 CpG 10 CpG 11 
Untransfected PHFK#1 0.88 2.3 3.0 0.0 3.6 0.0 3.8 0.0     
PHFK#1/HPV18 P4 0.67 3.2 3.9 2.5 3.8 0.0 5.5 4.9     
PHFK#1/HPV18 P9 0.67 3.2 3.5 2.9 2.6 0.0 4.6 4.1     
 
1 
 
COL5A3 
MC - 96.2 95.4 95.5 93.7 74.6 100.0 98.9     
               
Untransfected PHFK#1 1.16 9.7 15.3 16.6 0.0 11.3 2.7 5.1 0.0 6.2   
PHFK#1/HPV18 P4 1.00 10.1 16.3 12.2 0.0 8.9 7.5 5.8 9.6 4.9   
PHFK#1/HPV18 P9 0.63 6.7 14.4 11.5 0.0 9.8 5.1 9.3 9.7 7.4   
 
2 
 
NOL4 
MC - - 99.1 91.2 88.4 56.7 95.4 97.4 100.0 89.4   
               
Untransfected PHFK#1 0.88 50.9 56.9 65.0 36.1 64.2 13.5 54.2 59.6 62.6 36.0 56.7 
PHFK#1/HPV18 P4 0.50 49.6 54.3 61.7 18.8 61.4 11.3 51.6 59.0 52.5 41.2 52.6 
PHFK#1/HPV18 P9 0.88 56.7 62.0 67.2 12.6 62.4 10.2 62.5 76.3 77.4 66.0 78.9 
MC - 60.3 83.3 100.0 99.5 93.6 44.3 100.0 100.0 95.5 97.4 95.5 
             
  CpG 12 CpG 13 CpG 14 CpG 15 CpG 16 CpG 17 CpG 18 CpG 19 CpG 20 CpG 21  
Untransfected PHFK#1 0.88 53.2 47.2 54.4 39.5 55.0 32.6 57.9 57.2 60.2 46.8  
PHFK#1/HPV18 P4 0.50 53.6 46.0 46.7 35.0 49.3 30.8 52.7 51.3 54.1 47.9  
PHFK#1/HPV18 P9 0.88 76.9 67.0 57.0 65.1 64.8 42.5 61.9 69.2 74.6 63.3  
 
 
 
 
3 
 
 
 
 
NR2F1 
MC - 100.0 91.8 83.9 100.0 78.2 72.7 73.3 87.4 100.0 96.2  
 
 
 
 
Table 5.8b Pyrosequencing results for selected candidate genes in the PHFK-HPV18 cell line II. This table shows the number of CpGs analysed in the selected 
CpG island for the remaining 6 genes, and the methylation percentage at each CpG site using cells from untransfected PHFK (from donor #1), and PHFK from the 
same donor transfected with HPV18 at passage (P) 4 and P9. The corresponding cut/mock-cut ratios using the UHN HCGI12K array are shown. MC, methylated 
control.  
 
   Results 
   % Methylation 
No. 
Cut/mock-
cut ratio Gene Sample CpG 1 CpG 2 CpG 3 CpG 4 CpG 5 
Untransfected PHFK#1 0.88 86.2 88.4 96.7 70.1 100.0 
PHFK#1/HPV18 P4 0.68 82.3 90.3 94.7 70.5 100.0 
PHFK#1/HPV18 P9 0.77 87.3 87.9 89.7 73.4 94.5 
 
4 
 
CDH13 
MC - 96.5 91.7 97.8 74.0 100.0 
         
Untransfected PHFK#1 0.88 3.6 5.7 7.8 0.0  
PHFK#1/HPV18 P4 0.56 4.4 4.0 11.0 6.4  
PHFK#1/HPV18 P9 0.61 4.7 5.2 10.9 4.2  
 
5 
 
GAP43 
MC - 92.0 91.8 91.8 66.9  
         
Untransfected PHFK#1 0.92 15.7 16.9 15.6 19.3  
PHFK#1/HPV18 P4 0.48 16.1 16.9 13.1 11.3  
PHFK#1/HPV18 P9 0.76 15.2 20.6 13.2 6.5  
 
6 
 
UNC5B 
MC - 89.1 89.9 76.7 85.3  
 
Table 5.8b (cont) 
 
5.3.4 External validation: Comparison with genes previously reported to be 
methylated in cervical neoplasia  
Next, the results of the UHN HCGI12K arrays performed in PHFK (#1) following 
transfection with HPV18, were compared with genes previously reported to be 
methylated in cervical neoplasia. Of the 58 genes, 18 were represented on the UHN 
HCGI12K arrays in the PHFK-HPV18 cell line (post-filtering) (see section 5.2.6).  
 
Methylated in cervical neoplasia Change in methylation status 
Yes No 
Odds ratio 
(95% CI) 
No 
(n=1626) 
 
10 1616 1 
(reference) 
 
Significantly 
more methylated 
E or L Yes  
(n=986) 
8 978 OR = 1.3 
95% CI: 0.5-3.4 
p = 0.5565 
     
No 
(n=2318) 
 
13 2305 1 
(reference) 
 
De novo 
methylated  
E or L Yes 
(n=294) 
5 289 OR = 3.0 
95% CI: 1.1-8.7 
p = 0.0260 
 
Table 5.9 Frequency with which genes differentially more methylated or de novo methylated 
following transfection of PHFK (#1) with HPV18, are known to be methylated in cervical 
neoplasia. 
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Of these 18 genes, 8 (CDH13, HSPA2, ONECUT1, OPCML, RARB, RB1, ROBO1, 
SLIT2) were found to be significantly more methylated at early or late passages 
following transfection of PHFK (#1) with HPV18 (Table 5.9, top panel). However, 
compared to genes which did not become significantly more methylated, those which 
did were not significantly enriched for genes previously reported to be methylated in 
cervical neoplasia. 
 
When the analysis was restricted to genes that became de novo methylated (Table 5.9, 
bottom panel), of the 18 genes known to be methylated in cervical neoplasia, 5 
(CDH13, NKX6-1, RARB, SLIT2, SOX1) were found to be de novo methylated at early 
or late passages following transfection of PHFK (#1) with HPV18. This analysis 
revealed that compared to genes that did not become de novo methylated, genes that 
did were significantly enriched (3-fold) for genes previously reported to be 
methylated in cervical neoplasia. The 5 genes identified were CDH13, NKX6-1, 
RARB, SLIT2, and SOX1.  
 
 
In summary, in this section I have shown using the UHN HCGI12K array platform 
that 986 genes were significantly more methylated, and 51 genes significantly less 
methylated in PHFK (#1) following transfection with HPV18. De novo methylation 
was also observed in 294 unique genes, and in this group there was a significant 
enrichment for genes previously reported to be methylated in cervical neoplasia. 
Pyrosequencing analysis was successful in 9 genes, but de novo methylation was 
confirmed in only 3 genes. 
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In this section, I describe how the UHN HCGI12K arrays were used to assess the 
methylation status of cellular genes in early (P11) and late (P56) passages of the W12 
cell line, a disease progression model.  I first describe and compare using the methods 
outlined in preceding sections, the methylation changes seen at early and late 
passages, before investigating how often changes predicted on the array could be 
confirmed by pyrosequencing. Finally, I determine whether genes which were 
predicted to have increased methylation following progression of the W12 cell line 
were enriched for those previously reported to be methylated in cervical neoplasia. 
 
 
5.4 Methylation changes in the W12 disease-progression model 
The UHN HCGI12K arrays were also used to assess the methylation status of W12 
cells at passages 11 and 56, as described in section 5.3.  
 
For the data analysis all 6 arrays were analysed together. Only clones that were 
informative in all 6 arrays were selected: 1500 clones were filtered leaving 10692 
common informative clones on all 6 arrays, corresponding to 3014 unique genes.  
 
In W12 P11 cells, 2% (248) of the clones were classified as “heavily methylated”, 5% 
“methylated” (568), 21% “partially methylated” (2215) and 72% “not methylated” 
(7661) (Figure 5.8a).  
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2%
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Methylation status
 
Figure 5.8a Graph showing the distribution of the methylation status of the common informative 
clones in W12 passage 11 cells. 
 
 
In W12 P56 cells, 3% (340) of the clones were classified as “heavily methylated”, 7% 
“methylated” (771), 21% “partially methylated” (2277) and 68% “not methylated” 
(7304) (Figure 5.8b). 
3%
7%
21%
68%
0%
10%
20%
30%
40%
50%
60%
70%
% Clones
Heavily methylated Methylated Partially methylated Not methylated
Methylation status
 
Figure 5.8b Graph showing the distribution of the methylation status of the common informative 
clones in W12 passage 56 cells. 
 
These graphs show that there was no substantial change in the distribution of the 
methylation status of the common informative clones between W12 passage 11 and 
W12 passage 56. 
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5.4.1 Differentially methylated genes 
A gene was considered to be differentially methylated if the cut/mock-cut ratios of the 
associated clone between W12 passage 11 and 56, were found to be significantly 
different (p<0.05) using the t-test (see section 3.3.9.6). Table 5.10 shows that 108 and 
81 genes were significantly more and less methylated respectively, between W12 
passages 11 and 56.  
 
Comparison Change in methylation No. of clones No. of genes  
hypermethylated 193 108 
hypomethylated 145 81 
 
W12 P56 vs W12 P11 
Both* - 3 
 
Table 5.10 Number of clones differentially methylated between W12 passages 11 and 56, and 
their corresponding genes. 
*Both = genes identified as both hypermethylated and hypomethylated in non-overlapping regions 
 
5.4.2 Validation of methylation changes using pyrosequencing 
Pyrosequencing was used to validate some of the methylation changes observed 
between W12 passages 11 and 56, using DNA harvested from the same passages used 
to probe the UHN HCGI12K arrays. All the pyrosequencing analyses were performed 
twice.  
 
5.4.2.1 Criteria used to select genes for validating methylation changes in the W12 
disease progression model: 
Of the 108 genes which became hypermethylated between W12 passages 11 and 56, 8 
genes were selected for validation (Table A4, Appendix); 4 of these (BARD1, FANCL, 
HTRA1, PHOX2B) were known to have tumour suppressor activity and 4 genes 
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(CDH12, DOCK5, PAX2, PPP2CA) demonstrated the largest change in methylation 
status between passage 11 and 56. 
 
5.3.2.2 Pyrosequencing results 
The sequence provided in the annotation file was used to design pyrosequencing 
primers (see section 5.3.3.2). The primer sequences used are listed in Table A5 
(Appendix). 
 
Of the 8 genes selected for validation, 2 (BARD1 and PHOX2B) were very CpG rich 
and it was not possible to design any suitable primers. Two more (CDH12 and 
DOCK5) could not be analysed because no CpG sites were present in the sequence 
provided in the annotation file. These must be considered false positive results. For 1 
gene (PPP2CA) pyrosequencing analysis failed despite multiple attempts. 
Pyrosequencing analysis was successful for the remaining 3 genes. Increased 
methylation was confirmed in only 1 gene, PAX2, at CpG 4 (Table 5.11). For the 2 
other genes (FANCL and HTRA1) an increase in methylation was not demonstrated at 
any CpG site (Table 5.11). Furthermore, although FANCL and HTRA1 were both 
predicted by the array to be “not methylated” in W12 P11 cells, pyrosequencing 
revealed significant methylation at all the CpG sites for both genes. 
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% Methylation  
Gene 
 
Sample 
Cut/mock-
cut ratio CpG 1 CpG 2 CpG 3 CpG 4 CpG 5 CpG 6 CpG 7 CpG 8 CpG 9 CpG 10  
W12 P11 1.00 93.0 39.8 62.2 39.5 63.3 63.6 68.2 72.4 66.0 40.3  
W12 P56 0.73 77.9 35.1 36.0 47.2 68.7 67.5 73.7 63.6 62.4 29.3  
 
FANCL 
MC  97.9 59.1 73.6 74.3 71.4 70.6 77.6 79.9 49.7 30.9  
              
W12 P11 0.89 39.8 33.3 98.1 82.2 86.4       
W12 P56 0.63 42.8 35.6 97.4 82.3 87.7       
 
HTRA1 
MC  67.6 66.2 99.3 68.5 95.4       
              
W12 P11 0.96 3.8 44.0 36.4 7.0 5.9 5.4 3.4 5.9 3.6 0.0  
W12 P12 - 5.3 41.9 36.4 6.7 0.0 5.3 0.0 0.0 0.0 0.0  
W12 P13 - 4.8 44.5 34.4 7.2 6.0 5.9 3.8 5.1 4.1 6.1  
W12 P14 - 4.8 44.3 36.2 9.5 0.0 4.8 0.0 4.9 5.1 0.0  
W12 P15 - 6.6 45.8 36.2 9.3 5.9 6.8 0.0 4.5 0.0 5.2  
W12 P56 0.6 7.8 45.0 33.0 17.7 8.7 10.4 7.9 6.3 5.7 0.0  
MC  100.0 87.7 86.0 63.0 87.3 83.1 69.7 83.9 69.7 86.1  
             
  CpG 11 CpG 12 CpG 13 CpG 14 CpG 15 CpG 16 CpG 17 CpG 18 CpG 19 CpG 20 CpG 21 
W12 P11 0.96 5.0 3.1 6.0 6.0 4.2 6.4 5.1 3.8 6.2 4.4 4.2 
W12 P56 0.6 4.2 5.9 8.6 12.1 7.6 8.3 14.3 5.9 7.4 4.8 4.9 
 
 
 
 
 
PAX2 
MC  100.0 94.6 100.0 94.3 85.7 91.0 93.4 63.0 94.7 82.9 64.6 
 
 
Table 5.11 Pyrosequencing results for selected candidate genes in the W12 cell line. This table shows the number of CpGs analysed in the selected CpG island 
for each gene, and the methylation percentage at each CpG site using cells from W12 passage (P) 11 and P56. For the PAX2 gene, methylation of CpGs1-10 (primer 
set 1) was also analysed in cells taken from W12 P12-15. The corresponding cut/mock-cut ratios using the UHN HCGI12K array are shown. MC, methylated 
control.  
 
   Results 
To assess if the observed de novo methylation of PAX2 is related to the loss of 
episomal forms of HPV16 in the W12 cell line, pyrosequencing of the PAX2 CpG 
island was also performed in W12 cells from passages 11 to 15 (Table 5.11); I have 
previously shown that complete loss of viral episomes, with the emergence of 
integrated forms alone, occurs at passage 12 in this W12 cell line (Figure 5.9).  
 
 P11 P12 P13 P14 P15  P56 
PAX2 - CpG 4 7.0% 6.7% 7.2% 9.5% 9.3%                17.7% 
 
 
 
 
 
 
 
Figure 5.9 Viral integration in the W12 cell line. Five overlapping primers had been designed (by Dr 
Constandinou-Williams) to cover the HPV16 E2 gene (primer sets 1-5). PCR using DNA from serial 
passages of the W12 cell line shows that complete loss of HPV16 episomes occurs at passage 12 in this 
W12 cell line, in the presence of intact HPV16 E6 gene (ie presence of integrated forms only). Water 
was used as a template-free control for the PCR. The top panel shows for the PAX2 gene, the 
percentage methylation of CpG 4 between W12 P11-P15. 
413bp
223bp
242bp
206bp
348bp
161bp
Primer set 1
Primer set 5
Primer set 4
Primer set 3
Primer set 2
HPV16 E6 primers
HPV16 E2
P11 P12 P22P21P20P19P18P17P16P15P14P13 Water
 
Using pyrosequencing, methylation of CpG 4 of the PAX2 gene did not change 
substantially between P11 and P15, but was increased at P56. This analysis showed 
that the increased methylation of PAX2 in the W12 cell line is a late event, and one 
that cannot be directly linked to viral integration.  
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5.4.3 External validation: Comparison with genes known to be methylated in 
cervical neoplasia  
The results of the UHN HCGI12K arrays performed in the W12 cell line were 
compared with genes previously reported to be methylated in cervical neoplasia. Of 
the 58 genes, 21 were represented on the UHN HCGI12K arrays in the W12 cell line 
(post-filtering) (see section 5.2.4).  
 
Methylated in cervical neoplasia Change in methylation status 
Yes No 
Odds ratio 
(95% CI) 
No 
(n=2909) 
 
 
20 
 
2889 
1 
(reference) 
 
 
Hypermethylated in 
W12 P56 vs P11 Yes  
(n=105) 
 
1 
 
104 
OR = 1.4 
95% CI: 0.2-10.4 
p = 0.7485 
 
Table 5.12 Frequency with which genes differentially more methylated in W12 P56 compared to 
P11 are known to be methylated in cervical neoplasia. 
 
Of these 21 genes, one gene (CDH13) was found to be significantly more methylated 
at P56 compared to P11 (Table 5.12). However, compared with genes that did not 
become significantly more methylated during long term cultivation of the W12 cell 
line, genes that did were not significantly enriched for genes previously reported to be 
methylated in cervical neoplasia. 
 
My observation that only a small number of genes became differentially methylated 
between W12 passages 11 and 56 could be explained if most of the methylation 
changes have already taken place by W12 passage 11. To test this hypothesis, I 
examined how often genes previously reported to be methylated in cervical neoplasia 
were already methylated at W12 passage 11 (Table 5.13). 
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Methylated in cervical neoplasia Methylation status at p11 
Yes No 
Odds ratio 
(95% CI) 
Not methylated 
(n=1713) 
9 1704 1 
(reference) 
Methylated 
(n=1301) 
12 1289 OR = 2.0 
95% CI: 0.8-4.9 
p = 0.1275 
 
Table 5.13 Frequency with which genes known to be methylated in cervical neoplasia were 
detected in W12 P11 cells, stratified by methylation status. 
 
Table 5.13 shows that of the 21 genes known to be methylated in cervical neoplasia, 
12 were already methylated (“partially methylated”, “methylated” or “heavily 
methylated”) at W12 passage 11. This analysis revealed that compared to genes that 
were not methylated at W12 P11, genes that were methylated were twice as likely to 
be known to be methylated in cervical neoplasia, although this was not statistically 
significant. 
 
 
In summary, in this section I have shown that genes which became more methylated 
following long term cultivation of the W12 cell line were not significantly enriched 
for genes known to be methylated in cervical neoplasia. This may in part be explained 
by my observation that many of these genes were already methylated at W12 passage 
11. Pyrosequencing analysis was successful for 3 genes, but increased methylation 
was confirmed in only 1 of these.  
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5.5 Determinants of virus-associated methylation changes 
In this section, I investigate why the methylation status of some cellular genes is 
changed following transfection with HPV18, and others are not. I consider two 
hypotheses discussed in the introduction to this thesis. First, that the likelihood of a 
change in methylation status can be predicted from a gene’s CpG content and second, 
that genes which are reported to be marked by both H3K27me3 and H3K4me3 in 
human embryonic stem cells (HES) are more likely to be hypermethylated following 
transfection with this oncogenic virus. The analysis was restricted to genes found to 
be more methylated in the PHFK-HPV18 cell line only; the W12 cell line was not 
explored further because only a small number of differentially methylated genes had 
been identified. 
 
5.5.1 Datasets used in the analyses 
Three datasets were used in these analyses: 
• The UHN HCGI12K arrays performed in the PHFK-HPV18 cell line (n=2612). 
 
• A CpG content array. Weber et al (2007) classified genes as having low, 
intermediate or high CpG content. The total number of genes on this array was 
15,609. Following re-annotation of this dataset 14,899 named genes remained. 
 
• An array describing the distribution of histone marks. Zhao et al (2007) used 
chromatin immunoprecipitation coupled with the paired-end ditags sequencing 
strategy to profile 2 histone marks, H3K4me3 and H3K27me3, in HES. The total 
number of genes on this array was 17,468. Following re-annotation of this dataset, 
16,950 genes remained. 
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The final number of genes contributing to the analyses comprised 1885 genes 
common to all 3 datasets. 
 
5.5.2 Determinants of HPV18-induced methylation changes 
A univariate analysis was undertaken to examine if the susceptibility to methylation 
change in cellular genes was associated with CpG content and also to determine if 
genes marked by H3K4me3 or H3K27me3 in HES were more likely to be methylated 
in PHFK following transfection with HPV18 (Table 5.14). 
 
Determinant Methylation 
increased 
(n=728) 
Methylation 
not increased 
(n=1157) 
Odds ratio 
(95% CI) 
Methylation 
decreased 
(n=32) 
Methylation 
not decreased 
(n=1853) 
Odds ratio 
(95% CI) 
Low CpG 
content 
(n=250) 
 
94 
 
156 
1  
(reference) 
 
2 
 
248 
1  
(reference) 
 
Intermediate 
CpG content 
(n=231) 
 
81 
 
150 
0.9 
(0.6-1.3) 
p = 0.5636 
 
4 
 
227 
2.1 
(0.4-12.0) 
p = 0.3577 
High CpG 
content 
(n=1404) 
 
553 
 
851 
1.1 
(0.8-1.4) 
p = 0.5936 
 
26 
 
1378 
2.3 
(0.6-9.9) 
p = 0.2349 
       
Not marked 
by 
H3K4me3/ 
H3K27me3 
(n=247) 
 
91 
 
156 
 
1  
(reference) 
 
3 
 
244 
 
1  
(reference) 
Marked by 
H3K4me3 
alone 
(n=1320) 
 
506 
 
814 
1.1 
(0.8-1.4) 
p = 0.6578 
 
21 
 
1299 
1.3 
(0.4-4.4) 
p = 0.6584 
Marked by 
H3K4me3 & 
H3K27me3 
(n=318) 
 
131 
 
187 
1.2 
(0.9-1.7) 
p = 0.2933 
 
8 
 
310 
2.2 
(0.5-8.0) 
p = 0.2668 
 
Table 5.14 Distribution of the determinants of the gain and loss of methylation following 
transfection of PHFK with HPV18 – a univariate analysis. 
 
In the top panel of Table 5.14, the 1885 genes included in the analysis were stratified 
by CpG content; the CpG content was low in 250 genes, intermediate in 231 genes 
and high in 1404 genes. The proportion of genes in each category with increased 
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methylation following transfection with HPV18 was first examined, taking the low 
CpG content category as the reference (Table 5.14, top left panel). Of the 250 genes 
with low CpG content, methylation increased in 94/250 (38%). Of the 231 genes with 
intermediate CpG content, methylation increased in 81/231 (35%). Of the 1404 genes 
with high CpG content, methylation increased in 553/1404 (39%). Thus there was no 
association between CpG content and increased methylation. This assessment was 
repeated for the genes with decreased methylation (Table 5.14, top right panel). These 
analyses show that CpG content does not significantly increase the likelihood of a 
gene becoming more or less methylated following transfection of PHFK with HPV18. 
 
In the bottom panel of Table 5.14, the 1885 genes included in the analysis were 
stratified by whether the genes were known to be marked by neither H3K4me3 nor 
H3K27me3, by H3K4me3 alone, or by both H3K4me3 and H3K27me3 in human 
embryonic stem cells; 247 genes were not marked by either H3K4me3 or H3K27me3 
in HES, 1320 genes were marked by H3K4me3 alone, and 318 genes were marked by 
both H3K4me3 and H3K27me3. Next, the proportion of genes in each category with 
increased methylation following transfection with HPV18 was examined, taking the 
category of genes not marked by either H3K4me3 or H3K27me3 as the reference 
(Table 5.14, bottom left panel). Of the 247 genes which were not marked by either 
H3K4me3 or H3K27me3 in HES, methylation increased in 91/247 (37%). Of the 
1320 genes which were marked by H3K4me3 alone in HES, methylation increased in 
506/1320 (38%). Of the 318 genes which were marked by both H3K4me4 and 
H3K27me3 in HES, methylation increased in 131/318 (41%). Thus, being marked by 
H3K4me3 or H3K27me3 in HES does not increase the likelihood of a gene becoming 
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more methylated. This analysis was repeated for the genes with decreased methylation 
(Table 5.14, bottom right panel). These analyses show that being marked by 
H3K4me3 or H3K27me3 in HES cells does not significantly increase the likelihood 
of a gene becoming more or less methylated following transfection of PHFK with 
HPV18. 
 
 
In summary, in this section I have shown that neither CpG content, nor the presence 
of H3K4me3 or H3K27me3 marks in HES are predictive of changes in methylation 
following transfection of PHFK with HPV18. 
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In this section, I summarise the changes found when gene expression arrays were used 
to profile the transcriptional changes observed in PHFK following transfection with 
HPV18, and those found following long term-cultivation of the W12 cell line. I 
compare these changes with the results of one other study which has examined the 
transcriptional consequences of HPV18 infection and with a number of published 
arrays which compare the gene expression profile of tissue taken from women with 
cervical neoplasia with that taken from disease-free controls. Finally, I explore the 
extent to which the changes observed on my methylation arrays predicted the 
transcriptional changes seen on my gene expression arrays. 
 
 
5.6.1 Transcriptional changes following transfection of PHFK with HPV18 
The Affymetrix GeneChip® Human Genome U133 Plus 2.0 arrays were used to 
assess the transcriptional changes between untransfected PHFK (#1) and PHFK (#1) 
transfected with HPV18 at passages 4 and 9, as described in section 3.4.4 (Materials 
and Methods). 
 
Table 5.15 shows the number of probe sets that were differentially expressed or 
unchanged following transfection of PHFK (#1) with HPV18.  
 
No. of probe sets  Comparison Increased Decreased No change 
PHFK/HPV18 P4 vs untransfected PHFK 6580 4751 43344 
PHFK/HPV18 P9 vs untransfected PHFK 7130 4752 42793 
PHFK/HPV18 P9 vs PHFK/HPV18 P4 2187 1917 50571 
 
Table 5.15 Number of probe sets differentially expressed following transfection of PHFK (#1) 
with HPV18. 
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Thus it can be seen that most of the probe sets were unchanged following transfection 
of PHFK with HPV18.  
 
Table 5.16 shows the number of unique genes that were differentially expressed 
following transfection with HPV18. For genes with more than one probe set, the 
probe set with the highest baseline expression level (in untransfected PHFK) was 
selected.  
 
  No. of genes  Comparison Increased Decreased Both 
PHFK/HPV18 P4 vs untransfected PHFK 3158 3171 246 
PHFK/HPV18 P9 vs untransfected PHFK 3397 3127 298 
PHFK/HPV18 P9 vs PHFK/HPV18 P4 1342 1369 63 
 
Table 5.16 No of unique genes differentially expressed following transfection of PHFK (#1) with 
HPV18. 
 
There was an additional layer of complexity in that a subset of genes was identified 
with probe sets that were both up and down-regulated following transfection. For this 
subset of genes, the probe set for each unique gene with the highest expression value 
in untransfected keratinocytes, was used to re-allocate the final expression status of 
these genes following transfection (ie irrespective of the subsequent direction of 
change). Table 5.17 summarises the final number of genes used for all subsequent 
analyses. 
 
No. of genes  Comparison Increased Decreased 
PHFK/HPV18 P4 vs untransfected PHFK 3267 3308 
PHFK/HPV18 P9 vs untransfectedPHFK 3521 3301 
PHFK/HPV18 P9 vs PHFK/HPV18 P4 1370 1404 
 
Table 5.17 No of unique genes differentially expressed following transfection of PHFK (#1) with 
HPV18 – no overlap. 
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Most of the genes (>70%) that were up-regulated in PHFK (#1) following transfection 
with HPV18 were up-regulated at both early and late passages (Figure 5.10).  
Figure 5.10 Genes up-regulated 
following transfection of PHFK 
(#1) with HPV18 at early and 
late passages.  
 
  
1143889 2378 
Late vs control 
(n = 3521) 
Early vs control 
(n = 3267) 
 
Similarly, most of the genes (>80%) that were down-regulated in PHFK (#1) 
following transfection with HPV18, were down-regulated at both early and late 
passages (Figure 5.11).  
Figure 5.11 Genes down-regulated 
following transfection of PHFK 
(#1) with HPV18 at early and late 
passages. 
 
 
 
 
 
  
549 2759 542 
Late vs control Early vs control 
(n = 3301) (n = 3308) 
 
5.6.1.1 External validation: Comparison with published HPV-PHFK arrays 
There has only been one other published study which has compared the transcriptional 
profile of PHFK transfected with HPV18. Karstensen et al (2006) transfected the 
genome of wild type HPV18 into PHFK from a single donor, following which both 
untransfected and transfected keratinocytes were cultured on J2 fibroblast feeder cells. 
The HPV18 remained episomal following transfection. Affymetrix GeneChip® 
Human Genome U133A arrays were used to compare the gene expression profiles 
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using RNA harvested from untransfected PHFK (passage 3-5) and PHFK transfected 
with HPV18 (passage 5-9). Four independent biological replicates were processed and 
hybridised. Cross-comparisons between all 4 replicates in untransfected and 
transfected keratinocytes were performed: genes which were called ‘Present’ and 
‘Increased’ in at least 13 out of 16 comparisons, and which had an average signal log 
ratio (SLR) of greater than 1 were classified as ‘up-regulated’, and genes which were 
called ‘Decreased’ in at least 13 out of 16 comparisons and an average SLR of -1 
were classified as ‘down-regulated’. In this analysis, 147 and 82 genes were reported 
to be up-regulated and down-regulated respectively. 
 
Following re-annotation of this dataset, 145 named genes were found to be up-
regulated and 81 remained down-regulated: Of 145 genes up-regulated on the 
Karstensen array, 60 genes (41%) were also found to be up-regulated on our PHFK-
HPV18 array at early passage, 48 (33%) at late passage and 64 (44%) at either early 
or late passages (Figure 5.12). Of 81 genes down-regulated on the Karstensen array, 
50 genes (62%) were also found to be down-regulated on our PHFK-HPV18 array at 
early passage, 47 (58%) at late passage and 53 (65%) at either early or late passages 
(Figure 5.13). 
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 PHFK-HPV18 array Karstensen array 
 
   
Early 3207 60 85
N = 145N = 3267  
   
48Late 973473
N = 145N = 3521  
   
64Early or 4346 81
Late 
N = 145N = 4410  
Figure 5.12 Number of genes found to be up-regulated on my PHFK-HPV18 array, the 
Karstensen array, or both. 
 
 
 
 
 
Figure 5.13 Number of genes found to be down-regulated on my PHFK-HPV18 array, the 
Karstensen array, or both. 
  
53 283797
N = 3850 N = 81
  
47 343254
N = 3301 N = 81
 
3258
N = 3308
PHFK-HPV18 array 
 
 
Early 
Late 
Karstensen array 
 
50 31
N = 81
Early or 
Late 
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Next, I measured the number of genes which were concordantly or discordantly 
regulated on both arrays (Table 5.18). I defined concordantly regulated genes as those 
that were either up-regulated in both arrays or down-regulated in both arrays; and 
discordantly regulated genes as those that were either up-regulated on my PHFK-
HPV18 array but down-regulated on the Karstensen array or vice versa. This analysis 
was repeated for the PHFK-HPV18 array results at early passage, late passage and 
either early or late passage.  
 
 PHFK/HPV18 P4 PHFK/HPV18 P9 PHFK/HPV18 P4 or P9 
Concordant 110 (49%) 95 (42%) 117 (52%) 
Discordant 17 (8%) 26 (11%) 28 (12%) 
 
Table 5.18 Comparison between the Karstensen array and my PHFK-HPV18 array: number of 
concordant and discordantly regulated genes. 
 
This analysis revealed that 42-52% of the differentially regulated genes identified on 
the Karstensen array were concordantly expressed on my PHFK-HPV18 array, whilst 
only 8-12% of these were discordantly expressed. 
 
5.6.2 Transcriptional changes in the W12 disease progression model 
The Affymetrix GeneChip® Human Genome U133 Plus 2.0 arrays were also used to 
measure the transcriptional changes that occur during long term cultivation of the 
W12 cell line, as described in section 3.4.4. This analysis used RNA from passages 11 
and 56. Table 5.19 shows the number of probe sets that were differentially expressed 
or unchanged between these 2 passages. 
 
No. of probe sets Comparison Increased Decreased No change 
W12 P56 vs W12 P11 5196 7408 42071 
 
Table 5.19 Number of probe sets differentially expressed between W12 P11 and W12 P56. 
 
192 
 
   Results 
Table 5.20 shows the number of unique genes that were differentially expressed 
during long term cultivation of the W12 cell line. For genes with more than one probe 
set, the probe set with the highest expression level in W12 P11 cells was selected. 
 
No. of genes Comparison Increased Decreased Both 
W12 P56 vs W12 P11 3671 3939 215 
 
Table 5.20 Number of unique genes differentially expressed between W12 P11 and W12 P56. 
 
Again a subset of genes was identified with probe sets that were both up and down-
regulated on disease progression. For this subset of genes, the probe set with the 
highest expression value in P11 cells for each unique gene was used to reallocate the 
final expression status of these genes following transfection (ie irrespective of the 
subsequent direction of change). Table 5.21 summarises the final number of genes 
used for all subsequent analyses. 
 
No. of genes  Comparison Increased Decreased 
W12 P56 vs W12 P11 3560 3835 
 
Table 5.21 Number of unique genes differentially expressed between W12 P11 and W12 P56 – no 
overlap. 
 
5.6.3 External validation: Comparison with published cervical cancer arrays 
The results from the Affymetrix GeneChip® Human Genome U133 Plus 2.0 arrays 
performed in our 2 in vitro models were compared with the results from published 
arrays that have compared the gene expression profile of cervical cancer or CIN with 
that of tissue taken from disease-free controls, and which used the same Affymetrix 
platform as that employed in our experiments: 5 studies were identified (Table A6, 
Appendix). 
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Table 5.22 lists for each of these arrays, the numbers of cases and controls, and the 
criteria used by the authors to identify differentially expressed genes. All the genes 
from these arrays were re-annotated using the Nov 09 Affymetrix annotation. 
 
No. of genes First 
Author 
Platform Samples Criteria 
Increased Decreased 
Pyeon U133 Plus 
2.0 
8 normal cervices and 20 
cervical cancers  
(Re-analysed in-house by 
Dr Wei using GEO dataset) 
Rank Product with 
cut-off set at 10% 
percentage of false 
positives  
1301 1842 
Rosty U133A 5 normal cervices, 5 cell 
lines, 35 primary tumours 
including 5 replicates 
T-test with 5% 
false discovery rate 
999 N/A 
Santin U133A 11 primary cervical cancer 
cell lines derived from stage 
IB-IIA cervical cancers and 
4 normal cervical 
keratinocytes cell lines 
FC > 2; Wilcoxon 
rank-sum p value = 
0.009 
206 214 
Wong U133A 18 normal cervices and 29 
cervical SCC 
FC > 2 in at least 
two-thirds cervical 
SCC compared to 
normal cervices 
20 81 
Zhai U133A 10 normal cervices and 21 
cervical SCC 
FC > 1.5; p < 0.001 952 746 
Zhai U133A 7 HSIL and 21 cervical SCC FC > 1.5; p < 0.001 300 441 
 
Table 5.22 Published cervical cancer arrays: number of cases and controls, criteria used to 
identify differentially expressed genes, and the numbers of differentially expressed genes. 
(FC = fold change) 
 
First, the number of differentially expressed genes in these published cervical cancer 
arrays that were concordantly regulated in the W12 array, the PHFK-HPV18 array, or 
both was assessed (Table 5.23) 
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No. of genes concordantly expressed in:  First 
Author 
Samples No. of genes 
differentially 
expressed on 
array 
W12 PHFK  W12 
and/or 
PHFK 
(P56 vs 
P11) 
(P9 vs 
untransfected) 
Pyeon 8 normal cervices and 20 
cervical cancers 
3143 764 (24%) 460 (15%) 1106 (35%) 
Rosty 5 normal cervices, 5 cell 
lines, 35 primary tumours 
including 5 replicates 
999 551 (55%) 179 (18%) 652 (65%) 
Santin 11 primary cervical cancer 
cell lines derived from 
stage IB-IIA cervical 
cancers and 4 normal 
cervical keratinocytes cell 
lines 
420 236 (56%) 143 (34%) 321(76%) 
Wong 18 normal cervices and 29 
cervical SCC 
101 41 (41%) 47 (47%) 66 (65%) 
Zhai 10 normal cervices and 21 
cervical SCC 
1698 660 (39%) 544 (32%) 1034 (61%) 
Zhai 7 HSIL and 21 cervical 
SCC 
741 246 (33%) 173 (23%) 364 (49%) 
 
Table 5.23 Frequency with which genes that were differentially expressed in the published 
cervical cancer arrays were concordantly regulated on the W12 array, the PHFK-HPV18 array, 
or both. 
 
The number of differentially expressed genes on the published cervical cancer arrays 
ranged from 101 to 3143; this was not surprising given the different criteria used to 
identify differentially expressed genes (see Table 5.22). It can be seen that 24-56% of 
the differentially expressed genes on the cervical cancer arrays were concordantly 
expressed on the W12 array, and 15-47% were concordantly expressed on the PHFK-
HPV18 array. Remarkably, 76% of the genes found to be differentially expressed in 
primary cervical cultures derived from early stage disease when compared with 
cervical keratinocyte cell lines taken from disease-free controls, were concordantly 
expressed in the W12 array, the PHFK-HPV18 array or both. 
 
Next, in order to determine if the overlap with the cervical cancer arrays increases 
with further passaging, the number of differentially expressed genes in the published 
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cervical cancer arrays that were concordantly expressed at early and late passages of 
PHFK (#1) transfected with HPV18 was compared (Table 5.24). 
 
No. of genes concordantly expressed in: First 
Author 
Samples No. of genes 
differentially 
expressed on array 
PHFK(#1)/HPV18 
P4 
PHFK(#1)/HPV18 
P9 
Pyeon 8 normal cervices and 
20 cervical cancers 
3143 432 (15%) 460 (15%) 
Rosty 5 normal cervices, 5 
cell lines, 35 primary 
tumours including 5 
replicates 
999 182 (18%) 179 (18%) 
Santin 11 primary cervical 
cancer cell lines 
derived from stage IB-
IIA cervical cancers 
and 4 normal cervical 
keratinocytes cell lines 
420 159 (38%) 143 (34%) 
Wong 18 normal cervices and 
29 cervical SCC 
101 48 (49%) 47 (47%) 
Zhai 10 normal cervices and 
21 cervical SCC 
1698 571 (34%) 544 (32%) 
Zhai 7 HSIL and 21 cervical 
SCC 
741 171 (23%) 173 (23%) 
 
Table 5.24 Frequency with which genes that were differentially expressed in the published 
cervical cancer arrays were concordantly regulated on the PHFK-HPV18 array: comparison of 
early and late passages. 
 
The proportion of differentially expressed genes on the cervical cancer arrays that 
were concordantly regulated at P4 ranged from 15-49%, and at P9 ranged from 15-
47%. This analysis shows that the extent to which the transcriptional profile of PHFK 
transfected with HPV18 mimics the cervical transcriptome does not increase with 
increasing passages.  
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5.6.4 Comparison of CpG island and gene expression arrays 
Next, I wanted to examine the relationship between the methylation changes and the 
gene expression changes described above for both the PHFK-HPV18 cell line and the 
W12 disease progression model. 
 
5.6.4.1 Relationship between methylation and transcriptional changes in PHFK 
following transfection with HPV18  
The subset of genes used for these analyses comprised 2484 genes common to the 
UHN HCGI12K arrays (post-filtering) and the Affymetrix GeneChip® Human 
Genome U133 Plus 2.0 arrays performed in the PHFK (#1) following transfection 
with HPV18. 
 
Tables 5.25a and 5.25b show the methylation and gene expression status of all 2484 
genes in PHFK (#1) following transfection with HPV18 at passages 4 and 9, 
respectively. No change in methylation or gene expression was detected in 45% of the 
genes at either passage 4 or 9. Of the remaining genes, it can be seen that substantially 
more genes became hypermethylated than hypomethylated, whilst a similar 
proportion of genes became up- or down-regulated at these time points. 
 
Gene Expression  
No. of genes Increased 
(n=490) 
Decreased 
(n=490) 
Unchanged 
(n=1504) 
Increased 
(n=635) 
126 138 371 
Decreased 
(n=24) 
3 5 16 
 
 
Methylation 
Unchanged 
(n=1825) 
361 347 1117 
 
Table 5.25a Number of genes differentially methylated or differentially expressed following 
transfection of PHFK (#1) with HPV18 – passage 4. 
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Gene Expression  
No. of genes Increased 
(n=515) 
Decreased 
(n=495) 
Unchanged 
(n=1474) 
Increased 
(n=526) 
103 117 306 
Decreased 
(n=48) 
8 8 32 
 
 
Methylation 
Unchanged 
(n=1910) 
404 370 1136 
 
Table 5.25b Number of genes differentially methylated or differentially expressed following 
transfection of PHFK (#1) with HPV18 – passage 9. 
 
A univariate analysis was then undertaken to examine if there was any correlation 
between methylation and transcriptional changes in our PHFK-HPV18 cell line 
(Tables 5.26a and 5.26b).  
 
Methylation 
change 
Expression 
decreased 
 
Expression 
not 
decreased 
Odds ratio 
(95% CI) 
Expression 
increased 
 
Expression 
not 
increased 
Odds ratio 
(95% CI) 
Methylation 
not increased 
(n=1849) 
352 1497 1 
(reference) 
364 1485 1 
(reference) 
Methylation 
increased 
(n=635) 
138 497 1.2 
(0.9-1.5) 
p = 0.1409 
126 509 1.0 
(0.8-1.3) 
p = 0.9319 
 
Methylation 
not decreased 
(n=2460) 
485 1975 1 
(reference) 
487 1973 1 
(reference) 
Methylation 
decreased 
(n=24) 
5 19 1.1 
(0.4-2.9) 
p = 0.8910 
3 21 0.6 
(0.2-1.9) 
p = 0.3713 
 
Table 5.26a Relationship between methylation and transcriptional changes in PHFK (#1) 
following transfection with HPV18 - passage 4. 
 
For example, at passage 4 of PHFK (#1) transfected with HPV18, 635 genes were 
found to have increased methylation and 1849 genes had no increase in methylation 
(Table 5.26a, top left panel). Of 635 genes with increased methylation, expression 
was decreased in 138/635 (22%), and of 1849 genes with no increase in methylation, 
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expression was decreased in 352/1849 (19%). Thus no global association between 
increased methylation and decreased gene expression was found.  
 
These analyses were repeated for the common subset of 2484 genes at passage 9 of 
PHFK (#1) transfected with HPV18 (Table 5.26b): 
 
Methylation 
change 
Expression 
decreased 
Expression 
not 
decreased 
Odds ratio 
(95% CI) 
Expression 
increased 
Expression 
not 
increased 
Odds ratio 
(95% CI) 
Methylation 
not increased 
(n=1958) 
378 1580 1 
(reference) 
412 1546 1 
(reference) 
Methylation 
increased 
(n=526) 
117 409 1.2 
(0.9-1.5) 
p =0.1342 
103 423 0.9 
(0.7-1.2) 
p =0.4633 
 
Methylation 
not decreased 
(n=2436) 
487 1949 1 
(reference) 
507 1929 1 
(reference) 
Methylation 
decreased 
(n=48) 
8 40 0.8 
(0.4-1.7) 
p = 0.5679 
8 40 0.8 
(0.4-1.6) 
p = 0.4828 
 
Table 5.26b Relationship between methylation and transcriptional changes in PHFK (#1) 
following transfection with HPV18 - passage 9. 
 
These analyses show that there was no significant association between genes which 
gain or lose methylation and those with increased or decreased expression, following 
transfection of PHFK (#1) with HPV18, at early or late passage. 
 
5.6.4.2 Relationship between methylation and transcriptional changes in the W12 
cell line 
The subset of genes used for these analyses comprised 2877 genes common to the 
UHN HCGI12K arrays (post-filtering) and the Affymetrix GeneChip® Human 
Genome U133 Plus 2.0 array performed in the W12 cell line. 
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Table 5.27 shows the number of differentially methylated and differentially expressed 
genes in the common subset of 2877 genes. No change in methylation or gene 
expression was detected in 1494 (52%) genes. 
 
Gene Expression  
No. of genes Increased 
(n=599) 
Decreased 
(n=686) 
Unchanged 
(n=1592) 
Increased 
(n=100) 
21 22 57 
Decreased 
(n=76) 
19 16 41 
 
 
Methylation 
Unchanged 
(n=2701) 
559 648 1494 
 
Table 5.27 Number of genes differentially methylated or differentially expressed between W12 
P11 and W12 P56 
 
A univariate analysis was then undertaken to examine if there was any correlation 
between methylation changes and gene expression changes in the W12 cell line 
(Table 5.28). 
 
Methylation 
change 
Expression 
decreased 
Expression 
not 
decreased 
Odds ratio 
(95% CI) 
Expression 
increased 
Expression 
not 
increased 
Odds ratio 
(95% CI) 
Methylation 
not increased 
(n=2777) 
664 2113 1 
(reference) 
578 2199 1 
(reference) 
Methylation 
increased 
(100) 
22 78 0.9 
(0.6-1.6) 
p = 0.6595 
21 79 1.0 
(0.6-1.6) 
p = 0.9640 
 
Methylation 
not decreased 
(n=2801) 
670 2131 1 
(reference) 
580 2221 1 
(reference) 
Methylation 
decreased 
(n=76) 
16 60 0.8 
(0.5-1.5) 
p = 0.5627 
19 57 1.3 
(0.8-2.2) 
p = 0.3630 
 
Table 5.28 Relationship between methylation and transcriptional changes in the W12 disease 
progression model. 
 
For example, at W12 P56, 100 genes were found to have increased methylation and 
2777 genes had no increase in methylation (Table 5.28, top left panel). Of 100 genes 
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with increased methylation, expression was decreased in 22/100 (22%), and of 2777 
genes with no increase in methylation, expression was decreased in 664/2777 (24%). 
Thus no association between increased methylation and decreased gene expression 
was found. These analyses show that there was no significant association between 
genes which gain or lose methylation and those with increased or decreased 
expression, following long term cultivation of the W12 cell line. 
 
 
In summary, I have shown that the transcriptional changes observed in PHFK 
following transfection with HPV18 are consistent with those previously reported. In 
addition I have shown that many of the genes found to be differentially expressed in 5 
published cervical cancer arrays were concordantly regulated in PHFK following 
transfection with HPV18, the W12 cell line (the disease progression model), or both.  
This suggests that our 2 in vitro models can provide useful observations relevant to 
cervical neoplasia. However, no significant relationship between the global 
methylation and transcriptional changes identified in PHFK (#1) following 
transfection with HPV18 was observed. Similarly, in the W12 disease progression 
model, no significant relationship between the global methylation and transcriptional 
changes between P11 and P56 was identified. 
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In this section, I investigate using pyrosequencing whether the increased methylation 
which I observed in the retinoic acid receptor beta gene, RARB, in PHFK following 
transfection with HPV18 was also seen following the transfection of keratinocytes 
isolated from a different donor with HPV18 and with HPV16.  I also explore the 
methylation status of the RARB promoter in two HPV positive and in one HPV 
negative cervical cancer cell lines. I next explore changes in the expression of RARB 
and of the DNA methyltransferases in PHFK following transfection with HPV18. 
Finally, I investigate using chromatin immunoprecipitation how the binding of 
DNMT1 and of H3K27me3 to the RARB promoter changes following transfection, 
having first optimised this assay in HeLa cells. 
 
 
5.7 Investigation of possible ‘epigenetic switching’ using a candidate gene 
approach 
In a previous section (5.3.3.2), I confirmed the de novo methylation of 3 genes 
(NKX6-1, PLXDC2 and RARB) in PHFK (#1) following transfection with HPV18. 
These genes were of interest because they were not expressed and not methylated in 
untransfected keratinocytes, but they then became methylated for the first time 
following transfection with HPV18. These genes were therefore potential ‘epigenetic 
switching’ genes (see section 1.1.5.3). For 2 genes (NKX6-1 and PLXDC2), de novo 
methylation was observed at only one CpG site, whilst de novo methylation was 
observed at 3 CpG sites in the RARB promoter. RARB was thus selected for further 
analysis.  
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5.7.1 RARB is hypermethylated following transfection of a different PHFK donor 
with HPV18 
I first set out to determine if the methylation changes in the RARB promoter were 
specific to the PHFK isolated from donor #1. Pyrosequencing analysis of the RARB 
promoter was performed in untransfected PHFK from a second donor (#2), and in 
these PHFK (#2) following transfection with HPV18 at passages 4 and 9. These 
transfection experiments had been performed by Dr Christothea Constandinou-
Williams (post-doctoral fellow, our Institute). 
 
Using pyrosequencing, an increase in methylation at CpGs 1-3 was also detected in 
the RARB promoter in PHFK (#2) following transfection with HPV18 at passage 4 
(Table 5.29, Figure 5.14b). Methylation of these 3 CpG sites also increased between 
early and late passage.  
 
5.7.2 RARB is hypermethylated following transfection of PHFK with 2 variants 
of HPV16 
I next investigated if these methylation changes were specific to HPV18. 
Pyrosequencing analysis was performed in PHFK (#2) following transfection with 2 
variants of HPV16 – HPV16B and HPV16K. These 2 variants were originally isolated 
from condylomata acuminate lesions and they differ by one amino acid residue in the 
L1 major capsid protein (Kirnbauer et al, 1993). These transfection experiments had 
also been performed by Dr Christothea Constandinou-Williams. 
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  % Methylation 
Gene Sample CpG 
1 
CpG 
2 
CpG 
3 
CpG 
4 
CpG 
5 
CpG 
6 
CpG 
7 
CpG 
8 
CpG 
9 
CpG 
10 
CpG 
11 
CpG 
12 
CpG 
13 
CpG 
15 
CpG 
16 
CpG 
17 
CpG 
18 
CpG 
19 
Untransfected PHFK #1 3.7 5.1 3.8 3.5 1.9 2.3 3.7 2.4 4.7 2.9 7.0 5.8 9.9 7.0 4.1 4.9 13.0 17.1 
PHFK#1/HPV18 P4 15.1 16.8 13.7 4.9 4.0 3.5 5.0 2.0 4.7 4.6 14.2 7.0 14.6 7.6 4.3 5.5 24.7 30.3 
PHFK#1/HPV18 P9 19.6 22.7 17.9 5.1 3.8 4.7 5.1 4.1 9.1 5.2 14.0 10.5 19.6 4.5 3.4 7.0 22.2 34.0 
MC 94.8 97.2 95.7 93.1 96.4 60.1 90.4 77.6 92.6 95.2 100.0 91.0 97.0 100.0 100.0 100.0 95.9 91.4 
                   
Untransfected PHFK #2 10.2 12.9 9.6 6.5 3.1 5.6 4.8 4.4 6.3 0.0 5.0 6.6 9.9 8.6 6.0 4.9 13.7 18.4 
PHFK#2/HPV18 P4 14.6 18.0 14.2 5.8 5.1 8.9 3.4 5.0 5.5 2.9 7.0 5.9 11.7 7.9 5.5 6.0 16.0 20.5 
PHFK#2/HPV18 P9 20.9 23.0 19.0 7.9 3.3 9.1 5.3 5.7 6.4 3.7 7.7 4.1 10.9 6.8 5.7 4.5 15.2 17.0 
                   
Untransfected PHFK #2 10.2 12.9 9.6 6.5 3.1 5.6 4.8 4.4 6.3 0.0 5.0 6.6 9.9 8.6 6.0 4.9 13.7 18.4 
PHFK#2/HPV16B P4 19.9 25.5 19.3 6.3 4.0 7.4 3.5 5.7 6.2 3.5 8.6 5.9 17.6 5.6 4.6 4.7 9.0 30.6 
PHFK#2/HPV16B P9 12.1 12.4 10.9 5.4 0.0 6.6 3.3 4.1 7.0 5.0 13.2 7.4 25.8 6.0 4.5 3.2 10.8 32.7 
                   
Untransfected PHFK #2 10.2 12.9 9.6 6.5 3.1 5.6 4.8 4.4 6.3 0.0 5.0 6.6 9.9 8.6 6.0 4.9 13.7 18.4 
PHFK#2/HPV16K P4 17.3 19.1 14.7 11.4 4.4 6.3 5.5 3.9 3.2 0.0 7.5 6.1 13.2 6.1 5.0 4.8 12.9 13.3 
PHFK#2/HPV16K P9 12.4 13.3 11.7 5.3 4.1 8.6 8.2 5.5 7.4 5.1 30.9 14.4 22.6 11.6 5.7 5.6 25.7 29.0 
                   
CaSki 93.9 96.9 43.9 67.2 80.1 79.4 94.1 83.5 94.8 92.4 98.4 91.2 95.4 - - - 83.0 67.1 
HeLa 87.1 88.6 31.2 17.9 19.5 1.9 25.6 7.2 9.6 39.6 93.1 22.4 72.4 - - - 61.9 77.0 
 
 
 
 
 
 
 
 
 
RARB 
C33A 8.1 4.0 4.3 - - - - - - - - - - - - - 0.0 5.8 
 
 
Table 5.29 Pyrosequencing analysis of RARB. This table shows the methylation percentage at each CpG site in the RARB promoter. Pyrosequencing was 
performed in PHFK from 2 different donors, transfected with HPV18 and with 2 variants of HPV16 (B and K), and also in 3 cervical cancer cell lines; CaSki 
(HPV16 positive), HeLa (HPV18 positive) and C33A (HPV negative). MC, methylated control.  
 
   Results 
Using pyrosequencing, de novo methylation of CpGs 1-3 was again detected at early 
passage, but unlike the 2 PHFK isolates transfected with HPV18, methylation of 
CpGs 1-3 decreased between passages 4 and 9 (Table 5.29, Figures 5.14c and 5.14d). 
These changes were common to both the PHFK-HPV16B and the PHFK-HPV16K 
cell lines.  
 
In addition, an increase in methylation of a further 2 CpGs (13 and 19) was seen in 
both HPV16 cell lines. This was also detected with PHFK (#1) following transfection 
with HPV18 but not with the second donor. Additional increases in methylation were 
also detected in CpGs 11, 12 and 18 for the PHFK-HPV16K cell line alone.  
 
These results show that methylation of CpGs 1-3 of the RARB promoter is commonly 
observed following transfection with HPV, irrespective of the PHFK isolate or the 
infecting high-risk HPV type. 
 
5.7.3 RARB is hypermethylated in HPV positive cervical cell lines 
Pyrosequencing analysis of the RARB promoter was also performed using DNA from 
3 cervical cancer cell lines: CaSki, a HPV16-positive cell line; HeLa, a HPV18-
positive cell line; and C33A, a cervical cancer cell line that does not contain HPV. 
Using pyrosequencing, no methylation was detected at any CpG sites in the RARB 
promoter in the C33A cell line (Table 5.29). Conversely, in the 2 HPV-positive cell 
lines (CaSki and HeLa), most of the CpG sites in the RARB promoter were found to 
be heavily methylated (Table 5.29). These results are consistent with a role for HPV-
associated methylation changes in the RARB promoter. 
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Figure 5.14a RARB pyrosequencing analysis in untransfected PHFK (#1), and in PHFK (#1) 
following transfection with HPV18 at early and late passages. 
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Figure 5.14b RARB pyrosequencing analysis in untransfected PHFK (#2), and in PHFK (#2) 
following transfection with HPV18 at early and late passages. 
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Figure 5.14c RARB pyrosequencing analysis in untransfected PHFK (#2), and in PHFK (#2) 
following transfection with HPV16B at early and late passages. 
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Figure 5.14d RARB pyrosequencing analysis in untransfected PHFK (#2), and in PHFK (#2) 
following transfection with HPV16K at early and late passages. 
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5.7.4 RARB is not expressed in PHFK (#1) before and after transfection with 
HPV18 
The Affymetrix GeneChip® Human Genome U133 Plus 2.0 arrays performed in 
PHFK (#1) transfected with HPV18 showed that the expression of RARB was very 
low in untransfected cells, and this expression remained very low following 
transfection with HPV18 at early and late passage (Figure 5.15).  
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Figure 5.15 Expression of RARB in PHFK. The GCOS signal for RARB in untransfected PHFK 
(donor #1) is very low, and remains very low following transfection of PHFK (from the same 
donor) with HPV18 at early (P4) and late (P9) passage. 
 
 
Analysis of RARB expression was performed using RNA harvested from the same 
passages used to probe the expression arrays. Using RT-PCR, the expression of RARB 
was found to be undetectable in untransfected PHFK, and remained undetectable 
following transfection with HPV18 at passages 4 and 9 (Figure 5.16), confirming the 
expression array findings.  
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Figure 5.16 RT-PCR for RARB in PHFK. The expression of RARB was found to be undetectable in 
PHFK (from donor #1), and remained unchanged following transfection of PHFK (from the same 
donor) with HPV18, at early (P4) and late (P9) passage. C33A cervical cell line DNA was used as a 
positive control. GAPDH was used as a house-keeping gene. 
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5.7.5 Expression of DNA methyltransferases in PHFK following transfection 
with HPV18  
The Affymetrix GeneChip® Human Genome U133 Plus 2.0 arrays performed in 
PHFK (#1) transfected with HPV18 showed that DNA methyltransferase 1 (DNMT1) 
was expressed in untransfected cells, that this expression increased significantly 
following transfection with HPV18 at early passage, but that there was no further 
significant change in expression between early and late passage (Figure 5.17a). The 
array also showed that the expression of DNMT3A and 3B was low (GCOS signals 
<100) in untransfected PHFK (#1), and that this did not change following transfection 
with HPV18 at early or late passages (Figures 5.17b and 5.17c). 
 
Q-RT-PCR analysis of DNA methyltransferase expression was performed using RNA 
harvested from the same passages used to probe the expression arrays. By this 
analysis, DNMT1 was shown to be up-regulated (5-fold) in PHFK (#1) following 
transfection with HPV18 at early passage, but down-regulated between early and late 
passages (Figure 5.18a). For DNMT3A and 3B, no significant change in the 
expression of both genes was detected following transfection with HPV18 at early or 
late passages (Figures 5.18b and 5.18c), using Q-RT-PCR. 
 
Western blotting for DNMT1 was undertaken to determine if the differential gene 
expression of DNMT1 observed in PHFK (#1) following transfection with HPV18 
was translated to the protein level. This analysis was performed 3 times. 
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Figure 5.17a Expression of DNMT1 in PHFK. GCOS signals for DNMT1 in untransfected PHFK 
(from donor #1), and following transfection of PHFK (from the same donor) with HPV18 at early (P4) 
and late (P9) passage. 
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Figure 5.17b Expression of DNMT3A in PHFK. GCOS signals for DNMT3A in untransfected 
PHFK (from donor #1), and following transfection of PHFK (from the same donor) with HPV18 at 
early (P4) and late (P9) passage. 
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Figure 5.17c Expression of DNMT3B in PHFK. GCOS signals for DNMT3B in untransfected PHFK 
(from donor #1), and following transfection of PHFK (from the same donor) with HPV18 at early (P4) 
and late (P9) passage. 
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Figure 5.18a DNMT1 Q-RT-PCR in PHFK transfected with HPV18. Relative expression of 
DNMT1 in PHFK (from donor #1) transfected with HPV18 at early (P4) and late (P9) passage, 
compared to in untransfected PHFK (from the same donor). 
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Figure 5.18b DNMT3A Q-RT-PCR in PHFK transfected with HPV18. Relative expression of 
DNMT3A in PHFK (from donor #1) transfected with HPV18 at early (P4) and late (P9) passage, 
compared to in untransfected PHFK (from the same donor). 
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Figure 5.18c DNMT3B Q-RT-PCR in PHFK transfected with HPV18. Relative expression of 
DNMT3B in PHFK (from donor #1) transfected with HPV18 at early (P4) and late (P9) passage, 
compared to in untransfected PHFK (from the same donor). 
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Figure 5.19 Western blotting for DNMT1 in PHFK. The DNMT1 protein increases 
following transfection of PHFK (from donor #1) with HPV18 at early passage (P4), with 
further increased expression at late passage (P9). β-actin was used as a loading control. 
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Using western blotting, an increase in the expression of DNMT1 protein was seen 
following transfection of PHFK with HPV18 at early passage, with a further increase 
in expression observed between early and late passages (Figure 5.19).  
 
5.7.6 Chromatin immunoprecipitation 
Using RT-PCR, I have shown that the expression of RARB is undetectable in 
untransfected PHFK (#1). However, I have also shown using pyrosequencing, that the 
RARB promoter is not methylated in untransfected PHFK (#1). Following transfection 
of PHFK (#1) with HPV18, the expression of RARB remained undetectable. However 
pyrosequencing demonstrated de novo methylation of the RARB promoter, which 
increased with increasing passages. As I had also shown, using Q-RT-PCR and 
western blotting, that the expression of DNMT1 increased following transfection of 
PHFK (#1) with HPV18, I therefore set out to determine if these changes were a 
consequence of epigenetic switching (ie if RARB was initially silenced by 
H3K27me3, but then acquires DNA methylation silencing with loss of the H3K27me3 
mark). 
 
To determine if DNMT1 or H3K27me3 were bound to the RARB promoter in 
untransfected PHFK (#1) and if there was an increase in DNMT1 binding in these 
PHFK following transfection with HPV18, chromatin immunoprecipitation (ChIP) 
assays using antibodies specific to DNMT1 and H3K27me3 were performed. To 
preclude non-specific enrichment by ChIP, the IgG antibody was used as a negative 
control, and a no antibody control was also included in each experiment. 
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The ChIP assay was first optimised in HeLa cells. Wu et al (2008) have previously 
demonstrated binding of both DNMT1 and H3K27me3 proteins to the HOXA7 
upstream regulatory region in HeLa cells. This enrichment was specific to the 
promoter region (in Region E). No similar enrichment was seen in Region I, which is 
located between exon 1 and exon 2 (Wu et al, 2008). Using antibodies specific to 
DNMT1 and H3K27me3, I performed the ChIP assay twice in HeLa cells. Figure 5.20 
shows enrichment of both DNMT1 and H3K27me3 proteins in Region E of the 
HOXA7 gene, with no binding observed in Region I, thus reproducing the results 
from the paper published by Wu et al. The enrichment of DNMT1 and H3K27me3 
was confirmed using quantitative PCR (Q-PCR) (Figure 5.21). This ChIP assay was 
thus taken forward for use in PHFK cells. 
 
 
 
 INPUT H3K27 DNMT1 IgG WaterNo AB
Region E
Region I
HOXA7
523bp
494bp
 
 
 
 
Figure 5.20 ChIP analysis in HeLa cells. PCR for 30 cycles reveals enrichment of the H3K27me3 
and DNMT1 proteins in region E of the HOXA7 promoter, relative to IgG (non-specific antibody 
control), and the no antibody control (No AB). Conversely, in region I (located between exon 1 and 
exon 2 of the HOXA7 gene), no enrichment was observed. Water was used as a template-free control 
for the PCR.  
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Figure 5.21 ChIP analysis in HeLa cells – HOXA7. Q-PCR confirms enrichment of the H3K27me3 
and DNMT1 proteins in region E of the HOXA7 promoter, relative to IgG (non-specific antibody 
control). No AB, no antibody control. 
 
The ChIP assay was next performed in untransfected PHFK (#1) and in PHFK (#1) 
transfected with HPV18 at early passage (P4) using antibodies specific to DNMT1 
and H3K27me3. In untransfected PHFK (#1), a 2.5 fold increase of the DNMT1 
protein at the RARB promoter relative to the IgG antibody negative control was 
detected, whilst there was no enrichment of the H3K27me3 protein (Figure 5.22a).  
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Figure 5.22a ChIP analysis in untransfected PHFK (#1) – RARB. Q-PCR reveals a 2.5 fold 
increase of the DNMT1 protein at the RARB promoter relative to IgG (non-specific antibody control), 
but no enrichment of the H3K27me3 protein. No AB, no antibody control. 
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Following transfection of PHFK (#1) with HPV18, there was a marked enrichment of 
both the DNMT1 (7.5 fold) and H3K27me3 (8-fold) proteins relative to the IgG 
antibody negative control (Figure 22b).  
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Figure 5.22b ChIP analysis in PHFK (#1) transfected with HPV18 at passage 4 – RARB. Q-PCR 
reveals enrichment of the H3K27me3 (8 fold) and DNMT1 (7.5 fold) proteins at the RARB promoter 
relative to IgG (non-specific antibody control). No AB, no antibody control. 
 
The enrichment observed in each case was specific to the RARB promoter: no 
enrichment was observed in the downstream region of RARB (region D, located 2.5kb 
downstream from the end of the first exon) for either protein in untransfected PHFK 
(#1) or in keratinocytes transfected with HPV18 (Figure 5.23). This suggests that the 
increased binding of DNMT1 following transfection of PHFK (#1) with HPV18 may 
play a role in the observed de novo methylation in these cells. 
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Figure 5.23a ChIP analysis in untransfected PHFK (#1) – RARB region D. Q-PCR reveals no 
enrichment of the H3K27me3 or DNMT1 proteins in RARB region D (located 2.5kb downstream from 
the end of the first exon), relative to IgG (non-specific antibody control). No AB, no antibody control. 
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Figure 5.23b ChIP analysis in PHFK (#1) transfected with HPV18 at passage 4 – RARB region D. 
Q-PCR reveals no enrichment of the H3K27me3 or DNMT1 proteins in RARB region D (located 2.5kb 
downstream from the end of the first exon), relative to IgG (non-specific antibody control). No AB, no 
antibody control. 
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In summary, in this section I have shown that de novo methylation of the RARB 
promoter occurs in PHFK following transfection with both HPV16 and HPV18, 
irrespective of the PHFK isolate. I have also shown that methylation of the RARB 
promoter is high in 2 HPV-positive cell lines, but is absent in C33A, a HPV-negative 
cervical cancer cell line. In addition, I have demonstrated up-regulation of DNMT1 in 
PHFK transfected with HPV18. Finally, I have observed increased binding of 
DNMT1 and H3K27me3 at the RARB promoter following transfection with HPV18.
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Discussion 
In this chapter I begin by discussing my smoking and CDKN2A methylation results, 
before moving on to discuss the results of my work looking at the contribution of 
HPV infection to the methylation of cellular genes. 
 
6.1 Association between smoking and CDKN2A methylation 
Using the cervix uteri as a model, I have shown that smoking increases the risk of 
acquiring methylated forms of the tumour suppressor gene, CDKN2A, the epigenetic 
inactivation of which is frequently associated with the pathogenesis of neoplasia at 
many sites (Herman et al, 1995; Merlo et al, 1995). The CDKN2A gene product binds 
to and inhibits the cyclin dependent kinases 4 and 6, which normally phosphorylate 
the serine/threonine residues of the retinoblastoma (Rb) protein (Serrano et al, 1993; 
Weinberg, 1995). Thus, inactivation of CDKN2A enables initial phosphorylation of 
the Rb protein and subsequent progression of the cell cycle through G1 into S phase 
(Serrano et al, 1993; Weinberg, 1995). Our choice of study design and our unique 
study population allowed me to reveal, for the first time, the relationship between an 
incident exposure (smoking initiation) and the subsequent appearance of an epigenetic 
change (methylation of CDKN2A).  
 
These findings are consistent with those of a cross-sectional study reporting a non-
significant two-fold excess of methylated forms of CDKN2A in normal cervical 
smears taken from smokers, compared with those taken from non-smokers (Lea et al, 
2004); the higher prevalence of methylated forms of CDKN2A observed in my study 
may be because I used nested MSP, a more sensitive assay (Palmisano et al, 2000). 
Compared with never-smokers, current smokers who are cancer-free, but not 
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necessarily disease-free, are also reported to have a higher prevalence of methylated 
forms of the tumour suppressor genes fragile histidine triad (FHIT) and O-6-
methylguanine-DNA methyltransferase (MGMT) in bronchial lavages and plasma, 
respectively (Kim et al, 2004; Belinsky et al, 2005).  
 
I have also shown that loss of CDKN2A methylation can occur following smoking 
cessation. Consistent with this finding, in vitro and animal studies have shown that 
cigarette smoke and nicotine-induced methylation changes in TSG can be reversed 
following withdrawal of the exposure (Watson et al, 2004; Bachman et al, 2006; 
Soma et al, 2006; Liu et al, 2007). For example, in human oesophageal squamous 
epithelial cells, short term exposure to nicotine was sufficient to induce methylation of 
FHIT, with attenuation of FHIT protein expression; methylation of FHIT persisted 
throughout moderate to long-term nicotine exposure (Soma et al, 2006). Following 
cessation of nicotine exposure, irrespective of the duration of exposure, demethylation 
of FHIT was observed in association with re-expression of the FHIT protein (Soma et 
al, 2006).  
 
6.2 Mechanism of smoking-induced methylation changes 
The mechanism of smoking-induced methylation changes remains incompletely 
understood. In 1996, Belinsky et al published the first report demonstrating an 
increase in DNA methyltransferase activity and gene expression in A/J mice exposed 
to the tobacco specific carcinogen NNK, in association with a marked increase in 
overall methylation. Nicotine-induced methylation of FHIT in association with 
increased DNMT3A expression, has also been demonstrated in human oesophageal 
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squamous epithelial cells (Soma et al, 2006). In normal human liver tissue samples, 
expression of DNA methyltransferase was found to be significantly higher in smokers 
compared with non-smokers (Hammons et al, 1999). In patients with lung cancer, 
DNMT1 expression was also found to be significantly higher in smokers compared 
with never smokers, and in those with adenocarcinoma histology, patients who have 
smoked more than 65 pack-years had a 4.17 increased risk of increased DNMT1 
expression compared to those with a less than 45 pack-year smoking history (Kwon et 
al, 2007). More recently, it was found that the DNMT1, 3A and 3B proteins were 
highly expressed in a coordinate manner in 100 lung cancer samples (independent of 
cell proliferation), particularly in smokers (Lin et al, 2007). Furthermore, the 
increased expression of DNMT1 and DNMT3B was significantly associated with 
hypermethylation of the tumour suppressor genes, FHIT, CDKN2A and RARB, and 
using tissue chromatin-immunoprecipitation in a subset of samples, strong binding of 
DNMT1 and DNMT3B to the methylated promoters of these 3 TSG was observed 
(Lin et al, 2007). Thus exposure to tobacco carcinogens induces increased expression 
of the DNMTs which results in increased DNA methylation. 
 
However, rather than a general increase in promoter methylation across the genome, 
several lines of evidence demonstrate that smoking-induced DNA methylation is both 
gene- and tissue-specific. Using murine models, Belinsky et al (1996) examined DNA 
methyltransferase activity in different histological cell types of murine lungs before 
and after exposure to NNK; increased DNA methyltransferase activity was observed 
only in alveolar type II cells, which are thought to be the target cells leading to lung 
tumour formation, in association with an increase in DNA methylation level, whilst 
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no increase in DNA methyltransferase activity or DNA methylation was observed in 
the Clara (non-target) cells. In patients with lung cancer, DNMT1 expression was 
found to be significantly higher in adenocarcinomas compared with squamous cell 
carcinomas, while the average number of pack-years smoked was higher in squamous 
cell carcinomas than in adenocarcinomas, thus suggesting that the relationship 
between smoking and DNMT1 expression is tissue-specific (Kwon et al, 2007). Now, 
the p16 and p14ARF proteins are both encoded from the same locus on chromosome 
9p21 by alternative splicing. In 185 primary lung cancers, frequent methylation of p16 
but no methylation of p14ARF was detected, and the prevalence of p16 methylation 
was significantly higher in squamous cell carcinomas compared with 
adenocarcinomas (Kim et al, 2001). Similarly, RASSF1A and BLU are adjacent genes 
located on chromosome 3p21.3. Methylation of both genes was detected at a similar 
frequency in a series of primary lung cancers (47% and 43% respectively), however 
the prevalence of RASSF1A methylation was significantly higher in smokers, 
particularly in adenocarcinomas, whilst BLU methylation was more common in 
never-smokers (Marsit et al, 2005).  
 
Furthermore such gene-specific DNA methylation appears to be modulated by 
exposure to different carcinogens. Issa et al (1996) demonstrated that methylation of 
the oestrogen receptor gene (ER) in lung tumours in rats depended on the carcinogen 
exposure; the incidence of ER methylation in NNK-induced lung tumours was low 
(16.7%), compared to 38.1% in x-ray-induced lung tumours and 81.8% in plutonium- 
induced lung tumours. Similarly, Vuillemenot et al (2004) observed a high incidence 
of RARB methylation in lung tumours induced in mice following exposure to cigarette 
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smoke or NNK (90% and 85% respectively), compared to 56% in methylene chloride-
induced lung tumours and 60% in vinyl carbamate-induced lung tumours. 
 
It remains unknown what causes some loci to be more susceptible to smoking-induced 
methylation. The dynamic control of cis-acting elements may play a role. CpG islands 
are commonly flanked by repetitive sequences (eg Alu repeats) which are frequently 
methylated in normal tissues, and these may act as “de novo methylation centres” 
from which methylation can spread into adjacent sequences (Graff et al, 1997; Turkor 
& Bestor, 1997). Simultaneously, many CpG islands contain multiple Sp-1 binding 
sites located both upstream and downstream of the transcriptional start site, which are 
thought to protect CpG islands from the spread of methylation from methylation 
centres (Graff et al, 1997). It has been hypothesised that such cis-acting elements may 
become disrupted following exposure to tobacco smoke rendering some genes more 
vulnerable to methylation (Kim et al, 2003). The direct genotoxic effect of 
carcinogens in tobacco smoke may also play a role. Carcinogens in tobacco smoke 
can induce single- and double-strand breaks in DNA. Recently a high methylation 
index (defined as the methylation of 3 or more gene-specific promoters) in the sputum 
of cancer-free smokers, was reported to be associated with a reduced ability to repair 
double strand breaks (Leng et al, 2008). Indeed it has previously been demonstrated 
that DNMT1 is rapidly recruited to sites of DNA damage (Mortusewicz et al, 2005; 
Cuozzo et al, 2007). 
 
 
 
 
225 
 
Discussion 
6.3 Smoking-induced methylation and cervical neoplasia 
Smoking is an independent risk factor for cervical neoplasia (see 1.4, introduction), 
however smoking does not increase the risk of acquiring HPV infection, and it does 
not prolong the duration of HPV infection, thus other mechanisms must be involved 
to account for the association of smoking with cervical neoplasia (Collins et al, 2010). 
In order to determine if smoking-induced methylation changes are causally associated 
with cervical neoplasia, it will now be important to assess if the observed smoking-
induced methylation of CDKN2A in disease-free women, increases either the risk of 
women acquiring cytological abnormality, or the risk of progression to high-grade 
CIN in women with low-grade disease, or both. 
 
6.4 Implications for smoking cessation 
Smoking at an early age has been reported to increase the risk of both cervical and 
lung cancer, independent of smoking duration or intensity (Hegmann et al, 1993; 
Nordlund et al, 1997; Knoke et al, 2004; International Collaboration of 
Epidemiological Studies of Cervical Cancer, 2006b). Meta-analyses suggest that 
smoking cessation interventions have little effect on the behaviour of adolescents and 
young adults (Grimshaw & Stanton, 2006; Myung et al, 2009). Qualitative studies 
exploring smoking cessation in adolescent smokers have revealed that young smokers 
generally discount distant health risks such as cancer, because they believe that they 
don’t smoke enough to suffer any negative consequences or that they will have quit 
smoking before the cigarettes can harm them, and perceive themselves to be less 
vulnerable to the well known long term adverse health effects of smoking (Balch, 
1998; Goldman et al, 1998; McVea et al, 2009). It has been proposed that providing 
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more information on the immediate adverse heath consequences might help to 
challenge such disengagement beliefs (justifications to continue smoking) in young 
smokers (Kleinjan et al, 2009). My work provides such information. Perhaps the most 
salient motivational finding is the reversibility of epigenetic changes following 
smoking cessation. 
 
6.5 Reservations and limitations of smoking data 
Even allowing for possible inaccuracy in self-reporting, smoking behaviour is 
unlikely to account for all cases of CDKN2A methylation observed in my study. In 
women who have never smoked, epigenetic changes may be explained by other, as yet 
undefined, risk factors. For example, exposure to low-dose airborne benzene has been 
associated with the methylation of p15 (CDKN1B) in healthy individuals (Bollati et 
al, 2007).  
 
One limitation of this study may be the presence of sampling bias in the matched 
analysis. Disease-free incident smokers were first identified who tested negative for 
CDKN2A methylation in the sample taken immediately before they began to smoke. 
In this group serial samples were then tested until methylated forms of CDKN2A were 
detected or the end of follow-up was reached. For the controls – never smokers – only 
2 samples were tested for the presence of CDKN2A methylation. However this was 
not a major source of bias because the median number of samples tested in the 
incident smokers was 2.5. Another limitation of this study was the absence of a 
control group when evaluating the impact of smoking cessation on CDKN2A 
 
227 
 
Discussion 
methylation. Thus it remains possible that loss of CDKN2A methylation may not be 
directly associated with smoking cessation.  
 
6.6 Technical considerations 
I have used nested MSP to detect methylated forms of CDKN2A in cervical 
cytological samples taken from disease-free young women. This technique has 
previously been reported to have a sensitivity of 1:50,000 (Palmisano et al, 2000). 
However, I have struggled to determine reproducibly the sensitivity of my nested 
MSP assay, possibly because the assay may be functioning at the limits of detection. 
The minimum consistent sensitivity of my nested MSP assay was 1:1000, however 
the PCR band was very bright at this dilution, while the methylated bands observed in 
some cytological samples were faint, suggesting that the sensitivity of my nested MSP 
assay was greater than 1:1000. Nevertheless, a lower nested MSP assay sensitivity of 
1:1000 compared to the initial reports of 1:50,000 has also been reported by other 
authors (Cirincione et al, 2006).  
 
The high sensitivity of nested MSP is mainly achieved through the use of high 
number of PCR cycles. However, this in turn, increases the risk of false positive 
results as a consequence of mispriming (see section 3.3.4.3). I have attempted to 
minimise this problem by increasing the annealing temperature of the methylated 
primer, to ensure the highest specificity of amplification of only methylated alleles in 
the sample, and by diluting the stage 1 PCR product prior to use in the stage 2 PCR 
(section 3.3.4.3). Furthermore, the use of unbiased stage 1 PCR primers that recognise 
the bisulphite-modified template but do not discriminate between methylated and 
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unmethylated alleles, should also eliminate incompletely bisulphite-modified 
template, which can also be a source of false positives; although since the introduction 
of kits for bisulphite modification, this is now rarely seen. To definitively exclude the 
presence of false priming, I have sequenced a subset of methylated products, and in 
every case, methylation of all the CpGs within the CDKN2A primer sites was 
observed, suggesting that the optimisation steps have helped to minimise the 
occurrence of false priming. The relative absence of methylation of CpGs located in 
the region between the 2 CDKN2A primers is different to the heavy methylation 
pattern previously described for CDKN2A in this region, in invasive samples (Herman 
et al, 1996). However, this may not be unexpected given that the cytological samples 
used in this thesis have all been taken from disease-free young women. Furthermore, 
the consistent methylation of CpGs within the CDKN2A primer sites may suggest that 
these primer sites are acting as “de novo methylation centres” as discussed above. 
This could be confirmed by performing sequencing analysis on methylated samples 
taken from different stages of cervical carcinogenesis. 
 
In a few samples a double PCR band was observed following amplification with the 
methylated primers – with a second band smaller than the expected PCR product (eg 
Figure 4.11). Mispriming in a different region of DNA with some areas of similarity 
to the primer sequence may account for this: some of these smaller bands were 
analysed by direct sequencing, and in every case no recognisable sequence was 
detected (data not shown).   
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The primers I have used for nested MSP are published primers which have previously 
been well validated in several tumour sites (see section 4.3). Nevertheless, it is 
important to note that the expected product size following CDKN2A stage 1 PCR 
amplification is quite large - 273bp. This could be a potential source of bias, since 
bisulphite modification typically fragments DNA into small fragments. Despite this 
reservation, my direct sequencing data clearly confirms that PCR amplication of 
bisulphite modifified DNA at this size is possible, as has been demonstrated in other 
tumour sites (Herman et al, 1996; Palmisano et al, 2000; Esteller et al, 2001; Belinsky 
et al, 2002). 
 
In some of the initial nested MSP experiments a PCR product was sometimes not 
observed following amplification of the unmethylated control DNA or the methylated 
control DNA with the unmethylated or the methylated primers, respectively (eg 
Figures 4.5 and 4.6). Degradation of bisulphite-modified unmethylated and 
methylated control DNA following repeat freeze-thaw cycles is the most likely 
explanation for this. In all subsequent experiments, the unmethylated and the 
methylated control DNA were bisulphite-modified just prior to use, and this problem 
was not observed again. 
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6.7 Identification of HPV-induced methylation and transcriptional changes 
In an attempt to reveal epigenetic changes relevant to the pathogenesis of cervical 
neoplasia, I have performed gene expression and CpG island arrays on 2 in vitro 
models, a HPV replication model and a disease progression model.  
 
I have shown that the transcriptional changes observed in PHFK following 
transfection with HPV18 are consistent with those previously reported. There has only 
been one published study which has also compared the transcriptional profile of 
PHFK transfected with HPV18, and approximately 50% of the differentially regulated 
genes in this published array were concordantly regulated in my PHFK-HPV18 array 
(Karstensen et al, 2006). I have also compared the transcriptional changes observed in 
my 2 in vitro models with those reported in 5 published studies that have compared 
the gene expression profile of cervical cancer or CIN with that of tissue taken from 
disease-free controls, and which used the same Affymetrix platform that I have used 
(Rosty et al, 2005; Santin et al, 2005; Wong et al, 2006; Pyeon et al, 2007; Zhai et al, 
2007); many of the differentially regulated genes in these published arrays were also 
concordantly regulated on either the PHFK-18 array, the W12 array, or both. These 
comparisons suggest that our 2 in vitro models can provide useful observations 
relevant to cervical neoplasia. 
 
Using the UHN HCGI12K array platform, I have identified differentially methylated 
genes in our 2 in vitro models. However the external validation has been poor. Genes 
found to be differentially methylated in both the PHFK-HPV18 model and the W12 
cell line were not significantly enriched for genes previously reported to be 
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methylated in cervical neoplasia. Although genes found to be de novo methylated in 
the PHFK-HPV18 model did show an increased frequency of genes known to be 
methylated in cervical neoplasia. Furthermore, I have observed only a small number 
of differentially methylated genes between passages 11 and 56 of the W12 cell line. If 
most of the methylation changes have already taken place by passage 11, then this 
may explain the small number of differentially methylated genes observed during 
further cultivation of the W12 cell line; however an analysis of methylated genes at 
passage 11 alone revealed only a non-significant two-fold increased frequency of 
genes previously reported to be methylated in cervical neoplasia, thus this cannot fully 
explain the small number of changes observed. Validation of the predicted 
methylation changes has also been poor; pyrosequencing analysis was successful in 9 
genes in the PHFK-HPV18 model, but the methylation change was confirmed in only 
3 genes (NKX6-1, PLXDC2 and RARB), similarly, in the W12 cell line 
pyrosequencing analysis was successful for 3 genes, but increased methylation was 
confirmed in only 1 gene (PAX2).  
 
I have also attempted to explore possible determinants of HPV-induced methylation 
changes. However, I have found that neither promoter CpG content, nor the reported 
presence of H3K4me3 or H3K27me3 marks in human embryonic stem cells, were 
predictive of changes in methylation following transfection of PHFK with HPV18. 
Intermediate promoter CpG content (weak CpG islands) and the presence of a stem 
cell-like chromatin pattern (consisting of the simultaneous presence of the active mark 
H3K4me3 and the repressive mark H3K27me3), have both been reported to 
predispose genes to becoming methylated (Ohm et al, 2007; Weber et al, 2007). 
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Furthermore, I have found no significant relationship between the methylation and 
transcriptional changes observed in PHFK transfected with HPV18 compared to 
untransfected keratinocytes. Similarly, in the W12 disease progression model, no 
significant relationship between the methylation and transcriptional changes between 
passages 11 and 56 was observed. 
 
These disappointing results may either be due to the fact that the in vitro models 
assessed are not good models of changes occurring during cervical neoplasia, or that 
the CpG island array platform is a poor predictor of methylation changes. Now, as I 
have already shown that the external validation of the transcriptional changes 
observed in our 2 in vitro models was good, this suggests that the CpG island array 
platform was the main reason for the observed disappointing methylation results. 
Differential methylation hybridisation using CpG island microarrays has actually been 
successfully used by many investigators to reveal differentially methylated genes in 
many tumour sites (Huang et al, 1999; Yan et al, 2001; Wei et al, 2002; van Doorn et 
al, 2005; Wang et al, 2005; Lu et al, 2009; Lu et al, 2010). However, it is interesting 
to note that virtually all the published studies have utilised custom CpG island arrays. 
In particular, there is a significant paucity of publications reporting differentially 
methylated genes identified using the same UHN HCGI12K array platform as that 
used for my work - while this array has been commercially available for over 8 years 
now. This suggests that the limitation of the CpG island arrays observed in my thesis 
may be particularly limited to the UHN HCGI12K array platform. 
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One reason the UHN HCGI12K array may have a limited ability to assess changes in 
promoter methylation, may relate to its design. Each array contains 12,192 CpG island 
clones which were originally derived from a CpG island library established by Sally 
Cross at the Wellcome Trust Sanger Institute, Cambridge in the 1990s; CpG islands 
were isolated from male human genomic DNA using a methyl-CpG binding domain 
column (Cross et al, 1994). The CpG islands clones were only sequenced 
subsequently hence the selection of CpG island clones for use on this commercial 
array was not informed by a pre-determined knowledge of the location of these CpG 
islands in the genome (Heisler et al, 2005). Now, not all CpG islands are located in 
the proximal promoter regions of human genes, thus a proportion of the clones on this 
CpG island array cannot reveal aberrant methylation of promoter regions. The fact 
that DNA sequence information only became available later also helps to explain the 
false positive findings on my arrays; some clones which were identified as becoming 
differentially methylated did not contain any CpG sites in their sequence. Indeed, 
initial characterisation of the arrays suggested that approximately 80% of the clones 
corresponded to unique CpG islands but the remainder comprised ribosomal DNA, 
repetitive elements and mitochondrial DNA (Cross et al, 1994). 
 
Another limitation of the UHN HCGI12K array platform is that each CpG island 
clone is associated with three possible genes located either within the same strand 
(W), upstream (U), or downstream (D) of the transcriptional start site by a variable 
distance. Indeed many of the CpG islands are actually located a considerable distance 
from the transcriptional start site of the allocated gene. In an attempt to simplify the 
data analysis, Dr Wenbin Wei, head of Bioinformatics in our Institute re-annotated the 
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UHN HCGI12K array - using the chromosome start and end position for each CpG 
island clone; each clone was allocated the nearest gene using the criterion, “mid-point 
of the CpG island clone is within 7.5kb upstream of 5’ transcriptional start site of that 
gene through to 100bp downstream of the transcriptional end site”. However, 
following this re-annotation the UHN HCGI12K array was found to cover only 3379 
unique genes. 
 
There are also a number of reasons as to why I may have failed to reveal an 
underlying relationship between promoter CpG content, stem cell-like chromatin 
pattern and DNA methylation. Firstly, this may simply reflect the limited ability of the 
UHN HCGI12K array platform to detect methylation changes. Secondly, this analysis 
was inevitably restricted to a small subset of genes; only 1885 genes were included in 
the analyses of promoter CpG content and stem cell chromatin pattern. Thirdly, there 
may be no relationship between promoter CpG content, stem cell chromatin pattern 
and DNA methylation in PHFK transfected with HPV18. Indeed recent analyses of 
mouse embryonic stem cells have suggested that DNA methylation and histone 
modifications target different genes for repression, and an analysis of normal and 
malignant prostate cancer cells has demonstrated that gene promoters enriched with 
H3K27me3 are not more likely to become methylated in cancer (Fouse et al, 2008; 
Kondo et al, 2008). 
 
There are also a number of reasons as to why I have not found an association between 
global methylation and transcriptional changes. Firstly, this may again simply reflect 
the limited ability of the UHN HCGHI12K array to predict methylation changes. 
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Secondly, after filtering, the subset of genes available for these analyses was small. 
Thirdly, there may be no significant relationship between DNA methylation and gene 
expression. Although promoter methylation can directly repress gene expression 
(section 1.1.4.1, Introduction), several recent reports have revealed that DNA 
methylation frequently occurs in genes that are already repressed by Polycomb-
mediated histone modifications in embryonic stem cells (Ohm et al, 2007; Schlesinger 
et al, 2007; Widschwendter et al, 2007). Furthermore methylation- associated gene 
silencing may be more a function of local histone modifications rather than the DNA 
methylation per se. The recent ability to integrate information from both methylation 
and transcriptional arrays is now beginning to provide us with a more complete 
understanding of the relationship between global methylation and transcriptional 
changes. Indeed, several recent studies have revealed a relatively low negative 
correlation between DNA methylation and gene expression (Acevedo et al, 2008; 
O’Riain et al, 2009; Andrews et al, 2010). 
 
For these reasons, it will be important to repeat the array experiments performed in 
our 2 in vitro models using the high resolution promoter tiling arrays now 
commercially available. 
 
6.8 HPV18-induced up-regulation of DNMT1 
Using the PHFK-HPV18 model, I have shown that transfection with HPV18 induced 
a 5-fold increase in the expression of DNMT1, with no change in the transcription of 
DNMT3A or DNMT3B. In addition, the up-regulation of DNMT1 was associated 
with increased DNMT1 protein expression. Up-regulation of DNMT1 has also been 
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demonstrated using Q-RT-PCR in PHFK isolated from different donors following 
transfection with both HPV16 and HPV18 (Dr Afaf Diyaf, personal communication). 
Furthermore, HPV-induced up-regulation of the DNA methyltransferases has 
previously been reported in studies of both HPV-immortalised keratinocyte cell lines 
and cell lines derived from cervical cancer (Garner-Hamrick et al, 2004; Santin et al, 
2005). Thus, up-regulation of DNMT1 appears to be responsible for the methylation 
changes observed in our PHFK-HPV18 model. 
 
Interestingly, while up-regulation of DNMT1 was observed in PHFK transfected with 
HPV18 at early passage, this was followed by a decrease in expression between early 
and late passages, although at late passage DNMT1 expression was still higher 
(almost double) compared to that in untransfected cells. However, while DNMT1 
mRNA expression decreased between early and late passages of the PHFK-HPV18 
cell line, I have also shown that the expression of the DNMT1 protein increased 
progressively following transfection with HPV18. The reason for the observed 
discrepancy between the mRNA and the protein expression of DNMT1 is currently 
unclear. Previous attempts to correlate mRNA levels with protein expression have met 
with varying success. While for some genes, such as ERBB2 (HER2/neu), the 
expression levels measured using RT-PCR, immunohistochemistry and fluorescence 
in situ hybridisation have shown a highly significant correlation (Schlemmer et al, 
2004), for many genes the correlation between mRNA and protein has been poor 
(Chen et al, 2002; Lichtinghagen et al, 2002; Greenbaum et al, 2003; Pascal et al, 
2008). The fact that proteins can have very different half-lives as a consequence of 
varied protein synthesis and degradation, has been proposed as one possible 
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contributing factor (Greenbaum et al, 2003). Post-transcriptional and post-
translational modifications may also contribute to the poor correlation. For example, 
one study has revealed that genes with a high degree of variable expression during the 
cell cycle, indicative of the cell controlling mRNA levels at different points of the cell 
cycle to achieve desired protein levels, showed a high correlation between mRNA and 
protein levels (r=0.89) (Greenbaum et al, 2003). In contrast, genes with minimal 
variation in expression throughout the cell cycle showed minimal correlation between 
mRNA and protein expression (r=0.2), suggesting that the cell may be controlling 
such genes at the post-translational level, and thus the mRNA level is somewhat 
independent of the final protein concentration (Greenbaum et al, 2003). Indeed, it has 
recently been demonstrated in porcine cells that although the abundance of DNMT1 
mRNA plays an important role in protein regulation, DNMT1 is mainly regulated 
post-transcriptionally (Giraldo et al, 2009).  
 
In addition, although I have shown that the expression of the DNMT1 protein 
increased progressively following transfection with HPV18, I have also observed a 
decrease in methylation in some genes between early and late passages of the PHFK-
HPV18 model. To date no demethylase enzyme has been identified. However, one 
possibility for the observed hypomethylation may be that there is a change in the 
abundance of proteins which regulate the binding of DNMT1 to the gene promoters 
between early and late passages of the PHFK-HPV18 model; as cells divide during 
cultivation, the resulting lower bound DNMT1 levels will fail to fully re-establish the 
methylation patterns in all the daughter cells (passive demethylation). For example, in 
mice it has been found that Lsh, a member of the SNF2 chromatin remodelling family, 
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is necessary for recruitment of DNMT3B to its gene target, and depletion of Lsh 
results in DNA hypomethylation (Fan et al, 2008). However Lsh does not associate 
with DNMT1 (Zhu et al, 2006). Another example is poly (ADP-ribose) polymerase 
(PARP). High intracellular levels of PARP-1 and ADP-ribose polymers can bind to 
the  DNMT1 promoter, and inhibit its enzymatic activity, which will again lead to 
passive hypomethylation during subsequent rounds of cell division (Guastafierro et al, 
2008; Caiafa et al, 2009; Zampieri et al, 2009). It will clearly be interesting to explore 
these hypotheses further. 
 
6.9 HPV-induced methylation of RARB 
In addition to HPV18-induced up-regulation of DNMT1, I have also demonstrated de 
novo methylation of the RARB promoter in PHFK following transfection with HPV18, 
and this was associated with increased binding of DNMT1 at the RARB promoter. To 
my knowledge, this is the first time that HPV-induced up-regulation of one of the 
DNMTs has been associated with subsequent methylation of a TSG. Pyrosequencing 
analysis also revealed increased methylation of RARB in PHFK following transfection 
with HPV16, suggesting that methylation of RARB may commonly follow infection 
with high-risk HPV types.  
 
RARB was also found to be methylated in the only other study which has analysed 
methylation changes in PHFK following transfection with high-risk HPV types; using 
methylation specific-multiplex ligation dependent probe amplification, methylation of 
RARB was detected in both HPV16 and HPV18 immortalised cells but not in 
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untransfected keratinocytes (Henken et al, 2007). However, in this study, no attempt 
was made to demonstrate binding of the DNMTs to the RARB promoter.  
 
Down-regulation of RARB has been reported in many tumours including cervical 
carcinoma, suggesting that loss of RARB expression may be an important event in 
carcinogenesis (Xu et al, 1994; Geisen et al, 1997; Widschwendter et al, 1997; Xu et 
al, 1997b; Qiu et al, 1999; Lotan et al, 2000). However, while RARB is expressed in 
normal cervical epithelial cells it is not normally expressed in the skin or in 
keratinocytes derived from the foreskin (Zelent et al, 1989; Geisen et al, 1997; 
Reichrath et al, 1997). In these tissues, the important role of the retinoic acid receptors 
(RAR) in cell growth and differentiation may then be mediated primarily by the RAR 
alpha and gamma subtypes, which are highly expressed here; indeed RAR-gamma 
expression is predominantly confined to keratinising squamous epithelia, and the 
expression of RARB and RAR-gamma appears to be mutually exclusive (Dollé et al, 
1990; Viallet & Dhouailly, 1994; Reichrath et al, 1997). I have also shown that RARB 
was not expressed in untransfected PHFK and remained so following transfection 
with HPV18. This raises the question as to why HPV18 causes methylation of RARB 
in a setting where RARB is already silenced. 
 
Several in vitro studies have revealed that RARB inhibits proliferation through 
inhibition of the transcription factor activator protein-1 (AP-1) via both ligand-
dependent and ligand-independent mechanisms (van der Burg et al, 1995; Lee et al, 
1996; Lin et al, 2000; De-Castro Arce et al, 2004). AP-1 is a heterodimeric protein 
containing proteins from 2 major families, Jun (c-Jun, JunB, JunD) and Fos (c-Fos, 
 
240 
 
Discussion 
FosB, Fra-1, Fra-2) (Angel & Karin, 1991). Constitutive activation of AP-1 is known 
to be a common mechanism for tumour promotion in epithelial tissues irrespective of 
the tumour site (Angel & Karin, 1991; Prusty & Das, 2005; Hussain et al, 2009). In 
addition, AP-1 is also essential for transcriptional regulation of the HPV viral 
oncogenes; site-directed mutagenesis of the AP-1 binding site in the upstream 
regulatory region (URR) of HPV16 or HPV18 almost completely abolishes 
transcription of the E6 and E7 genes (Offord & Beard, 1990; Mack & Laimins, 1991; 
Thierry et al, 1992; Soto et al, 1999). Recently, it has been shown that ectopic 
expression of RARB selectively abrogates binding of AP-1 to the HPV18 URR 
independent of ligand, by selective degradation of the c-Jun protein. The inhibition of 
AP-1 binding induced de novo methylation and nuclear condensation of the URR and 
resulted in strong down-regulation of the transcription of the HPV18 viral oncogenes 
(De-Castro Arce et al, 2007). Thus, in HPV-associated cancers, methylation of RARB 
may be a mechanism for maintaining transcription of the HPV oncogenes E6 and E7. 
 
Currently, it remains unknown which of the HPV viral oncogenes may be responsible 
for the HPV-induced methylation of RARB, although E7 appears to be the most likely 
candidate. Previously, HPV16 E7 has been found to associate with DNMT1 (Burgers 
et al, 2006); 293T cells were co-transfected with pcDNA3-E7-F (which expresses 
Flag-tagged HPV16 E7) and Myc-DNMT1 (which expresses Myc-tagged full length 
DNMT1), followed by immunoprecipitation of the cell extracts with an anti-Flag 
antibody. DNMT1 was detected in the immunoprecipitated fraction by Western blot 
analysis. Furthermore, HPV16 E7 was found to bind directly to DNMT1; GST-tagged 
HPV16 E7 bound strongly to baculovirus-expressed DNMT1, and deletion analyses 
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demonstrated that this binding was mediated by the CR3 zinc finger domain of 
HPV16 E7 (Burgers et al, 2006). In addition, the binding of HPV16 E7 to DNMT1 
resulted in a significant up-regulation of DNMT1 enzymatic activity (Burgers et al, 
2006). However, in this study, the increased methyltransferase activity was not linked 
with the subsequent methylation of a TSG. The high-risk E7 protein is also known to 
bind to and degrade the Rb tumour suppressor protein, which releases the E2F 
transcription factor from Rb inhibition (Dyson et al, 1989). Now it has previously 
been demonstrated that DNMT1 contains E2F binding sites in its promoter region, 
and that binding of E2F regulates transcription of DNMT1, thus this may be an 
additional mechanism by which the high-risk E7 protein can cause up-regulation of 
DNMT1 (McCabe et al, 2005). 
 
It is interesting to note that in untransfected PHFK, DNMT1 was already bound at a 
low level to the RARB promoter, in the absence of detectable DNA methylation. It is 
possible that a low level of methylation is present at the RARB promoter, which may 
be contributing to the silenced RARB expression, but that the sensitivity of 
pyrosequencing precluded its detection. Alternatively it is known that the N-terminal 
catalytic region of DNMT1 can directly repress transcription, by recruiting histone 
deacetylases and other co-repressor proteins such as DMAP1, independently of its 
methyltransferase activity, and this may account for silenced RARB expression in the 
absence of DNA methylation (Rountree et al, 2000).  
 
The pattern of de novo methylation of the RARB promoter following transfection with 
HPV18 or HPV16, appears to target certain CpG loci, rather than consecutive 
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adjacent CpGs, suggesting the existence of several “de novo methylation centres”.  
This pattern may simply reflect the methylation pattern seen at the earliest stages of 
HPV-induced carcinogenesis - just following HPV infection. Consistent with this, 
pyrosequencing analysis of the RARB promoter in the HPV-positive cervical cancer 
cell lines, CaSki and SiHa, revealed that most of the CpG sites in the RARB promoter 
were heavily methylated. However, it remains possible that the observed non-
consecutive pattern of methylation is artefactual; bisulphite genomic sequencing of 
the RARB promoter would confirm the genuine existence of such a pattern if this 
pattern was also observed in individual clones. 
 
6.10 Relationship between DNA methylation and H3K27me3 
Following transfection with HPV18, I have also demonstrated increased binding of 
H3K27me3 at the RARB promoter. Consistent with this result, up-regulation of EZH2 
(which catalyses tri-methylation of lysine 27 at histone H3) was observed on my gene 
expression arrays following transfection with HPV18. Up-regulation of EZH2 has 
also been observed following infection of primary human keratinocytes with HPV18 
E6 and E7 genes grown in an organotypic raft culture system (Garner-Hamrick et al, 
2004), and down-regulation of EZH2 has been identified following inhibition of 
HPV18 E6 and E7 expression by RNA interference in HeLa cells (Kuner et al, 2007). 
Furthermore, in MCF-7 cells, the ectopic expression of high risk (HPV16 and 
HPV18) and low risk (HPV6b and HPV11) E7 has been reported to activate the EZH2 
promoter, via E7-mediated release of E2F from pRb and the other pocket proteins 
(Holland et al, 2008). However, when these experiments were repeated in primary 
human cervical or foreskin keratinocytes, HPV18 E7, in contrast to the other E7 
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proteins examined, did not seem to activate the EZH2 promoter (Holland et al, 2008). 
This latter finding is in contrast with my findings, where EZH2 was up-regulated 
following transfection of PHFK with HPV18. The reason for this discrepancy is not 
clear. 
 
Both H3K27me3 and EZH2 have been reported to be enriched at the promoters of 
many genes that are hypermethylated and silenced in cancer (McGarvey et al, 2006). 
However, the functional relationship between these 2 repressive mechanisms remains 
unclear. Vire et al (2005) demonstrated a direct interaction between EZH2 and the 
DNMTs both in vitro and in vivo, but several subsequent studies have provided 
compelling evidence that H3K27me3 and DNA methylation function independently 
(McGarvey et al, 2007; Kondo et al, 2008). The presence of both silencing marks 
(DNA methylation and H3K27me3) at the RARB promoter has been reported 
previously in the colon cancer cell line, SW48, where marked elevation of H3K27me3 
and high DNA methylation was observed at the RARB promoter, in association with 
gene silencing. However, in the prostate cancer cell line, PC3, marked elevation of 
H3K27me3 was also observed at the RARB promoter but with relatively low levels of 
promoter DNA methylation (Kondo et al, 2008). This clearly demonstrates that RARB 
can be targeted by both DNA methylation and H3K27me3, and suggests that the 
epigenetic silencing of RARB may be tissue and cell-line specific.  
 
Our viral replication model which allows for sequential observations to be made at 
successive passages does provide the opportunity to resolve the temporal ambiguity 
about the order in which the H3K27me3 and methylation marks are imposed. I have 
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observed increased binding of both DNMT1 and H3K27me3 in the 4th passage 
following transfection with HPV18, and it will be interesting to perform ChIP 
experiments in the preceding passages. 
 
6.11 Limitations of ChIP experiments 
The main limitation of this section of my work is that after troubleshooting my 
experiments, sufficient material was only available for the chromatin 
immunoprecipitation experiments to be performed once. It will therefore be important 
to repeat the ChIP experiments using PHFK from other donors that have been 
transfected with HPV16 and HPV18 which are available in our laboratory, to confirm 
that the observed increased binding of DNMT1 and H3K27me3 at the RARB promoter 
is reproducible and also not unique to the PHFK donor used for my work.  
 
6.12 Conclusions 
In conclusion, using the cervix uteri as a model, I have shown that smoking increases 
the risk of acquiring methylated forms of CDKN2A, in disease-free young women, 
which may become undetectable following smoking cessation. In addition, using a 
HPV replication model, I have also shown that HPV18 infection is followed by the 
up-regulation of the DNA methyltransferase DNMT1 which binds to the TSG, RARB, 
resulting in its de novo methylation.  
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Array No. of spots 
“flagged” 
No. with signal intensities 
near background (<25) 
Remaining 
spots 
Untransfected PHFK 1 444 1 11747 
Untransfected PHFK 2 733 11 11448 
Untransfected PHFK 3 474 5 11713 
PHFK/HPV18 Early 1 684 2 11506 
PHFK/HPV18 Early 2 417 10 11765 
PHFK/HPV18 Early 3 492 13 11687 
PHFK/HPV18 Late 1 3222 15 8955 
PHFK/HPV18 Late 2 1064 1 11127 
PHFK/HPV18 Late 3 924 3 11265 
 
Table A1. Filtering - number of spots filtered from each PHFK array prior to data analysis. 
 
 
Array No. of spots 
“flagged” 
No. with signal intensities 
near background (<25) 
Remaining 
spots 
W12 P11 a 769 36 11387 
W12 P11 b 766 53 11373 
W12 P11 c 736 41 11415 
W12 P56 a 1050 43 11099 
W12 P56 b 593 33 11566 
W12 P56 c 805 21 11366 
 
Table A2. Filtering - number of spots filtered from each W12 array prior to data analysis. 
 
 
Normalised cut/mock-cut ratios Gene UHN ID 
Untransfected 
PHFK#1 
PHFK#1/HPV18 
Early 
PHFK#1/HPV18 
Late 
No. of 
CpGs in 
probe 
No. of 
CpGs 
analysed 
CDH13 UHNhscpg0002264 0.88 0.68 0.77 5 5 
COL5A3 UHNhscpg0004024 0.88 0.69 0.67 42 7 
GAP43 UHNhscpg0001120 0.88 0.56 0.61 42 4 
KIT UHNhscpg0007511 0.89 0.54 0.65 9 - 
NKX6-1 UHNhscpg0005115 0.94 0.67 0.65 15 14 
NOL4 UHNhscpg0001134 1.16 1.00 0.63 9 9 
NR2F1 UHNhscpg0002537 0.88 0.50 0.88 29 21 
PLXDC2 UHNhscpg0001333 0.99 0.58 0.75 6 6 
RARB UHNhscpg0002561 0.93 0.56 0.95 19 18 
SLIT2 UHNhscpg0010610 1.05 0.71 0.55 0 - 
SOX1 UHNhscpg0009290 0.91 0.66 0.79 46 - 
UNC5B UHNhscpg0005197 0.92 0.48 0.76 5 4 
 
Table A3. Genes selected for pyrosequencing analysis in the PHFK-HPV18 cell line. 
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Normalised cut/mock-cut 
ratios 
Gene UHN ID No. of CpGs in 
probe 
W12 P11 W12 P56 
No. of 
CpGs 
analysed 
BARD1 UHNhscpg0002602 0.99 0.78 19 - 
CDH12 UHNhscpg0008894 0.83 0.46 0 - 
DOCK5 UHNhscpg0003319 0.77 0.36 0 - 
FANCL UHNhscpg0006579 1.00 0.73 10 10 
HTRA1 UHNhscpg0000708 0.89 0.63 5 5 
PAX2 UHNhscpg0010216 0.96 0.60 21 21 
PHOX2B UHNhscpg0000388 0.68 0.39 24 - 
PPP2CA UHNhscpg0011351 0.87 0.43 8 - 
 
Table A4. Genes selected for pyrosequencing analysis in the W12 cell line. 
 
 
Name Primer sequence 5'-3' Product size 
(bp)  
Annealing 
temperature (°C) 
FANCL PYRO F1 ATTGTTTATAGAGGGGGATATGTT  
CTCCATTCCCTCCTCCTATAACTA 
 
105 FANCL PYRO R1* 50 
FANCL SEQ1 ATAGAGGGGGATATGTTAT   
FANCL PYRO F2* TTTTGAAGAGGTTGAGGAAGTTT   
FANCL PYRO R2 AAAATCCTCCACAAAATCCTCAT 181 50 
FANCL SEQ2 CTCCACAAAATCCTCAT   
HTRA1 PYRO F1* ATAAAAATTGTGAAGGATATTGGT   
HTRA1 PYRO R1 CCACATATAAACACCAACTAAACTCT 217 50 
HTRA1 SEQ1 ACCAACTAAACTCTAAACTT   
HTRA1 PYRO F2 TTTGTGTTTTATGTTTAGTTGGTTA   
HTRA1 PYRO R2* TCCATTACATATAAAAAATTAACTTCTC 185 50 
HTRA1 SEQ2 TTATGTTTAGTTGGTTAGAG   
PAX2 PYRO F GAGGAAGGGAAATAAGTTAAAGAAAT   
PAX2 PYRO R* CCCTAAAATTCAACTTAAAATCCAA 287 52 
PAX2 SEQ1 GATTAAGAAGGAAGGGATAG   
PAX2 SEQ2 AAGGGGGTTAGGGTT   
Key: * = biotinylated primer   
 
Table A5. Primers for pyrosequencing (W12) 
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Name Primer sequence 5'-3' Product size 
(bp)  
Annealing 
temperature (°C) 
CDH13 PYRO F1 TTGGATTTAATTATTTTTTTGTTGAAA   
CDH13 PYRO R1* TCTAATTCATACCAAACATCTACC 269 50 
CDH13 SEQ1 TTTTTGTTGAAATTATTGAT   
CDH13 PYRO F2 AGATGTGTTTAGTTGGGATATTGT   
CDH13 PYRO R2* TCTAATTCATACCAAACATCTACC 216 52 
CDH13 SEQ2 TTGTTTTTGTATGTTAAAAT   
NKX6-1 PYRO F1* AATTGGAAGGTAGGAAAGTGAATT   
NKX6-1 PYRO R1 TCCCCCTAAATAACTAACACCAA 165 52 
NKX6-1 SEQ1 AACACCAACAAACTAACTAC   
NKX6-1 PYRO F2 GTTGGTGTTAGTTATTTAGGGGGAATT   
NKX6-1 PYRO R2* TCAAATCCAAACCATACTACCACTC 151 54 
NKX6-1 SEQ2 GTTAGTTATTTAGGGGGAA   
NOL4 PYRO F1 TTGGGAAGTTATTTATGTTGAGTAAT   
NOL4 PYRO R1* CCATTAAAATCCCACTAACAAATACCTT 380 50 
NOL4 SEQ1 TTGTTTTTTGTTTTTAGGA   
NOL4 PYRO F2 TAGGGTTGATGTTTAGTTTTTAAGTGTTT   
NOL4 PYRO R2* CCATTAAAATCCCACTAACAAATACCTT 212 54 
NOL4 SEQ2 GATAGTTGAGTAAATTAGTATTAGATG   
RARB PYRO F1* TAGTTGGGTTATTTGAAGGTTAGTA   
RARB PYRO R1 CACTTCCTACTACTTCTATCACACAA 110 50 
RARB SEQ1 CACACAAAATAAAAAATTAA   
RARB PYRO F2 GAGTTGTTTGAGGATTGGGATGT   
RARB PYRO R2* CCAAAAAAATCCCAAATTCTCC 141 54 
RARB SEQ2 AGTTGTTTGAGGATTGG   
RARB PYRO F3/4 TGGGATTTTTTTGGGAATTT   
RARB PYRO R3/4* CCATCAAACTCTACCCCTTTTTTA 178 52 
RARB SEQ3 GGATTTTTTTGGGAATTT   
RARB SEQ4 TGTTTGTTATAATTTATGAT   
SOX1 PYRO F TGTGGGGTTTGGATTGTGAAG   
SOX1 PYRO R* CTCCCAAAACCCCTACAAATTC 143 54 
SOX1 SEQ TTGGATTGTGAAGGTTT   
COL5A3 PYRO F GGGAAATGTAGTTTTAGTGTTGG   
COL5A3 PYRO R* CCCAACAACTCCCCATAAAA 157 52 
COL5A3 SEQ GGTGATAAATAGGAGTAAGG   
GAP43 PYRO F* GGGGAGAAATAAAGAGATGAGATT   
GAP43 PYRO R TACCTAATTTCCCTTCTCCAAATCAA 168 52 
GAP43 SEQ TTTCCCTTCTCCAAAT   
KIT PYRO F AGGAGATAGGTATAGAGGGGTGAA   
KIT PYRO R* CCTCCCAAATTTATCCTCTTCC 189 52 
KIT SEQ GGGGTGAAGTAATTTGA   
NR2F1 PYRO F1 AAGTGTAGAGGGTTAGGTAGGTTG   
NR2F1 PYRO R1* CACCAAACAAACACAAAATTCTT 186 50 
NR2F1 SEQ1 GGTTAGGTAGGTTGGGTG   
NR2F1 PYRO F2 TGTTTGGGAGTAGTTTTAATTGGT   
NR2F1 PYRO R2* AAAAAATCTCTTTTTCCCATACTT 249 50 
NR2F1 SEQ2 TTTAGTGTTTTTAGATTTTG   
NR2F1 PYRO F3 GGATGGATATGTAAGGTTAGTTGAAGTT   
NR2F1 PYRO R3* AAACCAATACCCCAACCAACC 191 62 
NR2F1 SEQ3 TTGAAGTTGTTTTTAGATAG   
PLXDC2 PYRO F1 TGGAGGGAAAAGAAAAGAAAATG   
PLXDC2 PYRO R1* CACCTTACCTAAAATCCCCAAATA 217 52 
PLXDC2 SEQ1 TGTGTAATTTAAATGATTGT   
PLXDC2 PYRO F2 TGGGGATTTTAGGTAAGGTGAATT   
PLXDC2 PYRO R2* ACACACCCCTTCAACCATAAATA 174 52 
PLXDC2 SEQ2 TTTTTGAGTGAAATTTATTA   
UNC5B PYRO F TGGAGTAGGAAAATTGGAGTAGAA   
UNC5B PYRO R* TAAAACCAAACCCTCACTCCTAA 163 50 
UNC5B SEQ GGAAAATTGGAGTAGAAAG   
Key: * = biotinylated primer   
Table A5. Primer sequences for pyrosequencing (PHFK-HPV18 cell line)
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 First 
Author 
Platform Samples Methods 
Pyeon U133 Plus 
2.0 
8 normal cervices and 20 cervical 
cancers 
Laser capture microdissected (LCM) 
samples; 2 rounds of amplification 
Rosty U133A 5 normal cervices, 5 cell lines, 35 
primary tumours including 5 
replicates 
Tumour samples contained >50% 
malignant cells 
Santin U133A 11 primary cervical cancer cell lines 
derived from stage IB-IIA cervical 
cancers and 4 normal cervical 
keratinocytes cell lines 
All cell lines harvested for RNA 
extraction at a confluence of 60–80%; 
2-15 passages; no significant 
differences in the no. of passages 
between normal and cancer cell lines 
Wong U133A 18 normal cervices and 29 cervical 
cancers (SCC) 
Tumour samples contained >80% 
malignant cells 
Zhai U133A 10 normal cervices, 7 HSIL and 21 
cervical cancers (SCC) 
LCM samples; 2 rounds of 
amplification 
  
Table A6. Published cervical cancer arrays: gene expression profiling in patients with cervical 
neoplasia and cancer-free controls using the U133 Affymetrix platform. 
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